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Abstract 
Ruthenium complexes are currently attracting much attention in the field of medicinal 
chemistry as they provide numerous properties which make them an appropriate 
candidate for drug design. Recently, a series of ruthenium tach complexes with 
extremely high in vitro activity and high solubility have been developed. Cis-1,3,5-
triaminocyclohexane (tach) provides a hydrogen bond donor through amine groups, 
which aids both solubility and interaction with biomolecules.  
The chemistry of the ruthenium tach complexes was developed in order to understand 
their activity in a biological environment. The parent compound, tach [2] was modified 
by the incorporation of a new functional group (benzyl) into the coordination sphere 
of the ligand and synthesis a new tach analogue, tachmb [3]. The coordination 
chemistry of [3] was performed with a range of different ruthenium precursors to yield 
[Ru(tachmb)(DMSO)Cl2] [5], [Ru(tachmb)(PPh3)Cl2] [7], and [Ru(tachmb)(dppb)Cl]Cl  
[9]. The anti-proliferative activity of the modified tach [3] and the complexes were 
evaluated with in vitro tests against A549 (human lung cancer) and A2780 (human 
ovarian cancer) cell lines. The activity of [3] showed mild activity in comparison to the 
non-toxic tach, [2]. Both complexes [7] and [9] showed high activity; in particular, the 
activity of [9] was found to exceed that of cisplatin in both cell lines. 
Two new analogues of ruthenium tach complexes tagged with fluorescent ligands were 
synthesised and fully characterised, [Ru(tach)(FL-I)Cl]Cl [10] and [Ru(tach)(FL-II)Cl]Cl 
[13]. Two previously reported complexes were also prepared; one complex with high 
cytotoxic activity ([Ru(tach)(dppp)Cl]Cl, [11]) and one complex with light sensitive 
behaviour ([Ru(tach)(phen)(DMSO)], [12]). The interactions of these complexes with 
Calf Thymus DNA (CT-DNA) and bovine serum albumin (BSA) were examined 
spectrophotometrically. The results show intercalation behaviour of [10] and [12] 
towards DNA while complex [11] instead exhibits high binding affinity towards BSA. 
The cytotoxicity of the complexes indicates that proteins may be the potential 
biological targets of ruthenium tach anti-cancer drugs. 
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1 Introduction 
1.1 General facts about cancer 
Cancer is the leading cause of death across the world and has a major impact on 
society.1 Globally, cancer was responsible for 8.8 million deaths in 2015, which equals 
to nearly 1 in 6.2 Nearly, 70% of deaths from cancer occur in low- and middle-income 
countries, and the number of new cases is expected to increase by about 70% over the 
next two decades.2 
Cancer, medically termed as malignant neoplasm, is regarded as an evolutionary 
process that results from the build-up of somatic mutations within the progeny of a 
regular cell, leading to a selective growth advantage within the mutated cells and in 
the long run to uncontrolled proliferation.3 Among the different tissues present in the 
human body, the most frequent human cancers arise in epithelial tissues inclusive of 
the pores and skin, colon, breast, prostate or lung, and collectively result in numerous 
deaths within 12 months.4 Cancer cells differ from normal cells in many ways. Normal 
cells divide and increase their number in a process called mitosis (to replace lost cells 
or to repair injuries) then stop dividing.5  Instead, cancer is an abnormal mass of cells 
which continue to grow when no longer needed and may grow into adjacent tissue or 
spread to distant parts of the body. This indefinite growth ends in the formation of a 
tumour. 6 
The uncontrolled growth takes place if there are mutations to DNA which cause an 
alteration to the genes involved in cell division, and some of these mutations can 
prevent the correction of the DNA damage and apoptosis. The end result of the 
accumulations of a series of such mutation is  uncontrollable cell growth.7, 8 
The tumour microenvironment is heterogeneous, containing mixtures of cells which 
are exposed to various concentrations of nutrients and oxygen.These variable levels of 
oxygen and nutrients can have an effect on the expression of genes and select for a 
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more aggressive phenotype inside regions of the microenvironment. Therefore, new 
blood vessels are required to provide nutrients for tumour cell proliferation (termed 
angiogenesis). Cells that are further away from the blood source are poorly 
oxygenated (hypoxia) and are generally slower growing or nonproliferative,9, 10 whilst 
poor clearance of cell breakdown products, such as lactic and carbonic acid, results in 
a low pH region.10 These features, together with the high interstitial pressures, make 
diffusion (in preference to convection) the dominant mechanism of extravascular 
delivery of nutrients and drugs in tumors.9, 11, 12 
The cell growth in the normal tissues is a carefully controlled process, regulated by 
several ‘checkpoints’ throughout the cell cycle. The two main steps of the cell cycle 
are; 1) interphase, where the cell prepares itself for replication and 2) 
mitosis, wherein the division of the cell’s nucleus takes place.13 Therefore, for 
replication to take place, the cell has to  pass through the various checkpoints. The 
deregulation of the normal cell cycle through loss of any checkpoint control (normally 
the p53-dependant checkpoint) leads to a decreased genetic stability and 
uncontrolled, unstructured and unregulated cellular growth, facilitating tumour 
developments. 13, 14  
Normally, there are several options of therapies available when a tumour is detected. 
This could be either surgical removal of a solid tumour followed by radiation therapy, 
or radiation therapy/chemotherapy, when surgery is not possible.15 
The hypoxic property of tumour cells also leads to a resistance to many 
chemotherapeutic treatments; thus, limitation of drug delivery has occurred as a result 
of the relatively long distance diffusion of chemotherapeutic agents. An additional 
reason for resistance is that several anticancer agents take effect through anti-
proliferative mechanisms of the malignant cells that have a greater proliferative rate 
than healthy cells such as drug target alteration, activation of prosurvival pathways, 
cell death inhibition or any combination of these mechanism .16  
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For potential drug development, the targeting of these mutations is a common 
objective in anti-cancer research. Indeed, there is much interest in the development of 
anticancer drugs which are able to be cytotoxic only when in the hypoxic environment 
of a tumour region to decrease the cytotoxicity of the drugs to the normal tissues.17, 18 
 
1.2 Platinum Anticancer Agents 
1.2.1 Cisplatin and its derivatives 
 
Cis-diamminedichloridoplatinum(II) and its trans analogue were first described by 
Peyrone in 1845.19 In 1893 Werner used these compounds as the first example of 
isomers in coordination chemistry. The anticancer properties were not discovered until 
1965, when Rosenberg realized that the generation of cisplatin at a platinum 
electrodes used in one of his experiments affected bacterial cell growth of Escherichia 
coli.20 
 
Figure 1.1: Chemical structure of cis and trans-diamminedichloridoplatinum(II). 
  
The world’s highest selling anticancer drug, cisplatin, has opened the door to the use 
of metal-based compound for cancer treatment.21 Cisplatin clinical trials on solid 
tumours in humans followed rapidly and the  Phase I clinical trials started in 1971,22 
receiving Food and Drug Administration (FDA) approval in 1978 under the name 
‘Platinol’.23 Cisplatin displays great efficacy against solid tumour types, such as 
testicular, ovarian, head, and neck cancers, and against small-cell lung cancer,24 with a 
cure rate rising to 90%.25  
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1.2.2 Mode of action 
 
The mechanism of action of cisplatin involves several steps (Figure 1.2).26 Once it is 
injected into the bloodstream, cisplatin binds to blood plasma proteins, foremost to 
albumin. The presence of high extracellular concentration of chloride ions (104 mM) 
prevents hydrolysis of the complex and maintains the drug in its neutral form.27 
Although the mechanism of cellular uptake of cisplatin has remained unclear, early 
research showed that passive diffusion is the main mechanism28, 29 although more 
recent work has indicated  the involvement of active transport mechanisms such as 
active copper transport proteins.30, 31 After the compound crosses the cell membrane, 
cisplatin becomes activated and undergoes hydrolysis due to the higher concentration 
of water and lower chloride concentration (4-20 mM) to produce [Pt(NH3)2Cl(OH2)]+ 
and [Pt(NH3)2(OH2)2]2+ These aqua products are potent electrophiles that can form 
numerous adducts  with a nucleophile, including the sulfhydryl groups on proteins and 
nitrogen donor atoms on nucleic acids.26, 32, 33  
 
 
Figure 1.2: Cisplatin mechanism and DNA binding in cells. 
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The ready interaction of platinum aqua complexes with many endogenous 
nucleophiles, such as glutathione (GSH), methionine, metallothionein, and protein, is 
a result of a relatively high intracellular concentration of the tripeptide glutathione 
GSH (0.5 –10 mM)34 and high affinity of the drug for sulfur. However, binding of 
cisplatin to intracellular components is consider to be disadvantageous for its 
anticancer activity and is often associated with cisplatin toxicity and resistance.35 
Ultimately, only a small percentage of the drug reaches the DNA of the genome which 
is the main cellular target for cisplatin.35 
The most favoured site for the platinum aqua complex to bind under physiological 
conditions is the N7 (the most nucleophilic positions on DNA) atoms of the purine 
residue guanine (Figure 1.3). Binding to adenine is less favoured and the other 
potential binding positions in DNA nucleobases are either protonated or involved in 
DNA base pairing at physiological pH (7.2 –7.4).36 Cisplatin binds with DNA in two steps; 
first, the monofunctional adduct with N7 guanine and mono-aquated species 
[Pt(NH3)2Cl(H2O)]+ is formed,  and then further binding with guanine or adenine forms 
a broad spectrum of intra- and inter strand crosslinks. The great majority of products 
are 1,2-intrastrand d(GpG) crosslinks which represent 60-65% of all the adducts 
formed, or 1,2-intrastrand d(ApG) adducts which account for 20-25% of adducts. Minor 
adducts include 1,3-intrastrand and interstrand crosslinks (Figure 1.4).26, 37-39 
 
 
Figure 1.3: Platinum binding at the N7 sites of adenosine (A) and guanosine (G). 
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Figure 1.4: Double stranded DNA distortions from a) intrastrand cross-link 1,2 d(GpG) 
(60–65 %), b) intrastrand cross-link 1,3 d(GpG) (2–3 %) and c) interstrand cross-link 
1,2 d(GpG) (1–5 %). Intrastrand 1,2 d(GpA) (20–25 %) not shown.40 
 
The DNA platination cause a structural distortion of the double helix.41 In intrastrand 
1,2-d(GpG) adducts, platination causes a bend towards the major groove of DNA of 40-
70° and also causes partial unwinding of the double helix up to 23° (Figure 1.4).42 On 
the other hand, the 1,3-d(GTG) adducts induce a kink on DNA of 27-33° towards the 
major groove43 and interstrand adducts cause a bend of the double helix towards the 
minor groove (20-40°) and a high degree of DNA unwinding (approximately 80°).43, 44 
The bending and unwinding of the double helix affects essential cellular processes. 
Several proteins are known to recognize the DNA bending induced by specific cisplatin 
adducts.41 For example, high mobility HMG-domain proteins (e.g. HMG1 and HMG2) 
which are non-histone chromosomal proteins involved in gene regulation and 
chromatin structure are known to recognize cisplatin-DNA adducts.45 The protein HMG 
binds with high selectivity to the DNA lesions structurally distorted by 1,2-d(GpG) 
crosslinks.46 Two mechanisms have been suggested to interpret how HMG proteins 
might control cisplatin cytotoxicity. The first mechanism postulates that HMG proteins 
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act as a shield and protect cisplatin-DNA crosslinks from recognition by the DNA repair 
mechanism of the cell known as “repair shielding model”.47 The other model, the 
“hijacking model”, proposes that HMG binding modulates cell cycle pathways by 
inhibiting the nucleotide excision repair  NER proteins,48 and it has been connected to 
mismatch repair MMR proteins, p53 activity (a tumour suppressor protein) and MARK 
pathway.49, 50 The recognition of 1,2-intrastrand adducts by these proteins may be 
responsible for the cytotoxic effects of cisplatin,51, 52 Finally, all the attempts to repair 
the damage in DNA leads to a programmed cell death known as apoptosis.26, 36, 53, 54 
Since transplatin is not able to form these adducts, it was considered initially as inactive 
in comparison to the cisplatin, however several platinum compounds with trans 
geometry have been proven to be antitumor active,55 such as [trans-PtCl2(pyridine)2].56 
Recently, single trans isomers of bis-picolinamide ruthenium(III) diiodide complexes 
showed high activity and selectivity with IC50 values in the nanomolar range.57 
It was found that trans compounds are also capable causing DNA structural distortions. 
Therefore, it is hypothesised that the inactivity of this compound is due to a greater 
kinetic instability, leading to increased deactivation of the compound.56, 58  
 
1.2.3 Cisplatin side effects 
 
Whilst cisplatin has had obvious success, there are several drawbacks with its clinical 
use that reduces the efficiency. Various studies confirmed that cisplatin induces the 
formation of Reactive Oxygen Species (ROS) accountable for several side effects such 
as organ toxicities. These  include nephrotoxicity, ototoxicity, hepatotoxicity, 
cardiotoxicity and neurotoxicity.59 These problems are coupled to the general side 
effects which result from cell damage such as nausea, vomiting, immunosuppression 
(decreased response of the immune system to infection), decreased blood cell and 
myelosuppression (platelet production in bone marrow).60, 61 
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In addition to these serious side effects, the resistance of some tumours cells to 
cisplatin is a common issue in cancer chemotherapy34, 62 For example, colorectal cancer 
and non-small cell lung cancer are inherently insensitive to cisplatin (intrinsic 
resistance).63 Other cancer cells, for instance, testicular and ovarian cancer, respond 
initially to the treatment but resistance then develops after repeated administrations 
of cisplatin (acquired resistance).64, 65 
All these side effects have triggered an intensive search for new platinum-based 
anticancer drugs to overcome or, to some extent, diminish the side effects.66 
 
1.2.4 Second and third generation platinum drugs 
 
New platinum-based anticancer drugs have been developed in order to overcome 
cisplatin side effects.  However, from over 3000 complexes screened for antitumor 
activity, only a few compounds have entered clinical trials (Figure 1.5).67  
The second-generation platinum drug, carboplatin, was one of the first complexes 
introduced into cancer therapy in 1989 with a reducing and non-overlapping toxicity 
in comparison with cisplatin. The replacement of the unidentate chloride ligands of 
cisplatin by a chelating cyclobutanedicarboxylate ligand of carboplatin (Figure 1.4) 
provides the complex with a reduced rate of aquation, good aqueous solubility and 
greater stability which leads to diminished side effects.68, 69 Carboplatin can be applied 
in higher doses in the treatment of several types of cancer such as ovarian cancer that 
exceeds the dosage of cisplatin. The main drawback is that carboplatin did not 
overcome the cross-resistant mechanism.70 
The cisplatin and carboplatin cross-resistance was first overcome by oxaliplatin (1R,2R-
diaminocyclohexane)oxalatoplatinum(II).71, 72 It has less cross-resistance and a more 
favourable toxicity activity due to a different carrier ligand, diaminocyclohexane.  
Oxaloplatin is effective against colorectal cancer when used in combination with 5-
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fluorouracil and folinic acid.73 The main reason for the lower cross-resistance is 
thought to be because of different adduct formation with DNA; the drug forms GpG 
intrastrand adducts with the bulky hydrophobic diaminocyclohexane ligand pointing 
into the DNA major groove and preventing DNA binding.74 Furthermore, the oxalate 
ligand is also known to reduce the severity of side effects in comparison with 
cisplatin.72, 75 Nedaplatin is also a second-generation cisplatin analogue with greater 
water solubility and significantly less nephrotoxicity than both cisplatin and 
carboplatin. It was approved for clinical in 1995 and it possesses good antitumor 
activity against non-small cell lung cancer, small cell lung cancer, esophageal cancer, 
head and neck cancers with fewer side effects.76 
 
 
Figure 1.5: Second-generation platinum(II) complexes that are approved for clinical 
use include carboplatin, oxaliplatin and nedaplatin. 
 
As discussed above, the second-generation platinum-based anticancer compounds 
have lower renal toxicity whilst retaining antitumor activity due to the replacement of 
the amine or chloride by more stable chelating ligands. However, the first and second 
generation are not orally bioavailable, which influenced research to develop these drugs 
by minimizing their side effects, resulting in the syntheses of third generation platinum 
drugs (Figure 1.6).77 Not all of these attempts, however, have been successful. Although 
satraplatin, a Pt(IV) octahedral centre, exhibits some activity in cisplatin resistant tumour 
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cell lines and showed increasing oral bioavailability, it has been unsuccessful in clinical 
trials.78 
Lobaplatin79 and heptaplatin80 are  two third generation drugs that gained approval for 
the treatment of cancer in certain regions of the world, and each of them shows some 
activities that are not established by cisplatin.81, 82 
 
Figure 1.6: Third-generation platinum(II) complexes that are approved for clinical use 
include satraplatin, heptaplatin, and lobaplatin.  
 
In all of the examples discussed above, the fact remains that many of these complexes 
are toxic to all tissues (cancer and healthy cells), are mutagenic, have severe side 
effects and act against a limited number of cancers. As a result, research directions 
have turned toward the exploration of other active transition metal complexes for the 
treatment of cancers that deviate in reactivity and mechanism of platinum-based 
anticancer drugs.83 
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1.3 Non-platinum anticancer agents 
 
Platinum is not the only metal used in anti-tumour drugs. There are various examples 
of other metals (Figure 1.7) incorporated into anticancer drugs.84  
Compounds of ruthenium, gallium, or titanium have already been tested in clinical 
phase I and phase II trials, whilst complexes of iron, gold, or cobalt have shown 
interesting results in preclinical research.85 
Figure 1.7 shows the most common compounds used as anticancer drugs. Many 
gallium complexes have been prepared with  promising anticancer properties such as 
the metallodrug, KP46 (tris(8-hydroxyquinolinato)gallium(III)).86 The simplest and first 
gallium complex that stimulated further research in the field is gallium nitrate Ga(NO3)3 
and it is consider as a standard against which newer gallium complexes should be 
compared due to its high activity. Ga(NO3)3 is approved for the treatment of 
hypercalcemia of malignancies by reducing the elevated Ca2+ levels in the blood.87, 88  
 
Figure 1.7: The most promising anticancer compounds, KP4 and MKT4. 
 
Titanium metal became very important in the field of antitumor metallodrugs since the 
discovery that titanocene dichloride [TiCl2Cp2] or MTK4 is an active anticancer drugs 
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against breast and gastrointestinal carcinomas.89 The activity of this compound was 
supposed to be in the same manner as cisplatin with DNA as the main target, but the 
aqeuous chemistry of MTK4 showed that DNA is not considered as a  site of action. 
Instead, the  inhibition of collagenase type IV activity, which is involved in regulation 
of cellular proliferation, protein kinase C and DNA topoisomerase II activities, seems to 
contribute to the biological activity of this compound.85, 90 Since this discovery there 
has been extensive research by Tacke, McGowan, Valentine, Meléndez, and Tshuva on 
many titanium compounds, many of which show promising anticancer activity.90 
In conclusion, it is clear that platinum is not the only metal that offers a high activity in 
the chemotherapy field, since many other metals (including gallium, titanium and 
ruthenium) have been used in the further development of metallotherapeuticals.  
 
1.4 Ruthenium complexes with anticancer properties 
 
One of the new strategies for the design of new anticancer drugs is finding an 
alternative metal centre to platinum that possesses new structures and modes of 
action to overcome the drawbacks associated with cisplatin therapy.85 Ruthenium 
complexes turn out to be the most promising metal in the field of anticancer 
compounds.91 Ruthenium complexes show similar ligand exchange kinetics to platinum 
under physiological conditions, which in both cases is slow.92, 93 Furthermore, 
ruthenium compounds are less toxic than platinum drugs.92 This low toxicity is 
supposed to relate to the redox potential of ruthenium complexes under physiological 
conditions that allows the administration of inert Ru(III) drugs which are activated by 
reduction to Ru(II) in diseased tissues (as cancer cells have a more chemically reducing 
environment than healthy cells owing to their lower oxygen concentration).94 The 
lower toxicity is also believed to be due to the ability of ruthenium to mimic iron in 
binding to many biomolecules, such as transferrin or albumin, which causes higher 
drug concentrations in cancer cells in comparison to healthy cells.95 This aids 
ruthenium complexes to be selectively activated in cancer tissues.92, 96 All of these 
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features, in combination with the ability of ruthenium to forms hexacoordinated 
complexes (which is markedly different to the well-known platinum drugs where the 
metal usually has a square planar geometry), makes ruthenium compounds suitable 
for use in biological applications.  Ruthenium-based drugs do not mimic cisplatin and 
its analogues in their mode of action.97 
1.4.1 Development of ruthenium(III) complexes 
 
Ruthenium compounds were first tested successfully for biological activity by Dwyer 
and coworkers in 1950.98 The complex fac-[RuCl3(NH3)3] was one of the earliest types 
of Ru(III) species and found to inhibit the growth of Escherichia coli cells in 1978, at 
similar concentrations to cisplatin99 Then, in 1980 cis-[RuCl2(NH3)4] was also observed 
by Clarke and coworkers to exhibit anticancer properties.100 The main concern with 
these two complexes was their poor water solubility that prevented their formulation 
as drugs.101 
To overcome solubility issues, highly water soluble [Ru(DMSO)4Cl2] was explored. 
Surprisingly, when the cis and trans isomers were investigated for anticancer activity, 
the trans isomer was much more cytotoxic than the cis isomer.102, 103 This behaviour is 
in stark contrast to the relative activities of the Pt(II) isomers, which pointed to the 
possibility of differences in the mechanisms of action of Ru(II) and Pt(II) complexes.104 
The search for more biologically active complexes related to trans-[Ru(DMSO)4Cl2] led 
to the development of trans-[RuCl4(Im)(DMSO)](ImH+), NAMI-A by Alessio (Figure 
1.8).105 This drug has been one of the most promising candidates, having completed 
Phase I clinical trials and also showing encouraging results in Phase II clinical trials, 
especially in colon, head, liver and neck and endometrial cancers.106, 107 NAMI-A has a 
negligible effect on the primary tumour; instead, it is known to be effective against 
tumour metastases, not only in preventing the formation of metastases but also in 
inhibiting their growth once established, particularly in the lungs.106 This is a very 
important activity since treating secondary metastases is still a clinical challenge. The 
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exact mechanism of action of NAMI-A remains to be elucidated.  Although NAMI-A is 
capable of binding to DNA, such binding is not believed to be relevant to their biological 
action,108 hence this drug undergoes aquation and hydrolysis within minutes at pH = 
7.4  in aqueous solution109 and has  non-cytotoxic behaviour in common cancer cell 
lines. The interactions with actin-type proteins on the cell surface,110 or 
with collagens of the extracellular matrix,111, 112 result in reduced mobility of invasive 
cancer cells and migration. These were suggested as possible mechanisms of anti-
metastatic action of NAMI-A.113, 114 
 
 
Figure 1.8: Two ruthenium(III) complexes in clinical trials, NAMI-A and KP1019. 
 
KP1019, [IndH][trans-RuCl4(Ind)2] (Ind = indazole) (Figure 1.8), developed by Keppler, 
was the second ruthenium anticancer drug to pass Phase I clinical trials.115 It is effective 
against cisplatin, resistant colorectal cancer, the second common type of cancer.116 
Although KP1019 largely resembles NAMI-A in chemical properties, it has different 
behaviour in vivo due to the ability to induce cell apoptosis (programmed cell death), 
which is attributed to the different protein binding interactions of the two 
complexes.114, 117 KP1019 can bind to iron pockets in transferrin, with two ruthenium 
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moieties residing in each iron binding site which results in the high accumulation of the 
drugs in tumour tissue due to the high iron requirement of tumour cells.114  Then 
apoptosis is induced via depolarization of mitochondrial membranes and activation of 
caspase-3 as well as down-modulation of the antiapoptotic factor bcl-2.118 The cell 
death by KP1019 drugs was found to be independent of the p53 status of tumour 
tissues, indicating that DNA is not the primary target and that DNA strand breaks may 
possibly contribute to the formation of reactive oxygen species in tumour cell lines.114 
 
1.4.2 Redox activation of ruthenium-based prodrugs as a 
hypothesis 
 
Ruthenium(III) drugs may remain in the same oxidation state until they reach the 
tumour site or partial reduction in biological media is sometimes possible.119 Drugs 
administered as inert Ru(III) complexes may be activated, once inside the cell, by a 
process called “activation by reduction”.120, 121 Increased amounts of in vivo  reduction 
is  expected to take place within cancer cells due to the lower oxygen (more hypoxic) 
content and the acidic environments due to insufficient formation of new blood 
vessels.122 Compared to healthy cells, cancer cells tend to be more dependent on 
glycolysis for their energy and an excess of lactic acid is produced; this in turn lowers 
the pH of the local environment123 which favours the production of Ru(II) intermediates 
from the Ru(III) precursors. Thus Ru(III) complexes are considered as pro-drugs.121, 124 
The biologically active Ru (II) species are more reactive to chlorido loss than the Ru(III) 
prodrugs. This is because reduction from Ru(III) to Ru(II) fills the dπ orbitals, causing π-
donor ligands such as chloride to dissociate more readly.121, 125    
Activation by ligand substitution in Ru(III) prodrugs is thought to be important for both 
NAMI-A and KP1019 drugs and the hypothesis that Ru(II) rapidly coordinates to 
biomolecules leads to generate an interest towards compounds that have a stable 
Ru(II) oxidation state, such as the organometallic Ru(II) arene complexes.126, 127 
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1.4.3 Ruthenium-arene complexes as anticancer agents 
 
In the field of modern medicinal chemistry, a new class of ruthenium(II) compounds 
featuring the ɳ6-arene ligand have attracted much attention for use as anti-cancer 
agents.126, 128  
 
Figure 1.9: General structure of piano-stool ruthenium(II) arene complexes. 
 
The “half-sandwich” ruthenium(II) arene compounds are also referred to as “piano-
stool” complex, and were developed by Sadler and co-workers of a general formula 
[Ru(η6-arene)(XY)(Z)], (Figure 1.9) where XY is a bidentate chelating ligand and Z is 
monoanionic labile ligand.129 Structure-activity relationships have determined that a 
chelating ligand (XY) can provide stability towards aquation by controlling the ligand 
exchange kinetics of the complexes, and ligand XY also influences the pKa of the 
compounds and selectivity of binding to the nucleobases. The nature of the arene, with 
three fac-coordination sites acting as a π-acceptor, can confer stability to the +2 
oxidation state. Finally, the monodentate leaving group (Z), such as halide, allows 
activation of the compound by providing a vacant coordination site for 
biomolecules.128, 129 
The first ruthenium(II) arene complex with identified cytotoxic activity was [Ru(η6-
C6H6)(DMSO)Cl2]. The complex shows strong inhibition of topoisomerase II activity, 
which play an important role in structural organization of the mitotic chromosomal 
scaffold during cell replication process.130 Replacing the DMSO ligand with 3-
aminopyridine, p-aminobenzoic acid or aminoguanidine ligands shows enhanced 
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efficacy of topoisomerase II inhibition and higher cytotoxicity against colon and breast 
cancer cells in comparison to the parent complexes (Figure 1.10).131 
 
 
 
Figure 1.10: Chemical structures of the [Ru(η6-C6H6)(DMSO)Cl2] and replacement of 
DMSO by a) 3-aminopyridine b) p-aminobenzoic acid or c) aminoguanidine. 
  
Since then, many Ru(II)-arene complexes containing chelating nitrogen ligands such as 
ethylenediamine (en) or N-ethylethylenediamine (en-Et), some of which are given in 
Table 1.1, were developed by Sadler and co-workers in 2001128 in order to exhibit 
desirable physical, chemical and biological properties. These ethylenediamine-based 
complexes were evaluated against the human ovarian cancer cell line A2780 and the 
obtained results show high in vitro and in vivo anticancer activities, some of them as 
potent as cisplatin and carboplatin.132 Some structure–activity relationships have been 
established (Table 1.1). Initially, complexes with extended hydrophobic arenes such as 
[(η6-tetrahydroanthracene)Ru(en)Cl]+ were found to be active with IC50 values 
equipotent with cisplatin (0.5 µM). This revealed the importance of the identity of the 
arene ligand and the increased hydrophobicity was assumed to increase the ability of 
the complex to passively diffuse through the cell membranes.126, 133 
The importance of the chelating ligand (Table 1.1) (R2-R2) for moderating anticancer 
activity was indicated when the chelating ligand (en) was substituted by relatively 
labile monodentate ligands such as [(p-cymene)Ru(CH3CN)2Cl]+ and [(p-
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cymene)Ru(isonicotinamde)2Cl]+. This led to less cytotoxic complexes (IC50 values > 100 
µM) compared to the chelated ligand-containing complexes which exhibited high 
activity (9 µM).128 The lack of activity was attributed to the high reactivity of the 
monodentate complexes which lead to inactivation of the complexes before reaching 
their target .134 
Other evidence of the importance of the ethylenediamine chelating ligand comes from 
comparison of the activity of [Ru(p-cymene)Cl(en)]+ with its monodentate analogue 
[Ru(p-cymene)Cl(NH3)2]+  The presence of two ammonia ligands instead of 
ethylenediamine showed loss of cytotoxicity in the three cell lines A549 (non-small cell 
lung carcinoma), CH1 (ovarian carcinoma), and SW480 (colon carcinoma). This lack of 
activity may be related to instability of the non-chelating analogue which leads to rapid 
hydrolysis of both Cl and NH3 ligands and formation of the [({p-cymene}Ru)2(µ-OH)3] + 
species, as found in the solid state.135 
Substitution of chloride by bromide or iodide has only a marginal effect on the 
cytotoxicity of ethylenediamine complexes. This was hypothesised to be due to the 
high intercellular chloride concentration, which leads to the exchange of any halogen 
ligand with chloride.136 
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Table 1.1: IC50 values of Ru(II) arene complexes [(R1)Ru(R2-R2)(R3)]+, carboplatin and 
cisplatin in A2780 human ovarian cancer cells after 24 h drug exposure. 
 
 
R1 R2— R2 R3 IC50 A2780(µM) Ref. 
benzene En Cl 17 128, 134 
p-cymene En Cl 10 128, 134 
biphenyl En Cl 5 128, 134 
Dihydroanthracene En Cl 2 128, 134 
Dihydrophenanthrene En Cl 1 137 
Tetrahydroanthracene En Cl 0.5 128, 134 
arene En Cl 1 138 
arene En Br 5 138 
arene En I 9 138 
p-cymene En I 9 126 
p-cymene En Cl 10 126 
biphenyl en-En Cl 6 128, 138 
p-cymene 2(Isonicotinamide) Cl >100 128 
p-cymene (CH3CN)2 Cl >100 128 
p-cymene Diamino benzene Cl 11 126 
biphenyl Diamino benzene Cl 5 126 
Carboplatin - - 6 134 
cisplatin - - 0.6 134 
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Overall it appears that a more hydrophobic arene ligand and a single ligand exchange 
site, with the two other sites occupied by a bidentate chelating ligand N,N- result in 
high  cytotoxicity.126 
Using a σ-donor / π-donor oxygen chelating ligand O,O-, such as acetylacetonate (acac)  
instead of a dinitrogen σ donor N,N-, results in a change to the reactivity of the 
ruthenium arene complexes (Figure 1.11). The activity depends upon the size of arene 
in the following order: p-cymene > biphenyl > dihydroanthracene > benzene, the 
changing in arene size leads to change the activity against A2780 ovarian cancer cells 
from an IC50 70 µM to 11 µM  and the most potent complex is achieved with [(p-
cymene)Ru(PhCOCHCOPh)Cl].126 It was hypothesised that the acac complexes 
hydrolyse rapidly and have poor solubility. Also the steric bulk around the metal centre 
in case of p-cymene and biphenyl appears to enhance the activity of these acac 
complexes because rotating components can shield the metal centre and protect the 
chelating ligand from displacement.126, 139 
 
Figure 1.11: Structure of ruthenium(II)-cymene complexes with N,O- chelating ligand 
[Ru(p-cymene)Cl(N,O)] where: N,O = 4-[N-(2-((2-hydroxy-5-Xphenyl)methyl 
imino)ethyl)]-N-butyl-1,8-naphthalimide (right) and O,O- chelating ligand [(p-
cymene)Ru(PhCOCHCOPh)Cl]  (left).  
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The N,O- chelating complexes of the type [(p-cymene)Ru(N,O)Cl] such as glycine, L-
alanine, O-alanine, L-phenylalanine, and 8-hydroyxquinoline have been found to be 
inactive towards the ovarian cancer cell A2780.126 Recently, a new family of 
ruthenium(II) arene complexes with naphthalimide conjugated chelating ligands of the 
general formula [Ru(p-cymene)Cl(N,O)] where: N,O = 4-[N-(2-((2-hydroxy-5-Br 
phenyl)methylimino)ethyl)]-N-butyl-1,8-naphthalimide, 4-[N-(2-((2-hydroxy-5-Cl 
phenyl)methylimino)ethyl)]-N-butyl-1,8-naphthalimide, and N-butyl-4-[N-(2-((2 
hydroxy-5-NO2-phenyl)methylimino)ethyl)]-N-butyl-1,8-naphthalimide, Figure1.11 
were synthesised and these complexes exhibit significant antiproliferative activities 
against the CRL8678 human melanoma skin cancer, with IC50 values in the ranges (0.70-
0.89 µM ).140  
 
1.4.4 Mechanism of action 
 
During the past decades, much research has been carried out exploring the mode of 
action of ruthenium (II) arene complexes. The studied complexes show remarkable 
activity against cisplatin-resistant cell lines, which may imply a different mode of action 
than that of cisplatin.141 
Activation through hydrolysis may be important for the mechanism of cytotoxic action 
of Ru(II) arene complexes and their chemical behaviour in aqueous media has been 
extensively studied. For example, hydrolysis of [Ru(ɳ6-arene)Cl(en)]+ is largely 
suppressed in the blood where high chloride concentrations are found (104 mM), 
whereas in the cytoplasm and nucleus, the chloride concentration is significantly lower 
than the extracellular concentration (20, 4 mM), respectively. Thus, under 
physiological conditions, the generated hydrolysis products (Ru–OH2/OH species) are 
likely to increase from about 30% in the cytoplasm to about 70% in the nucleus.  
 
Chapter 1 
43 
 
 
 
 
 
Figure 1.12: Proposed mechanism and DNA binding for ruthenium arene complexes. 
 
The hydroxo and aqua species will exist in varying ratios within a range of pH values. If 
the pKa of the aqua complex (Ru-OH2) is too low, the inactive hydroxo Ru-OH species 
will predominate (Figure 1.12). The deprotonated Ru-OH species is less reactive due to 
the less labile hydroxide ligand compared to water, which will not be displaced easily 
by biomolecule targets. Thus, ideally the pKa values of aqua complexes should be (>7.7) 
so that the deprotonation of the aqua products is negligible at physiological pH. 
Furthermore, the equation kinetics of ruthenium (II) arene complexes have also been 
studied since it is considered as an activation step for the complex for potential binding 
to DNA or other possible cellular targets, and it appear to be rapid about twenty times 
faster than that of cisplatin.142 
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The main cellular target for Ru(II) arenes, as for many metal-based drugs, is believed to 
be DNA. It is found that the aqua species has a high affinity for the N7 position of 
guanine (G) base, with different mode of binding to DNA, as the ruthenium arene 
complexes can form only monofunctional adducts while cisplatin forms bifunctional 
adducts.143 This behaviour has been verified by a comparative study with various DNA 
bases in aqueous solution. The reactivity of the various binding sites of nucleobases 
towards arene ruthenium ethylenediamine at neutral pH decreases in the order G(N7) 
> T(N3) > C(N3) > A(N7), A(N1), and binds very weakly to N(3) of cytidine and almost 
no binding to adenosine was observed.144 
 
 
Figure 1.13: Ruthenium(II) arene interactions within guanine (G) and adenine (A) 
adducts. 
 
The observed base selectivity can be justified in terms of hydrogen bonding 
attractions/repulsions. The ethylenediamine NH2 groups were found to form hydrogen 
bonds with exocyclic oxygens C6 of the guanine system whereas repulsive and non-
bonding interactions towards exocyclic amino groups of the nucleobases such as C6 of 
adenine system were observed (Figure 1.13).96, 128, 145 In addition, when bearing an 
extended arene ligand such as dihydroanthracene, and tetrahydroanthracene, the 
complexes nucleotide binding was promoted by hydrophobic arene-purine base π-π 
stacking interactions, therefore enhancing the cytotoxicity of those derivatives.99, 145 
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The experimental data in both the solid (X-ray crystal structures) and solution (NMR) 
state are in good agreement with Density Functional Theory (DFT) calculations on 
these complexes with isolated nucleobases.145 However, the affinity for adenine was 
found to be greater than guanine in case of ruthenium (II) arene complexes with O,O-
chelating ligands which is believed to be due to specific hydrogen-bond recognition of 
the complex by the bases.144  
Overall, these complexes are cytotoxic to several cancer cell lines,126 including cisplatin 
resistant strains, while [Ru(η6-biphenyl)(en)Cl]+ shows high activity against the MCa 
mammary carcinoma, reducing both the growth of the primary tumor  and growth of 
lung metastases.146 These promising activity has led to further efforts to  develop  
ruthenium(II) arene complexes. 
 
1.4.5  Second class of organometallic ruthenium (II) complexes 
 
A series of Ru-organometallic complexes of formula [Ru(II)(arene)Cl2(PTA)], known as 
RAPTA compounds have been developed by Dyson and co-workers.147 The piano-stool 
structure of RAPTA compounds are based on arene moieties and PTA ligands where 
PTA is 1,3,5-triaza-7-phosphatricyclo[3.3.1.1.]decane (Figure 1.14). The monodentate 
PTA ligand is the distinguishing feature of the RAPTA structure that differentiates this 
family of complexes from other ruthenium(II)-arene compounds evaluated for their 
anticancer activity. This sterically undemanding ligand increased aqueous solubility of 
the RAPTA complexes depending on the nature of the co-ligands.147, 148 
The first complex reported as a potentially interesting biological active agent is RAPTA-
C, as when it was incubated with supercoiled pBR322 DNA it exhibited pH-dependent 
DNA damage. DNA damage was observed at pH 7.0 and below  but not at physiological 
pH (pH ≥ 7.5), which provided a means to target cancer cells, since they exhibit reduced 
pH (hypoxic cells).149 
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Figure 1.14: Structure of RAPTA-C complex as anti-metastatic agent. 
 
Despite the obvious difference between RAPTA compounds and NAMI-A in oxidation 
state, ligand, and geometry, their behaviour in vitro and in vivo is very similar.149 These 
compounds show excellent inhibition of metastases growth in addition to high 
selectivity and a very low general toxicity.150 This remarkable activity of RAPTA-C has 
prompted the study of a large number of RAPTA analogues with a range of 
properties,149, 151 (Figure 1.16). 
 
1.4.6 Mechanism of action and structure development 
 
The RAPTA-C complex has been shown to undergo rapid hydrolysis in pure water, over 
20 minutes faster than both cisplatin and Sadler ruthenium arene complexes, and at a 
physiological concentration of 100 mM NaCl, the hydrolysis is suppressed.147 On the 
basis of these results, many studies have been done to highlight the activation steps of 
these complexes. Under physiological conditions of low chloride concentration (5 mM) 
the major species in solution is the mono-aqua adduct of the RAPTA complex, [Ru(η6-
arene)Cl(H2O)(PTA)]+, along with lesser amounts of [Ru(η6-arene)(OH)(H2O)(PTA)]+ and 
[Ru(η6-arene)Cl2(PTA)] also present. Equilibrium was reached after 20 min (Figure 
1.15),152 assuming that in vivo the drug, like cisplatin, is activated by hydrolysis in a low 
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chloride environment. However, another study revealed that the rate of hydrolysis 
does not support the mode of action as the replacement of the two chloride ligands by 
a chelating ligand such as oxalato (oxalo-RAPTA) leads to a decrease in the rate of 
hydrolysis, whereas reactivity towards a single stranded oligomer and in vitro activity 
remain unchanged.153 Furthermore, it was later found that this complex has a pKa of 
3.13, indicating that this complex is unlikely to be protonated under physiological 
conditions.147 
 
 
Figure 1.15: Hydrolysis of RAPTA-C under physiological conditions. 
 
After the initial report of the ability of RAPTA-C to damage DNA, three close analogues, 
[Ru(p-cymene)X2(PTA)] (X = Cl, Br, I, NCS), were evaluated. These RAPTA compounds 
possessed a degree of antibiotic activity. The level of observed activity against a 
particular microbe was related to the nature of the leaving group ligand (X), while in 
vitro DNA-damaging property of a particular RAPTA compound did not correlate with 
the observed antimicrobial activity, suggesting a non-DNA-based mechanism of 
action.154  
On the other hand, a study of incubation of RAPTA-C with E. coli, followed by the 
extraction and separation of intracellular proteins, then using laser ablation inductively 
coupled mass spectrometry (LA-ICP-MS) for examination, the results specified the 
formation of protein-ruthenium interactions, implying protein-binding may be a major 
influence in the activity of these complexes and indicating a non-classical mechanism 
for the cell killing mechanism of RAPTA-C and their analogues.155  
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In view of this, protein interactions of RAPTA compounds are extensively studied.99, 155, 
156 A study of the RAPTA compound with low molecular weight proteins or peptides 
mimicking the active sites of albumin and transferrin residues was performed using 
mass spectrometric analysis which demonstrated that a histidine residue is the major 
binding model and cysteine is also engaged in the binding but to a lesser extent.157 It 
is clear that the affinity of RAPTA-T for albumin and transferrin is higher than that of 
cisplatin, supposedly due to the direct reaction of RAPTA compounds with 
biomolecular targets without aqua adduct formation.155 
 
1.4.7 Structure-Activity Relationship (SAR) development of the 
RAPTA structure 
 
Promising antitumor activity of some of the original RAPTA structures, in particular RAPTA-
B, RAPTA-C, and RAPTA-T (Figure 1.16) prompted further investigations on the effect of 
modulating individual structural substituents of the RAPTA scaffold to achieve structure-
activity relationships to achieve more active compounds.  
In order to investigate the effect of PTA ligand, RAPTA-C and RAPTA-T were modulated 
with PTA-Me+ ligand shown in Figure 1.16, which lead to reduced selectivity compared to 
the original complexes. This supposedly confirmed the hypothesis that RAPTA complex 
activity originates from protonation of its PTA ligand.147 
Further indication of a different mechanism of action in RAPTA compounds activity 
resulted from introducing hydrogen bonding groups to the arene ligand, for instance, 
RAPTA-OH, RAPTA-N1 and RAPTA-N2 Figure 1.16, which are assumed to promote 
reactivity towards oligonucleotides. However in vitro they proved to be less active and 
selective, correlated to reduced uptake of these modified complexes into the cell.158 
A series of structural modifications of the PTA moiety were carried out to yield a series 
of RAPTA analogues with a chelating PTN (3,7-dimethyl-7-phospha-1,3,5 
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triazabicyclo(3.3.1)nonane) ligand in place of the PTA ligand (Figure 1.16). The chelate 
complexes were highly water soluble and strongly resistant to hydrolysis in addition to 
demonstrating little reactivity towards DNA. However, their in vitro activities are 
comparable to or better than those of their PTA analogues with high affinity for model 
protein ubiquitin.159 This finding was a clear indication that the interactions of RAPTA 
compounds with proteins play a greater role on the antitumor activity of these 
compounds. 
 
 
Figure 1.16: Family of RAPTA complexes. 
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To enhance drug efficacy and obtain more targeted compounds, facile 
functionalisation of the RAPTA structure has been exploited with ethacrynic acid, 
known as glutathione-S-transferases (GST) inhibitors (Figure 1.17).  Ethacrynic acid is a 
biologically important molecule known to inhibit GSTs, which are expressed in certain 
chemoresistant tumors. GST is an enzyme that calalyses the conjugation of intracellular 
xenobiotics with glutathione, leading to the xenobiotic being expelled out the cells by 
the GS-export pump.160 
The complexes were found to be competitive inhibitors with high cytotoxic activity 
against (A549, T47D, HT29), cell lines with high level of GST.155, 160 
 
 
Figure 1.17: RAPTA complexes as glutathione transferase inhibitors. 
 
A model RAPTA compound, for intracellular visualization by fluorescence microscopy, 
was developed by tethering some planar aromatic substituents (anthracene 
derivatives) to the arene ring of the RAPTA structure (Figure 1.18). The inclusion of 
anthracene derivatives also introduced a potential DNA intercalator into the structure. 
These complexes undergo aquation in aqueous solution and low toxicities were 
observed (IC50 > 200 μM) towards 12 cell lines (same as the parent RAPTA compounds). 
The intracellular localization in the A549 lung carcinoma cell line (24 h incubation, 
50 μM, λex 365 nm), was observed, but only weak fluorescence was monitored which 
prevented identification of precise intracellular localization of the complex.161 
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Further development in RAPTA complexes was done by incorporating cyclopentadienyl 
ligands and these complexes have been evaluated for their in vitro cytotoxicity. Recently, 
two new complexes have been developed with modified PTA ligand of acetylcholine 
and trimethylglycine containing quaternary ammonium groups (Figure 1.19).  
 
Figure 1.18: Functionalization of the arene ligand of RAPTA compounds with 
fluorescence anthracene for intracellular visualization purpose. 
 
These complexes were highly cytotoxic against A2780, SKOV3 and K562 cell lines with 
IC50 values in the ranges of 4.7–5.1 and 5.5–8.3 μM, respectively. The structurally 
related PTA analogues were designed to contain naturally occurring quaternary 
ammonium groups, including the neurotransmitter acetylcholine.  
 
Figure 1.19: Ruthenium cyclopentadienyl complexes with modified-PTA ligands, 
acetylcholine (left) and trimethylglycine (right). 
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It was suggested to explore if the specific activity results from either the structural 
similarity of the modified-PTA ligands to these naturally occurring ammonium ions or 
if the high cytotoxicity is simply result from modulation of the amphiphilic nature of 
the ruthenium complex.162  
Since then, RAPTA compounds have been expanded to include more than 80 
complexes with promising anticancer properties and suggesting more study with 
advanced proteomics as effective target.155 
 
1.5 Development of new ruthenium anticancer complexes 
 
On the basis of the apparent necessity of a face-capping aromatic ligand for anticancer 
activity in RAPTA complexes and other organometallics, a RAPTA analogue was 
prepared by replacement of the aromatic fragment with a 1,4,7-trithiacyclononane 
ligand (ttcn) [Ru(ttcn)Cl2(PTA)], (Figure 1.20).157  
 
 
Figure 1.20: RAPTA analogues with replacement of the aromatic ligand with a ttcn. 
 
The complex behaved in a similar manner to the RAPTA compounds in aqueous 
solution with slightly decreased cytotoxicity and selectivity in TS/A and HBL-100 cell 
lines. In contrast, when two coordinated PTA ligands were used, 
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[Ru(ttcn)Cl(PTA)2][OTf], the complex showed a selective mild cytotoxicity against the 
TS/A cell line with IC50 388 μM whereas it became inactive towards the HBL-100 cell 
line (IC50 > 1000 μM).163  
In the same study, the (ttcn) ligand was used to modify the ruthenium arene 
ethylenediamine complexes.The prepared complex [Ru(ttcn)Cl(en)][OTf], (Figure 
1.20), was found to be generally more active, but lack of data for the leading complex 
in the same cell lines prevents direct comparison.163 This study indicates the fact that 
the aromatic fragment may be effectively replaced by another face-capping ligand of 
similar steric demand without changing the compound activity.  
Further study on the (ttcn) complexes was explored using novel chelating ligand 1-(2-
picolyl)-4-phenyl-1H-1,2,3-triazole (ppt). The complex [Ru(ttcn)Cl(ppt)][CF3SO3] 
aquates faster and exhibited higher cytotoxicity in vitro  against human lung squamose 
carcinoma cell line (A-549) compared to cisplatin.164 
An expansion of the structure-activity relationship of the ruthenium (ttcn) complexes 
was done using neutral N–N, and anionic N–O and O–O chelating ligands, i.e. dach 
(trans-1,2-diaminocyclohexane), pic− (picolinate), and acac− (acetylacetonate) ligands, 
however the cytotoxicity was only evaluated for [Ru(ttcn)(dach)Cl]PF6 which showed 
less activity than [Ru(ttcn)(en)Cl]PF6. Moreover, this study also developed a new face-
capping ligand, 1,4,7-triazacyclononane (tac), (Figure 1.21). The new half-sandwich 
complexes did not show any activity (up to 300 µM)  against MDA-MB-231 human 
mammary carcinoma cells.165 
 
Figure 1.21: Ruthenium tac complexes with different chelating agent, en 
(ethylendiammine) and dach (trans-1,2-diaminocyclohexane). 
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On the basis of these results, many approaches to the design of anticancer drugs have 
been adopted and one of the strategies is to replace the arene ligand with new fac-
ligands with hydrophobic properties to achieve highly active anticancer complexes. 
 
1.5.1 New facially-capping ruthenium complexes  
 
Developing a series of new ruthenium half sandwich complexes is still a key pathway 
to discovering more efficient anticancer drugs. Ru(II) coordination compounds in 
which the aromatic ligand is substituted by a neutral tridentate macrocycle that 
occupies three facial coordination sites, for instance, cis-1,3,5-triaminocyclohexane 
(tach), are an emerging class of compounds for the design of such active drugs.  
 
1.5.2 The cis-1,3,5-triaminocyclohexane ligand 
 
The face capping N3, cis-1,3,5-triaminocyclohexane (tach) ligand forms the basis of 
many applications, particularly in bioinorganic chemistry,166, 167 and in the modelling of 
metalloenzyme active sites.168-170 
The tach ligand has been widely used due to its ability to provide three coordinating 
sites to different metals, similar to arene ligands, and many complexes have been 
reported.171-173 One of the important features is the ability of tach to be a framework 
for further ready modification by condensation with aldehyde to form Schiff base 
derivatives.168, 169, 172 
These derivatives have shown promising anticancer activity, for instance a novel metal 
chelator  N,N′,N″-tris(2-pyridylmethyl)-1,3,5-cis,cis-triaminocyclohexane (tachpyr), 
(Figure 1.22), was mainly studied for its cytotoxic effect in both murine and human 
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bladder cancer cell lines.171 Tachpyr exhibits an enhanced potency similar to 
desferrioxamine, an iron chelator known to treat acute intoxication by FeSO4, in which 
both compounds were found to induce inhibition of ferritin synthesis.174 
 
 
Figure 1.22: Structure of cis-tach (top) and N,N′,N″-tris(2-pyridylmethyl)-1,3,5-cis,cis 
triaminocyclohexane (tachpyr) (bottom). 
 
Several mechanisms have been proposed to describe the anti-tumor activity of 
tachpyr.  One of the possible mechanisms is iron deprivation which is based on the 
ability of tachpyr to coordinate to biologically important divalent metal, Fe(II) to form 
a 1:1 complex. The ligand then undergoes dehydrogenation of one, two or three of its 
aminomethylene groups to form mono-, di- and triimino Fe(II) complexes (an 
inseparable mixture) and results in cytotoxicity, due to tachpyr's oxidation process.171, 
174 
On the other hand, to further elucidate tachpyr mechanism of action and better 
evaluate its potential applications, several novel metal complexes of tachpyr were 
synthesised and tested on MBT2 and T24 cultured bladder cancer cells. The Ca(II), 
Mn(II), and Mg(II) complexes were as cytotoxic as tachpyr itself, while the Zn(II), Fe(II), 
and Cu(II) complexes showed no cytotoxicity.174 This initially supports the role of iron- 
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depletion in the cytotoxic mechanism of tachpyr. In order to obtain further support of 
this hypothesis, the sterically hindered tachpyr derivatives containing either methyl or 
ethyl groups at the three secondary amines were prepared. These nontoxic derivatives 
were demonstrated by the steric effect of the alkyl groups and also by the lengthening 
the bond distance between the metal and nitrogen atom.175   
A second proposed mode of action is the activation of caspases via a mitochondrial 
mechanism that culminates in apoptosis, however the alkylated derivatives of tachpyr 
did not exhibit any activation of these enzymes.176, 177  
As an ongoing effort to deduce the mechanism of action, recently, it was reported by 
Ciano 178 that DNA was found as a new possible target. The DNA-tachpyr binding was 
evaluated by linear dichroism (LD) that showed disruption in the linearity of the double 
helix, similar to the spermine derivative, which leads to suggest that tachpyr mimics 
spermine in binding to DNA in a non-intercalating fashion, probably with the 
phosphate backbone of DNA. Further evidence of this hypothesis was obtained by co-
crystallising tachpyr with a short DNA oligonucleotide, two consecutive nucleobases 
(GC), that highlight the non-intercalation binding with DNA and presence of tachpyr in 
close proximity of the phosphate backbone of the DNA. These results support that the 
iron chelation is unlikely to be the mechanism of action of tachpyr.178 
In the same study, a series of tach derivatives were synthesised to probe the structural 
effects in the cytotoxic activity. Different groups including heterocyclic, 
salicylaldehyde, and benzaldehyde derivatives were substituted on the three-amine 
nitrogen atom and two mono-substituents were also synthesised, illustrated in Figure 
1.23 and the biological evaluation of activity were performed against A549 and A2780 
cell lines by MTT assay. Some of the promising IC50 value are reported in Table 1.2. 
 As shown in Table 1.2, the change from basic nitrogen substituent, pyridine (pKa = 5.2) 
to acidic nitrogen, pyrrole (pKa = -3.8) leads to loss of activity, which indicates the 
influence of heteroatoms in increasing the cytotoxicity against cancer cell lines. The 
high activity obtained with benzaldehyde derivatives, in some derivatives even higher 
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than tachpyr, suggests that nitrogen atoms of the heterocyclic rings are not essential 
for high activity.  This also supports the earlier hypothesis that iron chelation is not 
involved in mechanism of anticancer activity of tachpyr. On the other hand, changing 
the substituent in the 4-position of the phenyl ring doesn’t correlate with changes to 
the IC50 value leading to the deduction that the steric of the substituent are not 
necessary for the high activity. The importance of the phenyl ring in the 
antiproliferative activity of tach derivatives was evaluated by the mono-substituted 
compound (cyclohexane and benzene ring) which both exhibited moderate activity 
with an IC50 value within the range (73-87 µM). Although the purity of the two 
derivatives was not confirmed by elemental analysis, the result still seems very 
promising. 
 
Figure 1.23: Structural modification of tach ligand synthesised by Ciano, tri-armed 
(top) with some example of the promising results, and mono-armed (bottom).178  
  
The structure-activity relationship of the tach-based derivatives showed the necessary 
of the presence of one substituent to improve the lipophilicity and hence the activity 
of tach ligand.178 
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Table 1.2: IC50 values for tach derivatives tested against A549 and A2780 cells. 
Compound IC50 (µM – A549) IC50 (µM – A549) 
Tach > 250 > 250 
Tach-pyridine 4.99 ± 0.02 4.01 ± 0.03 
Tach-pyrrole 188.2 ± 21.4 147.7 ± 7.1 
Tach-benzene 6.65 ± 0.21 3.03 ± 0.10 
Tach-4dimethylaminobenzene 1.03 ± 0.03 1.24 ± 0.02 
Tach-4fluorobenzene 3.49 ± 0.06 2.62 ± 0.04 
Tach-4methoxybenzene 2.42 ± 0.09 6.06 ± 0.07 
 
On the basis of these results, the tach ligand has been modified with one phenyl ring 
(chapter two). to generate an anticancer Ru complex which, all of the investigations 
with the tach ligand suggest that it is a good candidate for the development of 
synergistic anticancer drugs. In accordance with the fact that little is known on the 
cellular uptake or interactions with biomolecules, more work is needed within this 
field. 
 
1.5.3 Ruthenium tach complexes 
 
Over the years, much research has looked at the synthesis and properties of tach 
complexes, particularly divalent transition metals, and they have been studied as a 
chemotherapeutic agent.175  
The coordinating properties of cis-tach have been thoroughly investigated. A variety of 
metal species can be synthesised such as discrete complexes, molecular clusters and 
infinite architectures, where the three amine groups adopt an equatorial conformation 
in solution whilst the ring-flipped structure formed on coordination to a metal enforces 
an axial conformation of the three binding site in tridentate fasion,169  or in 
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hexadentate fashion in case of functionalised tach that the arms can also coordinate 
to the metal.175   
Mono-substituted tach complexes have been reported by Walton and co-workers in 
which the two arms have been cleaved upon coordination, (Figure 1.24), and this 
behaviour is limited only to benzaldehyde derivatives.166 Then the cleavage of arms 
was overcome  by using furfural or cinnamaldehyde to functionalise the tach structure 
and coordinate to Zn(II) to afford a model of the active site of enzymes (Figure 1.22).167, 
169 
Ruthenium tach complexes have attracted much attention since being reported by 
Gamble et al as promising anticancer agents.179, 180 A wide range of ruthenium tach 
complexes have been synthesised as shown in Figure 1.25 and the biological activity of 
ruthenium(II) tach complexes was assessed by MTT colorimetric assay against the A549 
lung adenocarcinoma and A2780 ovarian carcinoma cell lines. Some of the promising 
IC50 results are illustrated in Table 1.3. 
 
 
Figure 1.24: Cis-tach metal complexes with modified amine groups, monotach (left) 
and cinnamaldehyde tach (right). 
 
As shown in Table 1.3, the triphenylphosphine complex [Ru(tach)(PPh3)(DMSO)Cl]+ 
displayed low activity in both cell lines while the DMSO complex [Ru(tach)(DMSO)2Cl]Cl 
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was inactive. It is evident that the hydrophobic triphenylphosphine played a major part 
in obtaining moderate activity instead of DMSO ligand, and the poor lipophilic nature 
of the complex [Ru(tach)(DMSO)2Cl] (in addition of slow aquation) are thought to be 
the main reason of their inactivity. The N,N-chelating complex was inactive as well, 
presumably due to the poorly labile DMSO ligand which remained complexed to Ru 
even when exposed to harsh conditions such as boiling solvent, therefore the 
activation of this complex did not proceed.  
 
 
Figure 1.25: Ruthenium(II) tach complexes synthesised by Gamble.  
 
The most promising results were obtained with complexes containing diphosphine 
chelating ligand [Ru(tach)(P-P)Cl]Cl, some which have cytotoxicity that exceeds that of 
cisplatin. This activity was attributed to lipophilicity and the flexibility of the chelating 
diphosphine in combination with the enhanced solubility and hydrogen bond donors 
provided by cis-tach ligand and the reactive chloride ligand. 
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Table 1.3: IC50 values for ruthenium(II) tach complexes tested against A549 and 
A2780 cells. 
Compound IC50 (µM – A549) IC50 (µM – A549) 
[Ru(tach)(DMSO)2Cl]Cl > 300 > 300 
[Ru(tach)(PPh3)(DMSO)Cl]Cl 194 ± 4 67.8 ± 10 
[Ru(tach)(phen)DMSO]Cl > 300 > 300 
[Ru(tach)(dppp)Cl]Cl 1.02 ± 3 0.35 ± 1 
[Ru(tach)(dppb)Cl]Cl 1.15 ± 2 0.39 ± 1 
[Ru(tach)(dppe)Cl]Cl 9.88 ± 4 3.39 ± 12 
  
 
1.6 Aims of the project 
 
 Ruthenium-tach complexes have repeatedly indicated promising anticancer activity, 
however the actual cellular target for these complexes and the mechanism underlying 
their biological effects has not been clarified. The aim of this project was firstly to 
design a series of complexes in which the tach ligand was structurally modified, and 
then to investigate the effects of these structural changes on the biological activity and 
cytotoxic properties. 
The complexes were prepared by a structural modification to one of the nitrogen 
groups of the parent tach [2] in order to produce a mono-armed tach ligand. On 
incorporation of the mono-armed ligand into the ruthenium coordination sphere, 
shown in Figure 1.26, the activities of the new complexes were then compared to the 
non-toxic tach [2] in order to observe any differences in cytotoxicity. It was hoped that 
the structure activity relationships would provide further understanding of the 
mechanism of the anti-proliferative activity. 
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Figure 1.26: Proposed structural modification and development to ruthenium tach 
complexes.  
 
To explore the cellular uptake and the fate inside cells of ruthenium tach complexes, 
the mechanism of action was probed by the synthesis of labelled ruthenium tach 
complexes with fluorescent tags. This study contributed significantly to the 
understanding of the possible intracellular targets of the complexes.  
Another important aim is directed towards the interaction of Ru(II) tach complexes 
with biomolecules, in order to identify the main biological target for these complexes. 
This will be achieved by following the interaction of Ru tach complexes with both DNA 
and protein models using a range of spectroscopic methods including UV-Vis 
spectroscopy and fluorescence techniques. A range of modified tach ligands and 
complexes will be studied in vitro in order to examine their potential to inhibit tumour 
cell growth.  
  
Chapter 2 
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2 Synthesis and characterisation of tachmono-
substituted ligands. 
2.1 Introduction 
 
Schiff bases, named after Hugo Schiff,181, 182 are nitrogen analogues of an aldehyde or 
ketone in which the C=O group is replaced by a C=N-R group, (Figure 2.1). They are 
sometimes referred to as imines, azomethanes, aniles, aldimines or ketamines etc.183-
185    
 
R1, R2, and/or R3= alkyl or aryl  
Figure 2.1: General structure of a Schiff base. 
 
Schiff bases that contain aryl or aromatic substituents are more stable and more 
readily synthesised due to their extra stability through conjugation effects, while those 
with aliphatic substituents are unstable and readily polymerize or decompose.186  
The classical method to prepare Schiff base compounds is by condensation of an 
aldehyde or ketone with a primary amine under specific conditions.187 The 
modification of tach is usually performed using aldehydes as the resulting Schiff base 
is more readily formed than ketone,186 therefore the general mechanism shown in 
Figure 2.2 is for reaction with an aldehyde.  In general, the Schiff base formation is a 
two-step sequence: addition and elimination.183, 188 In the first part of the reaction, the 
electrophilic carbon atom can be attacked by the nucleophile amine which causes a 
proton transfer to produce an unstable product known as a carbinolamine. The 
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formation is generally driven to completion by elimination of water  and then the final 
neutral Schiff base is form by deprotonation of the imine product.189 
 
 
Figure 2.2: General mechanism of Schiff base formation. 
 
The mechanism of Schiff base formation is a reversible reaction as protonation of the 
imine causes hydrolysis of the Schiff base and conversion back to the aldehyde or 
ketone and amine starting materials. This backward reaction is catalysed by aqueous 
acid or base and, for this reason, imine formation should be performed under mildly 
acidic conditions (pH = 4.5).190 Additionally, imine compounds are rapidly hydrolysed 
by water and so the reactions have to be carried out under vigorously anhydrous 
condition such as via azeotropic distillation,183, 191, 192 or using molecular sieves to 
completely remove water formed in the system.193  
Schiff bases have a wide variety of applications in many fields including organic, 
analytical, biological, and inorganic chemistry. They have also gained importance in 
medicinal and pharmaceutical fields due to a broad range of biological properties, 
including anti-inflammatory,185, 194-196  antimicrobial,185, 197 anticancer,198, 199 
antiviral,200 and antioxidant201 behaviour. The azomethane linkage makes Schiff bases 
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good chelating molecules due to their ability to provide a lone pair of electrons on a 
nitrogen atom.186 
Although Schiff base molecules have a lot of applications especially in biological areas, 
the imine bond does have some limitations such as low water solubility and low 
stability in acidic media. The reduction of imines to amines is considered to be the best 
strategy to overcome these problems.202 The rapidly growing interest in these ligands 
resulted in enhanced research activity in the field of their coordination chemistry, 
leading to complexes of high stability, good solubility and very interesting hydrogen 
bond donor qualities which enhance the possibility of biomolecule interaction.202, 203 
The imine double bond of a Schiff base is readily reduced by complex metal hydrides.204 
Reduction of this type is probably the most efficient and convenient method for the 
conversion of C=N into amino compounds. Thus, lithium aluminium hydride205 and 
sodium borohydride206 can be used, the latter being a more effective reducing agent 
because of its inertness to a wider range of solvent media and because of its greater 
specificity.207 Therefore in this work the reduction for the Schiff bases was performed 
with sodium borohydride. 
 
2.1 Synthesis and characterisation of tach [2]: 
 
Cis-tach was obtained by following the procedure reported in the literature.178, 179 This 
method comprises of reacting cis-1,3,5-cyclohexanecarboxylic acid with 
diphenylphosphoryl azide (DPPA) in the presence of triethylamine, with benzene as a 
solvent. The tachcarbamate [1] was formed in good yield as a cream coloured 
precipitate. The benzyl protecting group was then cleaved by using strongly acidic 
conditions such as hydrobromic acid to give the hydrobromide salt of cis-tach, [2]HBr, 
summarized in Figure 2.3. 
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Figure 2.3: Synthesis scheme for cis-tach [2].178, 208 
 
Base-free cis-tach [2] was isolated after removing the hydrogen bromide by passage 
down an ion exchange column followed by sublimation, and was collected as a bright 
white solid.209 
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 Figure 2.4: Free tach [2] structure. 
 
It is possible to identify the symmetry of the cis-tach ligand from the nature of the 
resonances in the 1H NMR spectrum. Both the number of signals and the magnitude of 
the coupling constants can be explained by an analysis of the structure. The symmetry 
environment of the cis-tach can be identified from the 1H NMR resonances, (Figure 
2.5).  
 
Figure 2.5: The possible symmetry environments for free tach [2] ligand. 
 
The 1H NMR spectrum of the tach molecule shows only three environments, while the 
amine protons resonances are not observed due to fast exchange with the solvent. The 
non-equivalent proton resonances suggest a C3 symmetry centre, (Figure 2.4). The 
most deshielded proton is b due to its two-bond proximity to the electronegative 
nitrogen atom of the amine. The signal appears as triplet of triplets at 2.78 ppm, with 
a large coupling constant (ca. 12 Hz) to the two equivalent axial protons aax and the 
small coupling constant (ca. 4 Hz) to the two equivalent equatorial protons aeq. 
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The two other signals at 1.95 and 0.9 ppm are for geminal protons aeq and aax 
respectively. The aeq proton has a large J geminal coupling of ≈12 Hz with the aax 
proton. Proton aax appears as a quartet signal due to both axial-axial and geminal 
couplings being similar in magnitude. 
 
 
 
Figure 2.6:  1H NMR spectrum of free tach [2] in D2O.  
 
It was clear from the 1H NMR spectrum and multiplicities that the tach protons have 
an equatorial conformation in solution. 
 
2.2 Synthesis and characterisation of tachmb [3] ligand 
 
The synthesis of the mono-substituted tach compound was targeted in order to 
understand the importance of the monofunctionalised substituents on the biological 
activity.  The presence of substituents may either alter the level of solubility or affect 
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hydrogen bond interactions, which are by far the most important specific interactions 
in biological recognition processes.210 Several SAR (structure-activity relationship) 
examples from medicinal chemistry research illustrate the points made above.211 The 
structure of cis-tach  opens the possibility of adding different substituents on all of the 
three amines, however, the trisubstituted tach possesses high cytotoxicity compared 
to the non-substituted ligand which has much lower biological activity. This result 
provides support for synthesis of the monosubstituted analogue and benzaldehyde 
was chosen because the aromatic rings can act as acceptors of hydrogen bonds and 
interact with biomolecules. Furthermore, the varying biological activity between the 
mono-armed tach with the free-tach could be investigated, providing a comparison 
between their different complexes. 
For the preparation of modified tach, the two amine groups in the tach [2] first needed 
to be protected. Therefore, the first synthetic step was the protection of two out of 
three tach nitrogen atoms by reaction with di-tert-butyl dicarbonate (Boc2O), (Figure 
2.7). 
The tach.diBoc [3-a] was prepared following the reported literature procedures.178 
Here, two equivalents of triethylamine were added to one equivalent of tach.3HBr in 
methanol solvent. A dilute solution of Boc anhydride in methanol solution was then 
slowly added drop wise overnight to the tach.3HBr solution. 
The reason for adding the Boc2O very slowly was to prevent as much as possible the 
formation of tri-substituted tach. The solvent was then evaporated and the residue 
dissolved in water (pH=10). The tach.diBoc was extracted with ethyl acetate, leaving 
the unreacted tach and triethylamine in the aqueous layer. The organic layers were 
dried over MgSO4 and the di-protected product [3-a] was isolated as a white solid in 
good yield. The NMR spectrum showed complete selectivity for the tach.diBoc [3-a] 
due to the presence of characteristic signals in the 1H NMR spectrum. These 
resonances include the signal of an NH proton that appeared at low field region (6.9 
ppm) due to coordination to the carbonyl group, and the appearance of a signal 
corresponding to the tert-butyl protons (1.4 ppm integrating for 18 protons) indicating 
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the presence of two protecting groups. Furthermore, a peak at m/z 330.2388 was 
observed in the ESI-MS for the di-protected compound [M] + H+. It is worth noting that 
a small peak for the tri-protected tach was usually also present in the positive mode 
high-resolution ESI-MS at m/z 430.2898. However, the presence of a small amount of 
this compound was not considered to be a problem, as in the next synthetic step it 
cannot react with the benzaldehyde, and in the deprotection step it will be hydrolysed 
from the Boc group releasing free tach. 
 
 
 Figure 2.7: Synthetic scheme for tach.diBoc [3-a]. *Isolated yield. 
 
One equivalent of benzyldehyde was added to the tach.diBoc [3-a] in methanol as a 
solvent and the reaction mixture was stirred at room temperature for 24 hours. The 1H 
NMR spectrum showed the presence of unreacted aldehyde which implied the 
reaction was not complete. The reaction was therefore heated at reflux in toluene, 
with a Dean–Stark apparatus used to remove the water which was produced as a by-
product (as the removal of water minimises the reverse hydrolysis reaction). After 18 
hours, only a small peak for the desired compound was observed in the ESI-MS, in 
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addition to another unexpected peak for disubstituted compound at m/z 405.25. Due 
to this signal, it was suggested that heating may cause a cleavage of one Boc group. 
Therefore, the reaction was repeated at room temperature in methanol solution and 
molecular sieves were added to drive the reaction forward (by removal of water that 
is produced during the formation of Schiff base). The ESI-MS spectrum showed clear 
evidence for the Schiff base compound [3-b] at m/z 418.27. In the final step, the 
solvent was evaporated to leave a white solid which was washed three times with 
diethyl ether. 
The presence of the Schiff base compound [3-b] was indicated by the appearance of a 
characteristic singlet signal for the imine proton in the 1H NMR spectrum at low field, 
typically at 8.26 ppm in CDCl3, and the emergence of the benzyl protons resonances in 
the aromatic region at 7.6 ppm. Each of these signals implies the successful 
coordination of a benzyl substituent, while the presence of the tert-butyl and 
coordinated NH protons are clear evidence of the existence of the protecting groups. 
The imine bond in [3-b] was reduced with sodium borohydride, which was slowly 
added to a solution of tachmonoimbenz.diBoc [3-b] in methanol with stirring at room 
temperature for 16 hours, (Figure 2.8). An extraction with chloroform gave 
tachmonobenz.diBoc  [3-c] in high yield (78%) and high purity. 
The resulting 1H NMR spectrum of [3-c] showed the disappearance of the imine signal 
with the corresponding appearance of the methylene signal at 3.72 ppm. 
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 Figure 2.8:  Synthetic scheme of tachmb [3]. *Isolated yield.         
 
The last step for the synthesis of tachmb [3] was the deprotection step of the 
tachmonobenz.diBoc [3-c]. The hydrolysis of Boc was performed using concentrated 
HCl which was added to the solution of tachmonobenz.diBoc [3-c] in methanol and 
stirred for 3 hours. The solvent was then evaporated and the residue was taken up in 
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to acidic water (pH=2) and extracted with ethyl acetate. The organic layers were 
discarded, and the pH of the aqueous layers was modified to pH 14 and then extracted 
with dichloromethane.                                       
The final yields were usually low (approx. 45%). The ESI-MS showed evidence for the 
tachmonobenz [3] at m/z 220.18 and no peaks for the di-substituted compound were 
present. 
 
                              
Figure 2.9: Structure of Tachmonobenz.monoBoc [3-I]. 
 
When the deprotection reaction with HCl was performed on a large scale (0.6 mmol) 
the ESI-MS showed a peak for [3-I] compound, (Figure 2.9), at m/z 320.23 implying that 
the reaction was not complete. For this reason, the reaction was repeated again but it 
was left to stir for 18 hours in an ice-bath. Increasing the reaction time caused 
problems due to the hydrolysis of the benzyl arm of the ligand. However, the yield 
increased slightly to 51 % and full characterization showed clear evidence for the 
tachmb [3]. The 1H NMR spectrum showed the characteristic mono-substitution 
pattern (Figure 2.10). Using 1H NMR spectroscopy, it is possible to demonstrate the 
difference between tach signals, [2], to the benzyl substituted ligand, [3]. The benzyl-
arm of ligand [3] causes the loss of C3 symmetry and introduces a new Cs symmetry to 
the molecule. This leads to two sets of signals for each of the tach protons contained 
in the mirror plane and one for the others. The aromatic protons of the phenyl ring 
appeared at 7.26 ppm (Figure 2.10), and the COSY NMR spectrum (Figure 2.11), 
highlights the coupling between the tach protons. 
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Figure 2.10: 1H NMR spectrum of tachmb [3] in d4-MeOH. 
 
 It is possible to explain the splitting pattern of the aliphatic signals observed. The most 
deshielded protons b and b- at 2.7 and 2.5 ppm respectively, appear as triplet of triplets 
due to large geminal coupling (12.2 Hz) with the two axial protons aax, a-ax and small 
coupling (4 Hz) with the two equatorial protons aeq, a-eq, while the broad doublet of 
equatorial protons is a result of having the same coupling constant to both aax and b. 
Proton aax has two different coupling constants (3Jax-ax = 12 Hz; 3Jax-eq = 4 Hz). 
 
aax 
aeq 
a-eq 
 
b 
b- 
c e,f 
g 
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Figure 2.11: COSY NMR of tachmb [3](showing details of the aliphatic region only, 
recorded in d4-MeOH). 
 
The 13C NMR spectrum, along with the DEPT 135 helped to assign the carbons bound 
to two protons (a,a-) at 40.6 and 42.5 ppm for a and a- respectively.  The carbon 
attached to only one proton, b, appeared at 43.5 ppm while b- resonated at lower field, 
52.3 ppm, due to the proximity of the highly electronegativity amine groups. The most 
deshielded of the protons was for the quaternary carbon d which appeared at 140.3 
ppm. The identity of this signal was confirmed by the disappearance of the peak in 
DEPT spectra (although the DEPT is quite weak) as shown in Figure 2.12. 
 
 
 
aax 
aeq 
a-eq 
b b
- 
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 Figure 2.12:  13C{1H} NMR (top) and DEPT 135 (bottom) spectra for tachmb [3], 
recorded   in d4-MeOH. 
 
A long-range correlations 1H-13C heteronuclear experiment HMBC, (Figure 2.13), then 
assigned proton c from its correlation with carbons e and f and quaternary carbon d in 
the benzyl substituent, and also highlights the coupling between proton and carbon 
atoms in the aromatic ring (e, f, g). The HMQC allowed to complete and confirm the 
assignment of the 1H and 13C spectra and illustrates the direct, one-bond coupling 
between each of the protons and carbon atoms, (Figure 2.14). 
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Figure 2.13: HMBC spectrum of tachmb [3], recorded in d4-MeOH. 
 
An ATR spectrum was recorded which showed all the stretching and bending of the 
secondary amine at 3340 and 736 cm-1 respectively and the bending at 1570 cm-1 
assigned to the primary amine. The CH stretching and bending of the aromatic ring 
could be observed at 3059 and 698 cm-1 respectively.  
 
 
c e,f 
g 
g 
e,f 
d 
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Figure 2.14: HSQC spectrum of tachmb [3], recorded in d4-MeOH. 
 
Several crystallisation methods were attempted to obtain single crystals suitable for X-
ray diffraction, such as slow evaporation from methanol or water and methanol/ether 
diffusion, but all the attempts were un successful. The purity of the new ligand tachmb 
[3] was investigated by elemental analysis, which indicated the presence of water 
within the structure (also highlighted by 1H NMR spectroscopy). As mentioned 
previously, the aim of the benzyl modification was to explore the contribution of the 
one-armed tach ligands such as [3] to antiproliferative activity. In order to perform this 
study, the high purity and good water solubility of [3] were essential qualities. The 
effect of compound [3] in two cancer cell lines was investigated by MTT assay (Chapter 
5), and a study of the coordination of ligand [3] to ruthenium metal precursors can be 
found in (Chapter 3). 
 
aax aeq 
b 
c 
e,f 
g 
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2.3 Conclusion 
 
Developing the structure of cis-tach ligand [3] has been achieved by using 
benzaldehyde and following the Schiff base methodology. In order to selectively 
achieve a mono-substituted ligand, two of the three amine moieties were first 
protected using di-tert-butyl dicarbonate (Boc2O) to obtain a tach-diBoc [3-a]. Further 
reaction with the aldehyde under anhydrous conditions allowed the formation of imine 
compound-tachimben [3-b] which has been reduced to mono-amine compound [3-c] 
using sodium borohydride. Reduction to the amine compound increases both the 
stability and solubility of the molecule. To achieve the final target, the Boc 
deprotection has been performed and the tachmben [3] has been isolated with 51% 
yield and high solubility in water. The new ligand has been characterized by NMR 
spectroscopy, mass spectrometry and IR spectroscopy and the purity was indicated by 
CHN analysis.
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3 Synthesis and characterization of 
Ru(II)tachmonosubstituted complexes. 
 
3.1 Introduction 
 
Metal complexes consist of a coordination centre (which is a metal ion) and 
surrounding bound molecules or ions (known as ligands).212 Coordination or metal 
chelation is an outstanding method to increase the lipophilicity of a ligand and hence 
the bioactivity profile might improve.213, 214 On coordination to a metal, the inactive 
ligand may achieve pharmacological properties that turn it into a structure-selective 
binding agent for biomolecules or nucleic acids. Much research indicates that the 
pharmacological and medicinal activity depends strongly on the nature of the metal 
ion,214 as metal complexes offer many possibilities for the design of different varieties 
of drugs which are not available to organic compounds.215, 216 This versatility is due to 
a wide range of possible coordination numbers, geometries and oxidation states of the 
metal centre.217, 218 Furthermore, the ability of metals to undergo ligand exchange 
reactions allows them to coordinate to, and interact with, biological molecules.219 All 
of these properties have stimulated the research in medicinal chemistry field since the 
accidental discovery of cisplatin in the 1960s.220, 221 Platinum-and ruthenium-based 
complexes are the most commonly studied transition metals in this field.83, 222, 223  
Ruthenium metal complexes have attracted considerable attention in the 
pharmaceutical field, as they may overcome the negative aspects of platinum-based 
drugs.92 Different Ru(II) and Ru(III) complexes have been prepared with amine, imine, 
dimethyl sulfoxide, diphosphine, and N-heterocyclic ligands that exhibit interesting 
DNA binding properties,92, 99 however the main disadvantage of these complexes were 
their limited solubility in aqueous solution, hence the solubility of metal complexes are 
very important in administration and transport.92 The most soluble, and most 
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successful, ruthenium-based anticancer complex is [trans-RuCl4(DMSO)Im][ImH], 
NAMI-A, (Chapter 1) whose solubility is increased by presence of dialkyl sulfoxide 
ligands.216, 224  
On the other hand, previous studies suggest that the presence of hydrophobic PPh3 
ligand in the complex sphere of Ru compounds such as RAPTA[tpp]-C and RAPTA[tpp]-
O1, (Figure 3.1), results in more cytotoxic and less selective bioactivity, perhaps due to 
increased drug uptake.99 Recent study of the influence of the triphenylphosphine 
moiety on several ɳ6-arene ruthenium (II) complexes of the type [Ru(p-
cymene)Cl(PPh3)(L)] (where L are pyridine derivatives), showed that the PPh3 ligand 
leads to increased ruthenium complex antiproliferative activity in comparison to 
complexes lacking a PPh3 ligand.225 
 
 
 
Figure 3.1: Structure of two RAPTA complexes, RAPTA[tpp]-C (left) and RAPTA[tpp]-
O1 (right). 
 
The use of phosphine ligands in anticancer complexes is favourable as these ligands 
have both σ-donor and π-acceptor character and are therefore able to stabilize metals 
in both high and low oxidation states.226 Furthermore, biphosphine (P–P) ligands also 
play an important role in catalysis and in bioinorganic chemistry (which first started 
with gold(I) complexes).227, 228 Ruthenium(II) piano stool complexes incorporating a 
chelating diphosphine ligand showed high activity in several human cancer cell lines, 
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(Figure 3.2), and have been investigated in several studies229-232 ([(p-cymene)RuCl(p-
p)],  where p-p = dppm and dppe).233 
Most recently, three new ruthenium complexes with general formula 
[Ru(Spym)(bipy)(P–P)]PF6, [Spym = pyrimidine-2-thiolate; bipy = 2,2'-bipyridine; P–P = 
1,2-bis(diphenylphosphino)ethane, 1,3-bis(diphenylphosphino)propane or 1,1'-
bis(diphenylphosphino)ferrocene)] were synthesized and their in vitro antitumor 
activity was tested using the MDA-MB-231 human tumor cell line. All three complexes 
displayed a high degree of cytotoxicity, even higher than that of cisplatin at the same 
concentration.234 
Furthermore, several ruthenium(II) cis-tach complexes have been prepared using 
different precursors with promising in vitro cytotoxicity against two cell lines: A549 and 
A2780 mentioned in Chapter 1. Two complexes with diphosphine ligands showed 
activity higher than cisplatin in the A549 cell line.  
 
 
 
Figure 3.2: Structures of different ruthenium(II) diphosphine complexes exhibited 
anti-tumour activity [RuCl(p-cymene)(p-p)]PF6 (left) and [Ru(Spym)(bipy)(P–P)]PF6 
(right) 
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In view of the facts above, it was thought worthwhile to explore the coordination 
chemistry of tachmonoben [3] to expand the library of this promising set of ruthenium 
complexes containing the tach ligand. 
 
 
 
Figure 3.3: Three precursor Ru-A, Ru-B, and Ru-C used to synthesise new 
ruthenium(II)tachmb complexes. 
 
With the aim of developing a potent complex with the modified tach ligand [3], several 
ruthenium tachmb [3] complexes have been synthesised using different ruthenium 
precursors (Figure 3.3). Each of the metal precursors was chosen for a different reason. 
The well-known [cis-Ru(DMSO)4Cl2], Ru-A,  had already shown in vivo activity against 
metastases and binding affinity to DNA.102, 235 The formally sixteen electron complex 
[Ru(PPh3)3Cl2], Ru-B, has a relatively labile ligand (triphenylphosphine) that allowes for 
additional donors to coordinate236 (Figure 3.3). This precursor can coordinate different 
facially capping ligands such as tris(pyrazolyl)borate (Tp) and ɳ6-cyclopentadienyl (Cp) 
to produce [RuCl(PPh3)2(X)] (X = Tp and Cp),237 and therefore was selected to 
coordinate with [3]. Due to the background of promising biological activity for 
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ruthenium complexes containing diphosphine ligands mentioned earlier, the chemistry 
of Ru-C (containing a dppb ligand) was also investigated with modified tach ligand [3]. 
Upon coordination of ligand [3] to each of the ruthenium precursors, the resulting 
complexes were then studied in antitumor activity (Chapter 6). 
 
3.2 Reaction of tachmonoben [3] with [Ru(DMSO)4Cl2], Ru-I 
 
The preparation of tach-containing ruthenium(II)DMSO complexes employs a widely 
used starting material [cis-RuCl2(DMSO-O)(DMSO-S)3], which is prepared directly from 
the reaction of RuCl3.3H2O with DMSO as a solvent .238 This strategy has been improved 
by Alessio to overcome the main drawback and achieve Ru(II) DMSO complexes in high 
yield (approx. 80%) and excellent purity.102 
Gamble prepared [RuCl(cis-tach)(DMSO-S)2]Cl by heating [cis-RuCl2(DMSO-O)(DMSO-
S)3] with tach in DMSO at 130˚C for 30 minutes (Figure 3.4).179, 180 It was proposed that 
the reaction of tachmonoben [3] with [cis-RuCl2(DMSO-O)(DMSO-S)3] would follow a 
similar route, so identical conditions to those of Gamble were employed for the 
reaction. After 30 minutes of heating at 130 °C, ethyl acetate was added to the reaction 
mixture in DMSO with cooling to -20˚C, however no precipitate was observed (as was 
seen in Gamble’s preparation). Therefore, all of the solvent was evaporated to leave a 
yellow solid.  
 
 Figure 3.4: Synthesis of [RuCl(cis-tach)(DMSO-S)2]Cl, [4] by Gamble. 
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The 1H NMR spectra of the solid in deuterated DMSO solution did not appear to 
confirm that coordination of the ligand to the metal had occurred; the spectrum still 
exhibited the aromatic signals due to the benzyl ring of [3], and also only a slight shift 
in the position of the tach protons signals was observed. Furthermore, the 
complexation was evidenced by the observation of small peak of the molecular ion 
peak in ESI mass spectrum (at m/z 512) with the expected ruthenium and chlorine 
isotope pattern.  
Several crystallisation methods were attempted in order to isolate the complex and to 
obtain single crystals suitable for X-ray diffraction. Slow evaporation of a methanol 
solution of [RuCl(tachmonobenz)(DMSO-S)2]PF6 (obtained from chloride metathesis 
with sodium hexafluorophosphate) twice produced ruthenium-containing crystals. 
However, the crystals that appeared from both attempts were not those of the 
expected Ru(II) complex, but instead belonged to the starting material [cis-
RuCl2(DMSO-O)(DMSO-S)3], Ru-A. 
As these results were inconclusive, the complexation reaction between tachmb [3] and 
[cis-RuCl2(DMSO-O)(DMSO-S)3] was repeated in an NMR tube using deuterated DMSO 
solvent, so that the formation of the product could be monitored by NMR 
spectroscopy. The reaction was heated at 50 ˚C for two hour intervals, and the 1H NMR 
spectrum was recorded every two hours to follow the reaction. The NMR spectrum 
showed noticeable change after the first two hours, but heating for more than two 
hours did not cause any further change. Full characterisation of the compound was 
performed by NMR and MS spectroscopy. The 1H NMR spectrum showed two sets of 
signals for all the protons, (Figure 3.5). 
 As shown in Figure 3.5, the axial proton aax and the aromatic protons e, f, and g have 
two signals. The coordinated DMSO signals were too complicated to assign and again 
have more than two signals. Methylene proton c was expected to appear as a singlet 
but instead it existed as two singlet resonances. Moreover, the total integration of the 
protons gave more than the expected number of protons of only one complex, so it is 
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expected that two of the tach amine groups were coordinated with the ruthenium 
metal which leads to the presence of two or three isomers in solution.  
 
 
Figure 3.5: 1H NMR spectra of the reaction mixture of [Ru(DMSO)4Cl2] and tachmb [3] 
in DMSO solvent after 2 hours at 50˚C. 
 
Clear evidence for the isomer formation was given by ESI-MS. A peak was observed at 
m/z 565.12 (rather than at the expected m/z of 512) which corresponds to the 
[RuCl2(tachmb)(DMSO-S)2] compound. Therefore, it was presumed that these isomers 
were an intermediate for the reaction (Figure 3.6). 
aax DMSO 
c 
e, f 
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Figure 3.6: Proposed structure of [RuCl2(tachmonoben)(DMSO-S)2] isomers. 
 
The complexation reactions were repeated again with the same solvent (deuterated 
DMSO) in an NMR tube but the temperature was increased to 130°C for 30 min in order 
to drive the reaction to completion. The 1H NMR showed the disappearance of the two 
sets of the signals with small shift in proton signal and the appearance of a DMSO peak 
near 3.36 and 2.50 ppm but the integration showed more protons than expected. 
Furthermore, the ESI-MS showed an unexpected result. The peak with the greatest 
mass to charge ratio in the spectrum at m/z 538.6 was assigned to a dimer along with 
a small peak of the deuterated Ru-tachmonoben complex, so the protonated DMSO 
was used but the same result was found in both NMR and ESI-MS spectrum. Several 
crystallisation methods were tried in order to isolate the complex, slow evaporation of 
a methanol solution of the reaction mixture obtained from chloride metathesis with 
sodium hexafluorophosphate followed by filtration, gave crystals suitable for X-ray 
diffraction analysis. The obtained crystals did not belong to the expected ruthenium 
tachmb complexes, but to the ruthenium dimer shown in Figure 3.7. 
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Figure 3.7: the asymmetric unit of Ruthenium dimer (thermal elipsoids are at 50 %) 
(Left) , and the unit cell which shows the packing in the crystal (right). 
 
On the basis of these results, it was concluded that DMSO was not a suitable solvent 
for this reaction and choosing another solvent would be preferable.   
The complexation reaction has been performed in different solvents (MeOH, THF and 
H2O) and water was found to be the best solvent for the reaction of tachmonoben [3] 
and [Ru(DMSO)4Cl2] as clearly evidenced by the 1H NMR spectrum shown in Figure 3.8. 
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Figure 3.8: 1H NMR spectra of the reaction mixture of Ru(II)tachmonoben, [5] (top) and 
tachmonoben, [3] (bottom) in D2O solvent after heating for two hours.  
 
When both reagents were dissolved in D2O, the 1H NMR spectrum showed a small 
downfield shifting in the tachmb [3] resonances, while the ESI-MS spectrum did not 
show any peaks for the complex or Ru-fragmentations (only the free ligand was 
observed). Therefore, the reaction mixture was heated for 2 hours at 50 °C and 
followed by 1H NMR spectroscopy. The heating was stopped when the colour changed 
to deep yellow. The NMR spectra showed that the axial and equatorial (a) tach protons 
had been shifted to 1.24 and 2.26 ppm respectively with a high 2J coupling (14 Hz) 
between them. A resonance for coordinated DMSO at 3.2 and 2.3 ppm and the 
presence of the aromatic resonance suggested the coordination of tachmb [3] to 
ruthenium, so the solvent was evaporated to leave an oily residue which was 
recrystallized from methanol and diethyl ether and gave a brownish- yellow 
precipitate, dried under high vacuum in 66% yield. Clear evidence for the presence of 
the Ru-complex was given by LIFDI spectrum which showed the presence of 
[Ru(tachmonobenz)(DMSO)Cl2], [5] at m/z 469.04 with the expected ruthenium and 
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chlorine isotope pattern (Figure 3.9) along with unknown small peaks at m/z 335.05 
which leds to presume the presence of impurities.  
 
Figure 3.9: Preparation of [Ru(tachmonobenz)(DMSO)Cl2], [5] in H2O solvent 
 
The ATR-IR spectrum provided  further evidence for the presence and the coordination 
mode of the dimethylsulfoxide, in which the band appears at 1092 cm-1 at the same 
boundary for S-DMSO (1070-1233).224 
In the 1H NMR spectrum, the protons for the tachmb ligand exhibited resonances 
expected for a species in a C1 symmetry environment around ruthenium metal (the 
symmetry was discussed in Chapter 2) which is different from the symmetry of the 
starting ligand that has a CS symmetry, therefore it was hypothesised that a complex 
has been formed. In addition, the presence of two resonance for the DMSO methyl 
groups confirmed a C1 symmetry. The C1 symmetry possesses a one-fold axis so it is 
expected to present of all the 1H environments illustrated in Figure 3.10. 
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Figure 3.10: Scheme used for the characterization of Ru-tachmonoben , [5]  
 
Although there is some overlap in the signal peaks, particularly in the regions from 3.0 
to 3.5 ppm, the use of 2D NMR spectroscopy can improve this considerably. In the 
aliphatic region, the signal can be assigned by using the correlation spectroscopy 
(COSY) NMR that highlight the coupling between CH and CH2 protons. Furthermore, it 
was possible to assign the coupling between amine groups which are also partially 
overlapping with other signals. 
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Figure 3.11: Part of the 13C {1H} NMR for compound [5] recorded in D2O   
 
The 13C{1H} NMR spectrum in Figure 3.11 presents, as expected, six signals to the CH 
and CH2 protons for tachmb resonance and the CH2 signals were confirmed by DEPT 
135. The two inequivalent DMSO methyl groups and methylene proton c were assigned 
on the basis of HSQC NMR spectrum that highlights the 1JH-C couplings, correlating the 
protons to the carbon which they are bound to. The higher deshielding region shows 
three signals for the aromatic protons and the most deshielded signal at 137.4 ppm 
was assigned to d proton. 
  a2 a3 
a1 
b2   b3 S(1) 
S(2) 
b1 c g 
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Figure 3.12: HSQC spectrum of [5] recorded in D2O 
 
Although the assignment for the resonance in [5] can be performed, the integration of 
the resonance in the crowded area was more than actual number of proton within the 
complex. This indicates that there are some impurities as highlighted before in MS 
spectrum and it was further confirmed by unsuccessful elemental analysis. 
The complex could not be isolated with analytical purity, and a suitable crystal could 
not be obtained. Therefore complex [5] was excluded from biological evaluation 
carried out in Chapter 5, and also an alternative synthetic method must be explored.      
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3.3 Synthesis of Ru(II)tachmb triphenylphosphine complexes 
 
 As the preparation of a pure Ru(II)tachmb precursor was not achieved with 
[Ru(DMSO)4Cl2], Ru-B, as precursor, the use of another ruthenium complex was 
required. Dichlorido-tris(triphenylphosphine) ruthenium(II) is a preferable complex as 
the electron deficiency around the ruthenium centre (16 electrons) induced ligand 
binding. Furthermore, the triphenylphosphine ligand is relatively labile which allows 
for coordination to another electron donor.236 
 In order to explore the reaction of the modified ligand tachmb [3] with [RuCl2(PPh3)3],  
the reaction was performed using the same conditions as for the corresponding 
reaction with cis-tach.179 In a sealed NMR tube, one equivalent of tachmb [3] was 
added to [RuCl2(PPh3)3] in CD2Cl2 solvent. The colour changed from brown to orange 
then, after 10-15 min, a yellow solution was formed. 
 
Figure 3.13: Synthesis of [Ru(tachmb)Cl2(PPh3)] [7] from the reaction of tachmb[3] 
and [Ru(PPh3)3Cl2] in DCM. 
 
The complex formation was monitored by 31P {1H} spectroscopy and spectra were 
recorded every half hour (Figure 3.14). The first spectrum showed two doublet 
resonances at δp 36.3 and 46.7 ppm (2Jpp of 30 HZ), with two small singlet peaks at δp 
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61.5 and 67.4 ppm. In addition to a single sharp resonance at δp -11 ppm for the 
liberated triphenylphosphine, these spectra are distinctly different to the starting 
material spectrum which exhibits a broad resonance at δp 45ppm. The integrations 
showed a ratio of 1:2 for the liberated triphenylphosphane to the two doublets, 
suggesting two phosphine ligands remain coordinated to the metal as expected for 
[Ru(tachmb)(PPh3)2Cl]+, [6]+.  After one hour, the intensity of the two doublet 
resonances decreased with a corresponding increase of the small single peaks, at 61.5 
and 67.4 ppm suggesting that [Ru(tachmb)(PPh3)2Cl]+ is an intermediate in the reaction 
and a new product was formed. After several hours the peaks for  
[Ru(tachmb)(PPh3)2Cl]+, [6]+ were no longer observed with the presence of the two 
single peaks in a ratio of half that of the liberated triphenylphosphine suggesting the 
displacement of a triphenylphosphine group of [6]+and [Ru(tachmb)Cl2(PPh3)], [7] is 
the product from the charge-neutralization occurring between the chloride anion and 
[Ru(tachmb)(PPh3)2Cl]+, [6]+ yielding the neutral complex [Ru(tachmb)Cl2(PPh3)],[7] 
(Figure 3.14 and 3.15) and free PPh3.  
 
 
 Figure 3.14: 31P{1H} spectra for the reaction progress of [Ru(PPh3)3Cl2] and tachmb[3] 
in CD2Cl2. 
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The identity of [7] was assigned by cross-peaks in the 2D 1H-31P correlation spectrum 
(HMBC) that show long range correlations (from 2ꓙ to 4ꓙ coupling) (Figure 3.10). The 
first singlet peak at δp 67.4 ppm has four cross peaks two with ortho and meta protons 
of phenylphosphine and the other two with amine protons of the tachmb ligand and 
the adjacent CH proton (b), while the second singlet peak at δp 61.5 ppm also has two 
cross peaks with phenylphosphine (ortho and meta protons) while the two others were 
assigned to substituted amine NH and methylene proton (c) bound to it. The 2D NMR 
confirms the presence of structural isomers of [7] depending on the orientation of the 
triphenylphosphine relative to benzyl and based on the cross peaks, the two isomers 
A and B were presumed. Isomer A is the main product based on the intensity of the 
phosphorus peak and the integration that shows 1:0.5 for the two peaks. Also, the 
trans isomer shows high coupling than cis isomer (Figure 3.15). It was possible to 
explain the different intensities based on the statistical distribution expected for A over 
B is 2 to 1 since there were a possibility to couple to two different NH2 groups. 
 
Figure 3.15: 31P{1H} spectra for the reaction progress of [Ru(PPh3)3Cl2] and tachmb [3] 
in CD2Cl2. 
 
P(A) 
P(B) 
Ho 
Hm 
Hc b NH2 
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The conversion of complex [6] to [7] is further supported by LIFDI spectrum which 
exhibit high intensity peaks at m/z 880.24 immediately after mixing, with the expected 
ruthenium and chlorine isotope pattern assigned to [6]. Then, after 3 hours, one peak 
for [Ru(tachmb)Cl2(PPh3)], [7], was observed at m/z 653.24. 
 
 
Figure 3.16: The two isomers A and B for [Ru(tachmb)Cl2(PPh3)],[7] with scheme used 
for the characterization for [7]. 
 
This assignment is in accordance with that reported for a similar reaction with cis-
tach,180 but the reaction with tachmb [3] was faster than cis-tach as the conversion 
from [6] to [7] was happened within 6 hours while [[Ru(cis-tach)Cl2(PPh3)] has formed 
after 2 weeks which may be a consequence of the bulkier tachmb [3] ligand assisting 
phosphine dissociation. 
The tachmb [3] protons in 1H NMR spectrum exhibited different resonances when 
interacting with [Ru(PPh3)3Cl2]. The absence of axial-axial coupling (3JHH = 10 Hz) with 
the existence of large coupling (2JHH = 16.8 Hz), confirmed that the expected ring-flip 
on coordination to metal has occurred causing the appearance of a doublet for both 
aax and aeq protons, suggest that the ring-flip has occurred and all amine groups are 
adopting an axial conformation. This is confirmed by the appearance of the amine 
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resonance at higher field (4.5-6.5 ppm) and this would occur only when amine groups 
coordinated to ruthenium metal in a К3 fashion. 
The 1H NMR spectrum of [7] exhibited two sets of resonance belonging to the two 
isomers A and B that were presumed from the 2D 1H-31P NMR. The set of stronger 
signals indicates the formation of isomer A (major product) while the weaker one is 
assigned to isomer B (minor). The proton resonances from tachmb [3] or aliphatic 
groups were observed with considerable overlap in the high-field region from 1 to 3.5 
ppm. By considering the heteronuclear (HMBC and HMQC) spectra and DEPT 135 
spectrum this problem can be resolved (Figure 3.17), proton signals in this region were 
assigned to the resonance of CH2 and CH protons, while the signal observed at 3.8 ppm 
belongs to methylene proton c due on the observed cross peaks to d and f protons in 
phenyl arm in HMBC spectrum. The signals from 4.5 to 6.3 ppm were assigned to amine 
groups by disappearance of the cross peaks in 2D HMQC spectrum in comparison to 
the 1H NMR spectrum. Nine resonances were observed for the tachmb ligand in the 1H 
NMR spectrum [7] which suggests Cs symmetry around ruthenium metal. Furthermore, 
the single resonance for the coordinated phosphorus nuclei at 67.4 and 61.5 ppm 
indicates a Cs symmetry and free rotation of phenyl rings for each isomer.  
 
The signals in the low-field region below 6.5 ppm were attributed to protons of 
aromatic rings. The assignment of carbon signals in this region were doublets for the 
carbon of the phenyl ring in (PPh3) which is due to the 13C nucleus coupling to a single 
31P nucleus and this confirmed the presence of only one triphenylphosphine ligand 
coordinated to the metal complex. 
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Figure 3.17: HSQC spectrum of aliphatic region [7] recorded in CD2Cl2, black (A), red 
(B). 
 
Complex [7] was isolated by precipitation on addition of pentane to a dichloromethane 
solution (×3), giving a brown powder in good yield 64% and high purity as shown by 
elemental analysis. 
 
3.4 Synthesis of Ru(II)tachmb diphosphine complex 
 
To further develop ruthenium(II)tachmb complexes it was proposed to explore the 
coordination chemistry of [Ru(tachmb)Cl2(PPh3)], [7] with chelating diphosphine 
ligands. Therefore, a solution of [7] with an excess of dppp in CD2Cl2 was heated at 50◦C 
in a sealed NMR tube and monitored by 31P[1H] NMR spectroscopy. The spectrum 
showed a new species with two doublet resonance at -20.5 ppm and δp 48.6 ppm and 
these resonances are coupled to each other by a 2Jpp of 31 Hz. The resonance at -20.5 
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ppm is evidence of the coordination of the dppp in a К1 fashion (Figure 3.18). Further 
heating of the solution for two days in an attempt to obtain the target complex 
[Ru(tachmb)(dppp)Cl]Cl, resulted in no further change. 
 
Figure 3.18: Proposed structure of the complex formed in the reaction between 
[Ru(tachmb)Cl2(PPh3)], [7] and dppp. 
Due to problematic displacement of the chloride described above, an alternative 
synthetic method was sought to expand the library of Ru(II)-tachmb complexes, 
therefore it was suggested to prepare [RuCl2(PPh3)(P-P)] first then coordinate with 
tachmb [3]. 
 
Figure 3.19: 31P [1H] spectra for the reaction progress of [RuCl2(PPh3)(dppb)], [8] and 
tachmb[3] in CD2Cl2. 
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The preparation of [RuCl2(PPh3)(dppb)], Ru-C was previously reported.240 Reaction of 
two equivalents of tachmb[3] was performed with Ru-C in a sealed NMR tube in CD2Cl2, 
resulted in a colour change of the solution from deep green to yellowish-green. As 
illustrated in Figure 3.15 the 31P{1H} NMR spectrum of the solution exhibited two 
doublet peaks initially, then several doublet peaks in the region (35-50) ppm appeared 
that changed with time. After standing for one day the reaction appeared to reach 
completion and a yellow solution was formed. Spectroscopic evidence demonstrated 
the tachmb[3] has been incorporated within the coordination sphere by two of the 
nitrogen groups forming an intermediate [8] first (the same behaviour indicated 
previously), then transforming to [9]; the 31P{1H} NMR spectrum showed four 
characteristic doublet resonances at 35-50 ppm, in addition to singlet resonance at -
4.90 ppm assigned to liberated triphenylphosphane, suggesting the coordination of 
(dppb) to the ruthenium(II) metal (Figure 3.19). These resonance were mutually 
coupled (2Jpp of 35.2 Hz), demonstrating inequivalent phosphorus nuclei within the 
complex and the presence of two structural isomers of [Ru(tachmb)(dppb)Cl]+ [9] with 
respect to the phenyl arm (Figure 3.20). Further evidence for this compound was given 
by LIFDI spectrum that exhibited a peak for [Ru(tachmb)(dppb)Cl]Cl [9] at m/z 782.20 
without any fragmentation or other signal, and with the expected ruthenium and 
chlorine isotope pattern. 
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Figure 3.20: Synthesis of [Ru(tachmb)(dppb)Cl]Cl, [9]Cl from tachmb[3] and 
[Ru(PPh3)(dppb)Cl2] [8] in DCM solution 
 
Although the 1H NMR spectrum was very complex (Figure 3.21), it was able to provide 
an indication of the existence of the complex due to the presence of different 
resonance compared to the tachmb [3]. The spectrum showed the existence of the 
ligand signals and dppb signal, the presence of the coordinated amine resonances that 
appeared at low field region and the integration of the protons give the exact number 
of protons in aliphatic and aromatic regions. The assignment for each proton was 
difficult due to the decomposition of compound in solution thus 2D NMR did not give 
any helpful information. 
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Figure 3.21: 1H NMR spectra of Ru(II)tachmonoben, [9] (bottom) and tachmonoben, 
[3] (top) in CD2Cl2 solvent. 
 
The cationic species for [9] is readily obtained without chloride metathesis with weakly 
coordinating anions such as hexafluorophosphate and this will provide extra advantage 
in clinical preparation and avoids incorporation of potentially toxic species. The 
complex was isolated with good yield 71% and the purity was indicated by CHN analysis 
with three water of crystallization. The solvent composition was also verified by the 1H 
NMR spectrum. 
 
3.5  Conclusions 
The coordination chemistry of modified ligand [3] with ruthenium metal has been 
performed using different ruthenium complexes as coordination centres: 
H2O 
Ligand benzyl 
Phenyl(P) 
amine 
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[Ru(DMSO)4Cl2], [RuCl2(PPh3)3], and [Ru(dppb)(PPh3)Cl2]. Three complexes were 
obtained: [5], [7] and [9] respectively. 
Complex [5] was prepared and it was found that water was the best solvent for this 
reaction. This complex was isolated and fully characterized by a range of spectroscopic 
techniques but the purity could not be confirmed by elemental analysis. 
Complex [7] was readily obtained in DCM solvent after charge neutralisation reaction 
for [6]+ within two hours. This complex was isolated with high purity and full 
characterization has been done that showed the presence of pairs of isomer A and B 
which are attributed to the different types of coordination modes between the metal 
and ligand. This behaviour was also observed for [9] and confirmed by 31P NMR 
spectroscopy. Although this complex purity was approved by elemental analysis the 
characterisation could not be done due to the decomposition of the compound in 
solution. 
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4 Biomolecule interaction of Ru(II)tach complexes 
 
4.1 Introduction 
 
Numerous ruthenium (II) complexes have been utilized in chemo and photodynamic 
therapy and have been certified by in vitro and in vivo studies,92 since the discovery of 
two ruthenium(II) complexes [Ru(bpy)2(dppz)]2+ and [Ru(phen)2(dppz)]2+ that 
intercalate into DNA with the ability to act as a “light switch”.241, 242 
Anticancer compounds have a myriad of targets (DNA, proteins, membranes, etc.)  and 
in fact the true potential mechanism responsible for the biological activity of any given 
compound is often difficult to determine.243 
DNA represents a fertile target for metal complexes.32, 243 In cancer cells, DNA can be 
preferentially damaged either through interactions with the sugar-phosphate 
backbone or coordination to the bases. Furthermore, non-covalent interactions with 
DNA lead to additional targets and more specificity by three modes of action (Figure 
4.1): intercalation, groove binding and static electronic interactions.244, 245 In static 
electronic interactions, the molecules interact with the negatively charged DNA double 
helix externally through a non-specific interaction. Groove binding refers to molecules 
that bind DNA in the base edges of the major groove or minor groove.5  
The most commonly studied mode of action is intercalation, which is another DNA 
binding mode that is closely related to the antitumor ability of many anticancer 
compounds.246 Intercalative binding is the non-covalent stacking interaction with the 
DNA double helix in a reversible manner resulting from the insertion of a planar 
heterocyclic aromatic ring between the base pairs of the DNA double helix.247, 248  
Early work focused on intercalation by octahedral complexes containing at least one 
aromatic heterocyclic ligand for stacking, or partial intercalation, in between base 
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pairs.249 One of the first classes of ruthenium complexes that was shown to interact 
with DNA included Ru(II) tris(phenanthroline) complexes and derivatives; these 
complexes had good chemical stability, high luminescence and an intense metal-to-
ligand charge transfer (MLCT) band in the visible spectrum.10 Many ruthenium(II) 
complexes with phenazine derivatives have shown promising results as DNA-linkers 
and interact with nucleobase pairs of the DNA, as the 1,10-phenanthroline presents a 
rigid and planar structure with a highly conjugated electron cloud.250 In addition to all 
the properties noted above, Ru(II) complexes with a phenanthroline ligand display high 
redox potential, photo physical and photochemical properties.249 
 
 
 
Figure 4.1: Non covalent interaction with a double helical DNA. 
 
The polypyridyl ligands initially used were 2,2’-bipyridine (bpy), 1,10-phenanthroline 
(phen) and 4,7-diphenyl-1,10-phenanthroline (DIP)251 (Figure 4.2). By studying the 
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difference in photophysical properties in the presence of DNA, it was observed that 
[Ru(bpy)3]2+ has little or no binding to the nucleic acid, while results for [Ru(phen)3]2+ 
and [Ru(DIP)3]2+ suggested that binding could occur by two possible modes: 
intercalative or electrostatic interaction depending on the chirality of the enantiomer 
of the complex, where the ∆ isomer was able to intercalate, while the Λ isomer could 
only bind electrostatically, through interactions to DNA.  
 
 
Figure 4.2: Ru (II) polypyridyl complexes. 
 
The results suggest that the interactions with these nucleic acids are enantioselective, 
with the ∆ enantiomer of the complex binding more favourably than the Λ enantiomer. 
This shows that the twist of the Δ enantiomer is a better fit to the right-handed helix 
sense of the DNA backbone,249 and could therefore intercalate more effectively. 
Barton suggested an increase in ligand surface area would enhance the low binding 
affinity for these complexes for DNA (equilibrium binding constant Kb ~103 M-1) (Figure 
4.2).252 Recently the synthesis of Ru(II) complexes that have ligands possessing a large 
aromatic surface area for intercalation such as dipyrido[3,2-a:2’,3’-c] phenazine (dppz) 
and [2,3-h] dipyrido [3,2-a:2′,3′-c] phenazine (pdppz) have been developed. Their 
ability to interact with oligonucleotides has been studied since the discovery of two 
ruthenium complexes by Barton and co-workers [Ru(bpy)2(dppz)]2+ and 
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[Ru(phen)2(dppz)]2+. It was reported that the dppz-based complexes bind to DNA with 
a high affinity (Kb~106 M-1)241 and in the presence of DNA the luminescence was 
switched on, a property known as the “light switch” effect which is assigned to 
intercalation253, 254 (Figure 4.3). A DNA light-switch compound is a compound that is 
non-luminescent in water but is able to luminesce in the presence of DNA.  This 
property makes the complexes interesting as probes for cell studies using fluorescence 
microscopy.255 
 
 
 
Figure 4.3: Structure of [Ru(bpy)2(dppz)]2 +(A) and [Ru(phen)2(dppz)]2+(B). 
 
Polypyridyl ruthenium complexes have also been used as intercalating photodynamic 
agents (Chapter 5).256 To better understand the cellular behaviour of ruthenium(II) 
arene complexes, which are promising anticancer compounds, their luminescent 
behaviour was developed by coordination of the dppn ligand (dppn = 4,5,9,16-
tetraaza-dibenzo[a,c]naphthacene) to produce  [(p-cymene)Ru(dppn)(py)]2+, (py = 
pyridine). This complex displays emission enhancement behavior and photocleavage 
activity towards DNA as it can emit fluorescence from the dppn-based singlet excited 
state and generate singlet oxygen from the dppn-based triplet excited state.257 
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Figure 4.4: Structure of [(p-cymene)Ru(dppn)(py)]2+, (dppn = 4,5,9,16-tetraaza-
dibenzo[a,c]naphthacene py = pyridine). 
 
These results inspired us to make different variations in the structure of the Ru(II)tach 
complex and determine how such changes affect their properties. The new ligand with 
extended aromatic groups, fluorescent diphosphine ligand FL-I represents a useful 
model for the synthesis of a new family of ruthenium tach complexes and the 
investigation of the cellular DNA binding. 
As part of ongoing investigations on the biological potential of the ruthenium tach 
complexes, an exploration of the possible transport mechanisms should be carried 
out. In particular, serum albumin has been one of the most extensively studied 
proteins for many years, as albumin proteins represent the first possible targets for 
metallodrugs after intravenous administration.258, 259 Among various serum albumin, 
bovine serum albumin (BSA) is the most extensively studied owing to its structural 
homology with human serum albumin (HSA).260, 261 
Ruthenium complexes of known anticancer activity have been shown to interact with 
serum albumin.259, 262 For instance, the interactions between Ru-based drug candidate 
KP1019 and plasma proteins (serum albumin and serum transferrin) were investigated 
by UV–vis spectroscopy and showed a higher degree of binding to serum proteins (80-
90%) than transferrin.263 The binding strengths of NAMI-A toward human serum 
albumin and other biomolecules (such as DNA) were examined by electrochemical and 
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biochemical methods and all the results confirm the preferential interaction of NAMI-
A with proteins as compared with nucleotides.264, 265 Indeed, recently RAPTA-T was 
considered to be  more reactive and could also bind selectively to serum proteins 
albumin and transferrin, while cisplatin was found to be moderately reactive towards 
the protein without any selectivity.157 
Although it is widely known that binding to DNA nucleobases, resulting in the distortion 
of the biomolecule and causing the inhibition of cell proliferation, is the main 
mechanism responsible for cytotoxicity,54  protein targets have moved into the centre 
of attention for ruthenium-based complexes.157 However, the dual-targeting function 
of ruthenium compounds inside cells has remained unverified,266 and following entry 
of the drugs into cancer cells is valuable for drug discovery.267 Different methods have 
been used to localize metallodrugs in tumour cells and, in case of ruthenium 
complexes, this fields still needs exploration.268  Complexes with a DNA switch 
behaviour are considered as suitable models for DNA imaging. This is only done by the 
formation of lipophilic compounds, as the classical DNA switch [Ru(bpy)2(dppz)]2+ was 
unable to permeate into cells due to its poor lipophilicity.269 
 For all of these reasons, the development of anticancer complexes targeting both DNA 
and protein is highly desirable. In this chapter, the ruthenium tach complexes were 
expanded by the incorporation of a fluorescent probe into the coordination sphere, 
and then the investigation of the biological properties of the Ru(II)tach complexes have 
focused on both the binding ability towards calf thymus (CT-DNA) (performed with UV 
spectrometry, fluorescence spectrometry and competitive binding studies with 
ethidium bromide (EB)), and the affinity with bovine serum albumin BSA protein 
(performed with fluorescence spectrometry). 
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4.2 Synthesis of new Ru-Tach complexes 
 
Adding a fluorescent probe to the coordination sphere of ruthenium has provided 
much information about the properties of metal compounds in biological 
environments via cellular localization studies.270 Indeed, the added functional utility of 
inserted fluorescent probes has provided the capability to track and observe the 
distribution, influx, and efflux of metal−fluorophore compound in cells.271 
New fluorescent diphosphine ligand FL-I, (Figure 4.5), was chosen to interact with 
Ru(II)tach complexes in order to visualize the site of accumulation in cells using 
confocal microscopy. 
 
Figure 4.5: Structure of new fluorescent ligand FL-I. 
 
The fluorescent diphosphine ligand FL-I (provided by Prof. Paul Pringle) was 
coordinated to the metal by reaction with [Ru(cis-tach)(DMSO)2Cl]Cl, [4] which is 
readily synthesised from the reaction of cis-tach [1] and [RuCl2(DMSO)4] in DMSO 
solvent (Chapter 3).179 The same conditions employed for synthesis of [Ru(cis-tach)(P-
P)Cl] complexes (Figure 4.6) were performed.179 Two equivalents of FL-I were added to 
a solution of one equivalent [Ru(cis-tach)(DMSO)2Cl] [4] in CH3OH and heated at reflux 
under nitrogen for 18 hours. After filtration to remove unreacted phosphine, the 
complex [Ru(cis-tach)(FL-I)Cl]Cl, [10] was isolated by addition of diethylether to a 
saturated dichloromethane solution giving a yellow powder with good yield, 68% 
(Figure 4.7).  
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Figure 4.6:  Synthesis of [Ru(cis-tach)(P-P)Cl]Cl, from [Ru(cis-tach)(DMSO)2Cl] [4] and 
(P-P = dppe, dppm, dppp, dppv and dppb ) ligand in CH3OH as a solvent. 
 
The successful coordination of the diphosphine ligand was evidenced by 31P{1H} NMR 
which exhibited a single resonance for the two coordinated phosphorus nuclei at δp 
55.24 ppm, suggest the equivalent phosphorus nuclei for [Ru(tach)(FL-I)Cl]Cl, [10], 
(Figure 4.8).  
 
 
Figure 4.7: Synthesis of [Ru(cis-tach)(FL-I)Cl]Cl, [10] from [Ru(cis-tach)(DMSO)2Cl] [4] 
and FL-I ligand in CH3OH as a solvent. 
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Figure 4.8: 31P{1H} NMR spectrum of Ru-tach [10] in CD2Cl2.  
 
The 1H NMR spectrum showed both the cis-tach and aromatic protons of FL-I. In the 
high field region (1.0-4.3ppm) of the spectrum, nine proton resonances were 
identified, two of which are coincidentally overlapping and appear as a quartet, 
indicating the same symmetry CS as the starting compound [4]. The observation of a 
large 2J-geminal coupling (15.7 HZ) and absence of axial-axial cyclohexane J couplings 
confirms that the amine groups are coordinated to a metal centre in an axial 
conformation. 
The disappearance of a DMSO resonance in the 1H NMR spectra, with observation of 
singly charged [10] at 882.72 in the ESI-MS with expected ruthenium and chlorine 
isotope patterns, was indicative of the presence of a chloride ligand within the 
coordination sphere of the metal to complete the eighteen-valence electron count.  
The 1H NMR spectrum assignment for the tach protons was aided by the use of 2D 
homonuclear chemical shift correlation, COSY. According to the COSY spectrum (Figure 
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4.10), the CH ( b,b-) and CH2 (a,a-) protons were coupled to each other and give rise to 
the doublets (2J = 16.5 Hz), but the two broad peaks were observed for protons b and 
b- due to their location next to the electronegative NH2 groups. Two of the amine 
groups appear as a doublet (2J = 12.1 Hz) due to coupling to b- while one appears at 
1.49 ppm. This is outside of the typical ‘coordinated amine region’ between 2-5 ppm, 
but this resonance is consistent with many other ruthenium(II) tach complexes of this 
type179 and indicates that the amine groups are coordinated to ruthenium metal in a 
k3 manner. 
 
 
Figure 4.9: Numbering scheme for [10]. 
 
The aromatic region protons present eight signals, two of which are overlapping. Due 
to Cs symmetry present within the complex, only one half of the resonances for these 
aromatic protons were identified in the spectrum (Figure 4.9). The assignment of low 
field peaks can be achieved by the cross peaks in COSY spectrum (Figure 4.11) which 
can be used to differentiate between the phenyl substituent and heterocyclic protons 
(in conjunction with one bond heteronuclear chemical shift correlated 1H-13C NMR 
spectra when necessary). The heterocyclic protons appear in the higher field region 
than phenyl protons. Protons l resonate at 6.4 ppm and appear as a doublet of doublets 
due to the coupling to both m (3J = 5.9 Hz) and n (4J = 1.5 Hz). Protons m, which 
resonate at 7.2 ppm, are coupled to both l (3J = 5.9 Hz) and n (3J = 3.8 Hz) which 
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produces a doublet of doublets. The same multiplicity is observed for protons n (6.5 
ppm) that couple to both m (3J = 3.8 Hz) and l (4J = 1.5 Hz), giving rise to a doublet of 
doublets.  
 
 
Figure 4.10: COSY NMR of Ru-tach [10], detail of the aliphatic region, recorded in 
CD2Cl2. 
 
The other protons were assigned to phenyl rings, with the more deshielded protons d 
(in the ortho position) appearing as a virtual triplet, due to the coupling to protons e 
and phosphine with the same coupling constant (3J = 7.9 Hz). The other aromatic 
protons appeared as a multiplets and overlapped so the assignments were completed 
using HMQC spectroscopy (Figure 4.12).  
 
NH2(1) 
a-  a- a b b
- NH2(2) 
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Figure 4.11: COSY NMR of Ru-tach [10], detail of the aromatic region, recorded in 
CD2Cl2, S is for the thiophene ring, P is for the phenyl protons). 
 
The carbon signals were identified by both HMQC (Figure 4.12) and DEPT spectra that 
can provide additional information to complete the assignment. The CH2 groups have 
the opposite phase to CH groups, and also identify the quaternary carbon resonances 
by the disappearance of the signals. The ipso carbons are observed as triplets due to 
virtual coupling with two 31P nuclei, confirming the coordination of the two equivalent 
phosphorus nuclei. This was demonstrated earlier by the single resonance in 31P{1H} 
NMR spectrum. 
 
L-S e-P1 n-S 
m-S  f-P1 
f-P2 
d,e-P2 
d-P1 
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Figure 4.12: HMQC spectrum of [10] in CD2Cl2, aliphatic region (top) and aromatic 
region (bottom). 
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All the attempts to obtain single crystals of [10] were unsuccessful, however the 
complex was isolated with analytical purity without any anion metathesis. The purity 
was confirmed by elemental analysis. 
The good solubility of [10] in water, and the fluorescent behaviour further discussed 
later, make the complex a good candidate for a biomolecule interaction study. The 
successful synthesis and promising properties of complex [10] also inspired the 
coordination of another fluorescent probe FL-II to the ruthenium tach complex.  
 
4.3 Synthesis of Ru-tach [13] 
 
To expand the range of promising diphosphine tach complexes of type [Ru(tach)(P-
P)Cl]Cl, a new fluorescent ligand FL-II with an extended aromatic ring (Figure 4.13) was 
coordinated to Ru-tach complex [4], following a similar route and conditions as the 
previous complex, to give a yellow product. The 31P{1H} NMR spectrum exhibits two 
doublets centred at 69.5 and 74.1 ppm with a coupling constant (2Jpp of 8.77 HZ), 
suggesting inequivalent phosphorus nuclei for [Ru(tach)(FL-II)Cl]Cl, [13] (Figure 4.14), 
which may be due to different arrangements of the phenyl and pyrenyl group. 
 
 
Figure 4.13: Synthesis of [Ru(cis-tach)(FL-II)Cl]Cl, [13] from [Ru(cis-tach)(DMSO)2Cl] 
[4] and FL-II ligand in CH3OH as a solvent. 
 
Chapter 4 
122 
 
The 1H NMR could not be used to give further indication of the complexes identity but 
the tach and aromatic protons could still be observed. The ESI mass spectrum 
supported the formation of complex [13] by the observation of the expected molecular 
ion at 912.21 m/z with ruthenium and chlorine isotope patterns, shown in Figure 4.14. 
 
 
Figure 4.14: 31P{1H} NMR spectrum of Ru-tach [13] in CD2Cl2 (left) and ESI spectrum 
(right). 
 
The new complex [13] was isolated in low yield (45%) therefore it could not be used 
for biological evaluation performed later. 
On the other hand, two previously synthesised Ru-tach complexes were chosen to 
explore the in vitro evaluation of biomolecular interaction with new complex [10] to 
gain an understanding of how the structural characteristics affect their in vitro 
activities with CT-DNA and BSA (Sections 4.6 and 4.7) and in vivo potencies in the 
A2780 and A549 cell lines (Chapter 5). One complex was chosen due to the higher 
cytotoxicity in anticancer cells, [Ru(tach)(dppp)Cl]Cl [11], while the other was inactive 
[Ru(tach)(phen)(DMSO)]Cl2, [12]. 
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4.4 UV-Vis absorption-fluorescence emission based studies for 
Ru-tach complexes 
 
The electronic absorption spectra and emission spectra of the Ru(II) tach complexes 
are presented in Figure 4.15. All of the complexes show long tail absorption bands that 
occur in the lower energy region (340–550 nm) due to metal-to-ligand charge transfer 
(MLCT) and lie in the typical range of MLCT transitions found in other octahedral 
ruthenium complexes.272-274 The very intense bands in the UV region between 230-310 
nm can be assigned to ligand-centred π → π* transitions.275, 276 
Upon excitation at 350 nm, the emission spectra for [11] at room temperature showed 
a broad emission band with maximum emission at 430 nm. On addition of the new 
ligand FL-I to the coordination sphere of the Ru-tach complex, a red shift was observed 
for the emission wavelength of [10] to 440 nm and the emission was of higher 
intensity. Excitation of the free ligand (at 350 nm at room temperature) showed a 
broad emission band with a maximum emission at 465 nm. The emission observed for 
these complexes can be assigned to intra-ligand π → π* transition mixed with metal-
to-ligand charge transfer. Complex [12] showed a broad emission band with a 
maximum at 600 nm upon excitation at 450 nm shown in Figure 4.15. This emission is 
caused by a radiative process from the MLCT state to the ground state.277 
Complex [10] and its corresponding ligand L [1] have different emission intensities and 
therefore the fluorescence quantum yield (Qy) of the complexes [10] and L[1] with [11] 
and [12] could be determined using the comparative method.278, 279 This method 
involves the use of different references with known fluorescence quantum-yield.280  
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Figure 4.15: UV-Vis spectra (solid line) and fluorescence spectra (dash line) for [10], 
[11], and [12] excited with 350 nm for [10] and [11] and 450 nm for [12]. 
[11] 
[12] 
[10] 
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Anthracene (R1), phenanthrene (R2) and rhodamine 6G (R3) were chosen as the 
references and the quantum yield (Qy) of each reference sample was calculated 
relative to each other. The area of emission spectra was integrated using a/e-UV-VIS-
IR spectral analysis software, and the quantum yield was calculated by using the 
equation:   
𝑄 =  𝑄𝑅 [
𝐺𝑟𝑎𝑑
𝐺𝑟𝑎𝑑𝑅
] ⌈
𝑛2
𝑛𝑅
2 ⌉ 
Equation 4.1: Quantum yield equation. 
 
Where the subscripts R denote reference, Q is the fluorescence quantum yield, Grad 
the gradient from the plot of integrated fluorescence intensity vs absorbance, and ŋ 
the refractive index of the solvent.281 
 
Table 4.1: Quantum yield for FL-I and Ru-tach complexes [10], [11], [12] and the 
references R1, R2. 
compound λex 
(nm) 
Solvent Emission 
range (nm) 
Quantum 
yield 
Molar 
absorptivity(M-
1cm-1) 
Ru-tach [10] 350 Chloroform 360-600 0.080 ± 0.012 8546.0 
FL-I 350 Chloroform 360-600 0.160± 0.109 8625.9 
Ru-tach [11] 350 Chloroform 360-550 0.047± 0.122  
Ru-tach [12] 450 Water 550-700 0.062± 0.214 7442.3 
R1 350 Ethanol 360-480 0.270± 0.081 - 
R2 310 Ethanol 345-500 0.125± 0.092 - 
R3 460 Ethanol 500-700 0.511± 0.021 - 
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The quantum yield of [10] was approximately half when compared to the related ligand 
FL-I. This suggests that the fluorescence of FL-I was quenched when coordinated to 
[Ru(tach)(DMSO)2Cl]Cl. In addition, [11] and [12] have lower quantum yields (Qy 0.047 
and 0.06) than the free ligand FL-I.  
These good fluorescent behaviours and quantum yields allow these complexes to be 
ideal candidates for further study in the field of biomolecules interaction, in order to 
open a window into their mechanism of action. 
 
4.5 Stability of the investigated Ru-tach complexes. 
 
Stability is the major requirement for the biological evaluation of  a DNA/BSA binding 
interaction study, therefore checking the stability of the complexes in the same buffer 
solution used for study is very important.282 The stability of [10], [11], and [12] 
complexes in 5 mM Tris-HCl was measured over  24 h using a scanning kinetic program 
on a UV-Vis spectrophotometer. The UV-Vis spectra recorded directly after dilution of 
complexes [10] and [11] did not show any appreciable changes in either the intensity 
or the position of the absorption bands after 24 h, which indicates the stability of the 
complexes in aqueous solution, while the spectra of complex [12] showed a 
remarkable decrease in the absorption band intensities. In particular, the MLCT band 
at 370 nm gradually weakened, and new bands started to appear near 500 nm with the 
presence of an isobestic point at 430 nm. Equilibrium was reached within 180 seconds 
(Figure 4.16).  
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Figure 4.16: Photoreaction of [12] (0.15mM) in 5mM Tris-HCl buffer, pH 7.2, 
irradiated with normal laboratory light followed by UV/Vis absorption. Insert: photo 
ejection kinetics for [12] in 12 hours. 
 
Complex [12] is indefinitely stable in the dark conditions. However, exposure of such 
solution to normal laboratory light causes a distinctive colour change from light yellow 
to a deep orange colour in water and to a red colour in methanol. Thus, this complex 
is considered to be a light sensitive compound. The presence of an isobestic point at 
430 nm noted in the absorption spectra of the solution undergoing photolysis, (Figure 
4.16), confirms clean conversion of [12] to its photoproduct. 
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Figure 4.17: Photoejection of DMSO ligand of [12] in H2O and MeOH solvent after 
irradiation with white light. 
 
The nature of the photoproduct was further confirmed by electrospray ionization mass 
spectrometry (ESI) which indicated the ejection of DMSO ligand with the formation of 
[Ru(tach)(phen)(H2O)]2+ at m/z 214.32 in water and formation of 
[Ru(tach)(phen)(MeOH)]2+ at m/z 221.55 in methanol solvent. This indicates the 
replacement of the DMSO ligand with a solvent molecule (Figure 4.17). The photo 
substitution reaction is clean and gives only a single photoproduct, as confirmed by the 
NMR photolysis experiment reported for [12] (Figure 4.18). Indeed, new sets of NMR 
signals are formed upon light excitation which correspond to free DMSO, while the 
coordinated DMSO signal decreased in intensity and integration accordingly.   
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Figure 4.18: 1H NMR spectra for [12] in D2O (bottom) and after irradiated with white 
light after 3 hours (top). 
 
This new behaviour for [12] as a light sensitive complex stimulated the screening of its 
interaction with biomolecules in dark and light environment and checking its 
cytotoxicity within the same conditions (Chapter 5). 
 
4.6 DNA binding studies 
 
DNA binding with small molecules is very important in the field of designing of new 
and efficient anticancer drugs.283 Thus, the interaction between DNA and metal 
complexes is important for understanding the mechanism of action. Therefore, the 
types of binding of the new ruthenium (II) tach complex [Ru(tach)(L1)Cl]Cl [10] as well 
the two previously prepared Ru(II)tach complexes[Ru(tach)(dppp)Cl]Cl [11] and 
[Ru(tach)(phen)(DMSO)]Cl [12] with CT-DNA were studied by using UV-Vis 
spectroscopy and the fluorescence quenching techniques. 
Coordinated DMSO 
Free DMSO 
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4.6.1 Electronic Absorption Titration  
 
Electronic absorption spectroscopy is the most common technique used to examine 
the binding affinity of metal complexes with DNA.284 This technique is based on 
monitoring the changes that occur in the UV-Vis spectrum of the metal complex or the 
UV-Vis spectrum of DNA upon their interaction. The binding ability of the complexes 
to CT-DNA can be easily determined by examining the modifications of the maximum 
of one of the absorption bands, either in the UV region or in the visible region, when 
the nucleic acid is present in different concentrations.253, 284, 285 
“Hyperchromic” and “hypochromic” effects are the two spectroscopic features of DNA 
regarding its double helical structure.286 The hyperchromic effect has been attributed 
to electrostatic interactions, hydrogen bonding or groove (minor or major) binding 
along the outside of the DNA helix. This increase in the absorption intensity is 
attributed to the decrease in base-base interactions and lowering of the hydrogen 
bond strength, which is a result of the change in the structure and conformation of 
DNA. The disruption of the double helix leads to separation of the double helix to two 
single strands that cause the hyperchromism.287, 288 Observation of hypochromism 
(with or without bathochromism) is indicative of an intercalative binding mode that 
involves a strong stacking interaction between an aromatic chromophore and the base 
pair of DNA. This causes a decrease in the distance between the complex and the DNA 
bases and leads to a combination of the π electrons from both components. Therefore, 
the energy level of the π-π* electron transition decrease and causes a red shift. 
Furthermore, the coupling π orbital is partially filled with electrons that decrease the 
transition and the absorbance as well.289 
An absorption titration experiment was carried out to study the DNA interaction with 
Ru(II)tach complexes. The intense absorption band around 340 nm observed for [10] 
was used to characterize the interaction of the complexes with calf thymus DNA in 5 
mM Tris-HCl (30 mM NaCl) buffer at pH 7.2. As the CT-DNA concentration is increased 
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(0-50 µM), the MLCT bands of the [10] complex exhibit a hypochromic shift from 0.48 
to 0.30 with a small red shift of 2 nm for the band centred at 340 nm (Figure 4.19).  
 
 
Figure 4.19: Absorption titration spectra of [Ru(tach)(L1)Cl]Cl, [10] with increasing 
concentrations (0-10 µM) of CT-DNA (5 Mm Tris-HCl buffer, pH 7.2, 30 mM NaCl), 
Insert: plot of [DNA] versus [DNA]/ɛa-ɛf with R2=0.998. 
 
However, complex [11] showed a very weak decrease in the absorbance around 320 
nm and this change was attributed to a dilution effect only. The change in the 
absorption spectra of [Ru(tach)(phen)(DMSO)]Cl2 [12], with increasing concentration 
of CT-DNA is shown in Figure 4.20. At constant concentration of [12] (7 µM) in the dark, 
the presence of increasing concentration of DNA (0-10 µM) led to a gradual decrease 
in the intra ligand (π-π*) absorption band around 262 nm (16 %) and the MLCT band 
around 370 nm showed hypochromism (32%). 
 In contrast, when the same titration was repeated for complex [12] in the presence of 
normal laboratory light, the hypochromism around 268 nm and 364 nm increased 
significantly to 30% and 41%, respectively (Figure 4.20). The more significant decrease 
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in the absorbance observed for [12] compared to [10] can be explained by a stronger 
intercalation between the chromophore of the extended aromatic moiety and the 
chromophore of the base pair in DNA in the form of π-π stacking. This is common for 
complexes which contain phenanthroline as ancillary ligand.253 The results suggested 
that complexes [10]  and [12]  bind to DNA by intercalation in a manner similar to 
known intercalators such as [Ru(IP)(DPPZ)].290 
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Figure 4.20: Absorption titration spectra of [Ru(tach)(phen)DMSO]Cl, [12] in the dark 
(top) and light (bottom) with increasing concentrations (0-10 µM) of CT-DNA (5 Mm 
Tris-HCl buffer, pH 7.2, 30 mM NaCl). Insert: plot of [DNA] versus [DNA]/ɛa-ɛf with 
R2=0.966 (top) and 0.987 (bottom). 
 
To compare quantitatively the binding strength of the complexes [10] and [12] with 
CT-DNA, the intrinsic binding constant or association constants (Kb) have been 
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calculated based on the variation in absorption at MLCT band for complex [10] and 
[12] with increasing concentration of DNA according to the Benesi-Hildebrand 
equation, modified by Wolfe et al:291, 292 
[𝐷𝑁𝐴]
(ε𝑎 − ε𝑓)
=
[𝐷𝑁𝐴]
(ε𝑏 − ε𝑓)
+
1
𝐾𝑏(ε𝑏 −  ε𝑓)
 
Equation 4.2: Benesi-Hildebrand equation.  
           
where [DNA] is the concentration of DNA base pairs, εa, εf and εb correspond to 
Aobserved/[complex], the extinction coefficient of the complex in its free form, and the 
extinction coefficient of the complex in the fully bound form, respectively; Kb 
represents the binding constant in M-1. When each set of data were fitted to Equation 
4.2, a straight line with a slope of 1/(εa-εf) and a y-intercept of 1/ Kb (εb- εf): Kb is 
obtained by the ratio of the gradient to intercept. 
The Kb values of these complexes are (3.42±0.23)x104, (9.98±0.13)х104 and 
(7.52±0.12)х105 M-1 for [10] and [12] in dark and light respectively. These results 
suggest that the size and the shape of the plane area (intercalated ligand) has a 
significant effect on the binding affinity to DNA and the most suitable intercalating 
ligand, phenanthroline, leads to the highest binding affinity. This finding is further 
conformed by other techniques below, while the difference in activity in dark and light 
is attributed to the presence of the water ligand in the light complex. Since this is 
smaller than DMSO this leads to higher insertion than there parent DMSO complex.  
 
4.6.2 Fluorescence titration 
 
Fluorescence titrations have been widely used to study interactions between small 
molecules and DNA. The fluorescence emission of interacting compounds can be 
quenched (decrease of fluorescence emission) or in some compounds, the 
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fluorescence intensity increases as the compound-DNA interactions can prevent the 
compound fluorescence emission from being quenched by polar solvent. The 
hydrophobic environments inside the DNA helix reduces the accessibility of polar 
solvent molecules and the compounds mobility is restricted at the binding site, which 
leads to decrease of relaxation and hence fluorescence intensity increase.293 
 
Figure 4.21: Emission spectra of complex [10] (top), and [12] (bottom) with increasing 
concentrations (0-10 µM) of CT-DNA (5 Mm Tris-HCl buffer, pH 7.2, 30 mM NaCl). 
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The intensity of emission from MLCT exited states from Ru(II)tach complexes [10] and 
[12] around 440 nm for [10] and 600 nm for [12] was found to depend on the DNA 
concentration. In the absence of CT-DNA, the emission for complex [10] was fully 
quenched in Tris-HCl buffer, but the complex becomes highly emissive upon binding to 
CT-DNA with a blue shift of 6 nm. However, Ru(II)tach complex [12] emission in Tris-
HCl buffer increased remarkably with a red shift of 3 nm. The emission intensity was 
higher with light than the dark condition as shown in Figure 4.21. This behaviour 
further confirmed the findings of the UV-vis results and this enhancement is believed 
to be due to removal of the water molecules surrounding the complexes due to the 
intercalation of the complexes between DNA base pairs. 241, 294 
 
4.6.3 Competitive DNA binding studies 
 
UV-Vis and fluorescent titration studies clearly indicated effective binding of [10] and 
[12] complexes with CT-DNA. 
The competitive binding experiment based on the displacement of the intercalating 
dye, ethidium bromide (EB), from CT-DNA was carried out to obtain further proof for 
the binding of the Ru(II)tach complexes to DNA.  
 
Figure 4.22: Ethidium bromide structure (EB). 
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Ethidium bromide (3,8-diamino-5-ethyl-6-phenyl phenanthridium bromide, EB) (Figure 
4.22) is a planar cationic dye, known to be a carcinogen, mutagen and antimicrobial 
agent because of its ability to inhibit DNA synthesis, translation and gene 
transcription.295 EB is a very useful sensitive fluorescent probe for DNA, which shows 
high fluorescence intensity when bound to the nucleic acid. The emission of free EB 
molecule is quenched in buffer solution and it shows a significant enhancement in 
fluorescence when intercalating to the base pair of CT-DNA.284, 296 However, the 
enhanced fluorescence can be decreased or quenched when there is another species 
that can replace the EB or break the secondary structure of DNA.297 
The affinity of Ru(II)tach complexes towards DNA can be measured by an EB 
competition assay, which is a measure of the extent of the fluorescence intensity 
reduction of the EB-DNA adduct. The competitive binding experiments have been 
undertaken following the emission spectra of the species in the wavelength range of 
530-750 nm with an excitation wavelength at 518 nm, which is chosen to selectively 
excite EB only as none of the Ru(II) tach complexes exhibit fluorescence when excited 
at 518 nm.  
Upon addition of the complexes (0-60 µM) to CT-DNA (10 µM) pre-treated with EB(µM) 
([DNA]/[EB]=5) in 5mM Tris-HCl, 30 mM NaCl buffer at pH 7.2, the emission intensity 
of DNA-bound EB at 584 nm decreased significantly with the increase of the 
concentration of [10], while [12] (irradiated with normal light) showed a higher 
decrease in emission intensity around 584 nm compared with the dark condition 
(Figure 4.23). These results indicate that the complexes [10] and [12] substitute DNA-
bound EB and emphasize interaction via intercalation. 
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Figure 4.23: Effect of addition of [10] (left) and [12] (right) on the emission of the CT-
DNA-bound EB at different concentration titrations (0-60 µM) in (5 Mm Tris-HCl 
buffer, pH 7.2, 30 mM NaCl). 
  
The fluorescence quenching can be well described by the Stern-Volmer equation:284 
𝐼°
𝐼
= 1 + 𝐾𝑠𝑣 [𝑄] 
  Equation 4.3: the Stern-Volmer equation. 
 
where I₀ and I are the fluorescence intensities of the EB-DNA adduct in the absence 
and presence of the quencher respectively, Ksv is the Stern-Volmer quenching constant 
and [Q] is the quencher concentration. The Stern-Volmer plots of I₀/I versus [Q] are 
shown in Figure 4.24. These illustrate that the quenching of EB bound to CT-DNA by 
[10] and [12] are in good agreement with the linear Stern-Volmer equation. The Ksv 
values were given by the ratio of the slope to intercept. The Ksv values for the tested 
Ru(II)tach complexes are listed in Table 4.2.  
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Furthermore, the EB displacement study provides information about the strength of 
the complex-DNA interaction through the apparent binding constant (Kapp) by using 
the following equation: 
KEB[EB] = Kapp[complex] 
Equation 4.4: Equation to calculate the apparent binding constant. 
 
where KEB = 1х107 M-1, [EB] is the concentration of EB used in this experiment which it 
was [5µM] for all complexes and [complex] is the concentration of the Ru(II)tach 
complexes [10] and [12] used to obtain a 50% reduction in the initial emission intensity 
of EB. Metal complexes that show a strong interaction with DNA give Kapp values with 
magnitudes in the order of 105-106 M-1.284, 287, 298   
 
Figure 4.24: The Stern-Volmer plot of I₀/I versus [Q] for [10] and [12] complexes with 
CT-DNA, R2 0.98([12] light), 0.99([12] dark, 0.93([10]). 
 
From Equation 4.4, the apparent binding constants at room temperature have been 
calculated to be in the order shown in Table 4.1. The data suggest that the binding 
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ability of complex [12] is greater than complex [10], which is in good agreement with 
the conclusion drawn from the absorbance titration (Section 4.2.1). The small 
difference between the two sets of binding that were obtained from fluorescence and 
absorbance titration is due to differences in the error between the two spectroscopic 
techniques and different calculation method, but they are comparable. The Kb, Ksv and 
Kapp values for complex [12] in the light are 10-fold higher than [10], and this strongly 
supports the intercalative mode of phenanthroline ligand,241, 253, 294 presumably due to 
the plane area and hydrophobicity.299 There is a difference in activity of [12] under light 
and dark conditions as the flat aromatic structures are known to intercalate between 
two DNA bases so place the metal in close proximity to the bases and facilitate direct 
photo-induced oxidation of guanines or DNA cleavage.300 Moreover, complex [10] 
shows a lower binding strength to DNA due to the presence of diphenyl phosphine 
groups at the heterocyclic ligand which cause steric hindrance. The phenyl groups may 
come into close proximity of the base pairs at the intercalation site and lead to only 
partial insertion of the heterocyclic group in complex [10],301 shown in Figure 4.25. 
 
 
 
Figure 4.25: Schematic representation of the two intercalation Ru(II) tach complexes 
[10] (right) and [12] (left). 
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Table 4.2: Intrinsic binding constant values (Kb), (Ksv) and (Kapp) from absorption and 
fluorescence spectroscopy.  
Complex Kb (M-1) Ksv (M-1) Kapp (M-1) 
[Ru(tach)(L1)Cl]Cl, [10] (3.42±0.23)х104 (3.84±0.31)х104 (2.04±0.05)х106 
[Ru(tach)(phen)DMSO]Cl, 
[12] Dark 
(9.98±0.13)х104 (2.16±2.32)х105 (1.65±1.12)х106 
[Ru(tach)(phen)DMSO]Cl, 
[12] Light 
(7.52±0.12)х105 (9.68±2.02)х105 (2.05±2.11)х107 
 
 
4.7 Protein binding studies 
 
Interactions between bovine serum albumin BSA and metal complexes have attracted 
interest due to BSA’s structural homology with the most abundant human blood 
protein, human serum albumin. Bovine serum albumin (BSA) is usually preferred over 
other proteins in the protein binding studies because of its abundance, low cost, 
stability, medical significance, ligand binding properties and ease of purification.302-304 
The highly fluorescent properties of BSA are related to the presence of aromatic amino 
acids tryptophan, phenylalanine and tyrosine residues.305, 306 The emission behaviour 
of BSA is mainly contributed to by tryptophan alone, due to the fluorescence 
quenching of tyrosine when it is ionized and the very low quantum yield of 
phenylalanine (Qy).The relative ratio of fluorescence intensity for the three amino acids 
(tryptophan, tyrosine, and phenylalanine) residues is (100:9:0.5) and thus, the 
emission intensity of BSA mainly comes from two tryptophan residues (Figure 
4.26).307Trp-212 is located within the hydrophobic binding pocket in sub-domain IIA 
and Trp-134 is located on the surface of sub-domain IB.308, 309 
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The fluorescence behaviour of BSA can provide significant information about the 
dynamics, structure and protein folding. Also, it is an efficient approach for evaluating 
the interaction with metal complexes. In the case of an interaction with the metal 
complex, the fluorescence emission of the protein at 345 nm decreases regularly as 
the concentration of the compound increases, and in the case of a red or blue shift of 
the emission maximum in the fluorescence spectrum of the BSA suggests an increase 
in the hydrophobicity of the microenvironment around the tryptophan residues.308, 310 
 
 
Figure 4.26: BSA structure with tryptophan residue Trp-212 and Trp-134 in green. 
Image adapted from Belatik et al.311 
 
Fluorescence quenching experiments have been performed using a solution of BSA 
(5µM) in buffer (5 mM Tris-HCl,30 mM NaCl buffer at pH 7.2) and the concentration of 
complexes [10], [11] and [12] (dark and light environment) were varied (from 0 to 50 
µM). In the absence of any Ru complex, BSA has a strong emission peak at 345 nm 
(when excited at 295 nm). An intrinsic fluorescence decrease at 345 nm, within the 
range of 33% to 12% hypochromism was observed when BSA was titrated with the test 
Ru(II)tach complexes shown in Figure 4.27. These changes in emission indicate the 
interaction of all the tested complexes with BSA protein. The different hypochromism 
suggests the binding affinity of the free complexes is in the order [11]> [10]> [12].  
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Figure 4.27: Flurescence spectra of BSA in the absence and presence of complex [11] 
in (5 mM Tris-HCl buffer, pH 7.2, 30 mM NaCl). 
 
The fluorescence quenching is illustrated by the Stern-Volmer equation:308   
 
𝐼°
𝐼
= 1 + 𝐾𝑠𝑣 [𝑄] 
Equation 4.5: the Stern-Volmer quenching constant for BSA. 
 
where I₀ and I are the fluorescence intensities of BSA in the absence and presence of a 
quencher (i.e. the metal complex), Ksv is the Stern-Volmer quenching constant and [Q] 
is the concentration of the quencher. 
A linear I₀/I vs [Q] plot indicates that a single type of quenching mechanism is involved, 
whereas a deviation from linearity indicates a mixed quenching mechanism.312 The Ksv 
values for Ru(II)tach complexes were obtained as a slope from the plot I₀/I vs [Q], 
(Figure 4.28).  The values of Ksv were in order of 104 and the Ksv with a magnitude order 
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of 104 M-1 are indicative of moderate to strong interaction between BSA and the 
Ru(II)tach complexes.308, 313, 314 
 
Figure 4.28: The Stern-Volmer plot of I₀/I versus [Q] for [11], [10] and [12] complexes 
with BSA, R2 0.98([11]), 0.98([10]), 0.97[12] light, 0.99[12] dark. 
 
In addition, according to the well-known connection between the Ksv and the Kq  
𝐾𝑞 =
𝐾𝑠𝑣
𝜏°
 
Equation 4.6: Quenching rate constant. 
 
the quenching rate constant Kq can be calculated. Taking in to account the value of the 
fluorescence lifetime of protein in the absence of quencher is 10-8 s.313 The Kq values 
for the Ru(II)tach complexes are shown in Table 4.2 and they fall in the order of  1011 L 
mol-1 S-1. These values are higher than the maximum value for dynamic quenching (2.0 
х 1010 L mol-1 S-1) which suggests the involvement of a static quenching mechanism by 
the Ru(II)tach complexes.285 
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Further confirmation of the quenching mechanism type can obtained by UV-Vis 
absorption spectroscopy which is a simple method used to distinguish between the 
type of quenching.306 The absorption spectra were recorded in the absence and 
presence of increasing amount of the Ru(II)tach complexes. The BSA absorbance shows 
two characteristic bands; one around 210 nm is due to the α-helix structure of the 
protein while the other band at 278 nm is assigned to the aromatic amino acid 
residues.313 A marked decrease in the 210 nm absorbance is indicative of the 
perturbation of the secondary structure of the BSA, whereas the changes remarked in 
the 278 nm band are more subtle, and point out, to some extent, the environment of 
the aromatic amino acid residues is altered.308, 313, 315 
Figure 4.29: Absorption spectra of BSA in the presence of complexes [10] and [11] 
(top), [12] within dark and light (bottom) in (5 mM Tris-HCl buffer, pH 7.2, 30 mM 
NaCl). 
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For dynamic quenching, the absorption spectrum of the fluorophore is not changed or 
modified as only the excited-state fluorescence molecule is influenced by the 
quencher. Alternatively, static quenching refers to a new species formed between the 
ground-state of the fluorophore and a quencher which leads to significant changes in 
the absorption band at 278nm.316 
The absorption spectra of a fixed concentration of BSA (5 µM) and an increasing 
concentration of the Ru(II)tach complexes are shown in Figure 4.29.  As can be seen in 
Figure 4.29, addition of Ru(II)tach complexes to BSA leads to an increase in the 
absorption maximum at 278 nm with a small blue shift. 
These results revealed the static quenching mechanism occurred during the 
interaction between BSA and Ru(II) tach complexes and these are in good agreement 
with the observation made from the fluorescence titration of the Ru(II)tach complexes 
against BSA protein.305, 306 
To analyse the binding constant (Kb) and binding sites when a small molecule binds 
independently to a set of equivalent sites on a macromolecule, the equilibrium 
between free and bound molecules can represented by the Scatchard equation298, 303, 
308 
log [
𝐼° − 𝐼
𝐼
] = log 𝐾𝑏 + 𝑛 log[𝑄] 
Equation 4.7: Scatchard equation for binding constant (Kb) calculation. 
 
where I₀ and I are the fluorescence intensities of the protein in the absence and 
presence of quencher respectively, Kb is the binding constant, [Q] is the concentration 
of the quencher and n is the number of binding sites. 
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Figure 4.30: Plot of log(I₀-I)/I vs log [Q] for Ruthenium(II)tach complexes [10], [11], 
[12](in dark and light condition, R2 0.99 (for all complexes). 
 
Figure 4.30 shows the double-logarithm curve log(I₀-I)/I vs log [Q]. The double-
logarithm plot yields a straight line and the binding constant Kb and n can be calculated 
from the slope and the intercept of the linear plot respectively. The binding constant 
(Kb) and n values for the Ru(II)tach complexes are given in Table 4.3. 
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Table 4.3: The quenching constants(Ksv) (Kq), binding constants (Kb), number of 
binding sites (n) of BSA-[10], [11], [12] complexes. 
Complexes Ksv (M-1) Kq (M-1 S-1) Kb (M-1) n 
[Ru(tach)(L1)Cl]Cl, 
[10] 
(2.78±0.17)104 2.78х1011 (7.94±0.09)104 (0.88±0.02) 
[Ru(tach)(dppp)Cl]Cl, 
[11] 
(4.47±0.11)104 4.47х1011 (5.01±0.08)105 (1.03±0.02) 
[Ru(tach)(phen)DMSO
]Cl, [12] Light 
(2.24±0.13)104 2.34х1011 (6.31±0.06)103 (0.67±0.01) 
[Ru(tach)(phen)DMSO
]Cl, [12] Dark 
(1.88±0.07)104 1.88х1011 (4.02±0.03)102 (0.55±0.01) 
 
From the value of Kb and n, it can be concluded that the complexes bind to BSA in a 1:1 
molar ratio as the value of n is nearly 1 for all the complexes (except [12] which has a 
considerably lower value than others), and they show strong to moderate binding 
affinity for BSA in the order of [11]>[10]>[12]. Kb values with a magnitude order in the 
range 103-106 M-1 are reported as being indicative of an efficient interaction with 
protein.298, 308, 314 It is known that the binding constant of a compound to serum 
albumin should be sufficiently high to ensure that a significant amount gets 
transported and distributed through the organism, but also low enough so that the 
compound can be released once it achieves its target. Generally, an ideal range is 
thought to be 104-106 M-1.308 
The higher affinity of Ru(II)tach complexes [11] and [10] compared to [12] can be 
attributed to the hydrolysis of chloride ligand in the case of complexes [10] and [11] 
and the subsequent formation of aqua adducts. The aqua adducts provide active 
coordination centres which increase the reactivity towards the BSA protein target 
shown in Figure 4.31. The hydrolysis of the chloride ligand in [11] is so fast that the 
reaction rate cannot be calculated (as stated by Gamble).179 Furthermore, the 
presence of diphenyl phosphine group has been shown to increase the affinity toward 
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albumins as previously reported for platinum complex [Pt(2-phenylpyridine)(dppm)Cl], 
dppm=bis(diphenylphosphinomethane), that has Ksv 1.27х105 M-1.313 As a result, the 
interactions between [11] and [10] with albumins can be mainly attributed to the 
interaction of hydrophobic ligand and whole complex with tryptophan site. The activity 
of [12] in the dark and laboratory light that showed a very low activity towards BSA 
(4.02±0.23)102 M-1 due to the presence of DMSO ligand which is resistance to 
substitution while their reactivity has increased to (6.31±0.06)103 M-1 within light due 
to the formation of aqua complex.  
 
 
Figure 4.31: Possible interaction between BSA and [10], [11], (top) and [12], (bottom) 
where L-L (dppp, L1 and phen).  
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4.8 Conclusion 
 
New Ru-tach complexes [10] and [13] incorporating fluorescent chelating diphosphine 
ligands L [1] and [2] were prepared. Complex [10] was fully characterized by NMR 
spectroscopy, mass spectrometry and UV-Vis spectroscopy and shown to be 
analytically pure. The obtained complexes [10] and [13] possess high fluorescent 
properties when excited at 350 nm in comparison to [11] and [12], which is valuable 
for further applications of these complexes. The biological potential of the complexes 
will also be explored (Chapter 5).   
The binding affinities of Ru(II)tach complexes [10], [11], and [12] with CT-DNA have 
been investigated by UV absorption and fluorescence spectrometry. The results 
obtained suggested an intercalative mode of interaction for both [12] and [10] due to 
the presence of aromatic heterocyclic ligand for stacking, or partial intercalation, in 
between base pairs. Instead, complex [11] does not show any reactivity to CT-DNA and 
these findings is in agreement with previous reports that [11] did not alter the mobility 
of the plasmid DNA in gel electrophoresis assays.179  
The complexes’ affinities to protein were investigated and BSA was selected as a 
relevant model. This study was monitored by UV-vis spectrometry and fluorescence 
spectroscopy. The experimental results indicated that [11] has a higher binding affinity 
than the other complexes tested and that the quenching of the fluorescence intensity 
of serum albumin operated via a static quenching mechanism.
  
 
Chapter 5 
Biological evaluation of Ru-tach complexes 
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5 Biological evaluation of Ru-tach complexes 
5.1 Introduction 
 
A number of common chemotherapy drug compounds in clinical use are unselective 
for cancer cells. Cisplatin and its derivatives, carboplatin and oxaliplatin, which are 
widely used chemotherapeutic agents for cancer treatment, are typical examples of 
this class of unselective compounds.317 The lack of selectivity is the main reason for 
their severe side effects (toxicity, nephrotoxicity, vomiting, nausea, etc.).318 
In the attempt of overcoming the problem of side effects, a prodrug can be used319, 320 
which means that the compound is administered to the patient in a non-active form, 
and subsequent activation must occur to transform the prodrug into the active species 
when it has localized in specific tissue. To activate the prodrugs, two kinds of stimuli 
can be employed; either an internal or an external one. An example of the first case, 
the stimulus can be provided by chemical reduction (cellular condition, enzymatic 
reaction, hypoxia, etc.). The disadvantage of this approach is that there is no control 
on the activation process, as it relies on intracellular parameters. On the contrary, this 
drawback can be overcome when an external stimulus (such us temperature, magnetic 
field or light irradiation) is employed.321-323 By using such approach, complete spatial 
and temporal control on the generation of the actual toxic molecule can be done by a 
physician. Light activation of a prodrug is the most commonly applied technique in the 
clinic for the treatment of certain age related macular degeneration, skin-related 
diseases and cancer.324 In the field of anticancer study, the light mediated activation 
of prodrugs can be divided in to two main classes: photodynamic therapy (PDT) and 
photoactivated chemotherapy (PACT).300, 323, 325-327 
PDT relies on the combination of a non-toxic photoactive compound known as a 
photosensitiser (PS), light and molecular oxygen to induce cell death using an oxygen-
dependent mechanism. More precisely, the (PS) is irradiated with light at specific 
wavelength to reach its singlet excited state, (PS*), which must then undergo an 
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intersystem crossing (ISC) to achieve a triplet character (3PS*). At this point, a proton 
or electron transfer to the surrounding biological substrate can take place to form 
radicals that can further react with molecular oxygen to generate reactive oxygen 
species (ROS, type I). In parallel, an energy transfer from (3PS*) to oxygen in its triplet 
ground state (3O2) can occur which leads to the formation of oxygen in its singlet state 
(1O2, type II) shown in Figure 5.1.324 
 
 
 
  
Figure 5.1: Mechanisms of action of PDT.300 
 
The 1O2 is a very reactive and toxic form of oxygen and this high reactivity leads to a 
short diffusion distance 0.02 µm with an estimated half-life of 40 ns in a biological 
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environment, generating cellular damage that leads to cell death.328, 329 As a 
consequence, PDT induces cell death with spatial and temporal control, and the most 
approved PSs act via a type II mechanism.330 The most extensively studied complexes  
as potential photosensitizers in photodynamic therapy (PDT) are porphyrin 
derivatives,331 however a drawback or disadvantage of  PDT is its lack of efficiency on 
cancers as most tumours are hypoxic (low oxygen tension) in their internal core.16 To 
overcome this drawback, researchers have developed novel photo-activation 
strategies that do not depend on an oxygen-dependent mechanism. Such strategies 
are known as photoactivated chemotherapy (PDAT), which has several activation 
pathways to produce the toxic species and induce cell death such as ligand ejection, 
DNA crosslinking and caging pathways.300 
Over the past few years, considerable research has been focused on using transition 
metal complexes in the fields of PDT and PACT,332, 333 with a particular focus on 
ruthenium complexes as attractive alternatives to platinum anticancer drugs.92 
Ruthenium (II) complexes have shown to be well suited as novel agents for 
photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) due to their 
interesting features as DNA intercalating probes241, 334, 335 and their 1O2 production near 
the genetic material.336, 337 Furthermore, these complexes are good PS candidates due 
to the existence of triplet excited states. The main drawback of these compounds is 
the presence of MLCT absorption maximum in the range 450-500 nm, while the PDT 
relies on the excitation at higher wavelengths (>600 nm) that allow for deep tissue 
penetration.338 Therefore, focus on the other mechanism of PDAT is required to 
overcome the limitations mentioned above. The PACT has different photo-activation 
strategies either by metal-based DNA photobinder acting or photo activated release 
approaches. Glazer and coworkers have developed a new series of Ru(II) polypyridyl 
complexes shown in Figure 5.2,339 which photoeject a methylated ligand followed by 
the formation of an aqua species that can bind either to DNA or protein. The in vitro 
study showed no toxicity (IC50 > 100 µM) under dark conditions in HL60 leukemia and 
A549 cell lines and after irradiation at > 450 nm, their cytotoxicity was enhanced within 
the range of 2.6-1.1 µM. The activity of the photoproduct has been confirmed by using 
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plasmid DNA pCU19 in which complex A showed DNA photobinding whilst complex B 
showed DNA damage and photobinding.339 
 
 
Figure 5.2: Structure of the photolight activated complexes A and B synthesized by 
Glazer and coworkers.339 
 
As long as the covalent bonding to DNA is not the only target for ruthenium complexes, 
Feyter’s and Wang’s groups highlight the intercalation in DNA that nicking the activity 
upon visible light irradiation (Figure 5.3).340, 341 
 
 
Figure 5.3: Intercalating ruthenium complexes that absorb visible light.300 
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Driven by these promising in vitro results with ruthenium polypyridyl complexes as PDT 
and PACT agents, and in combination with the high binding affinity of Ru(II) tach 
complex [12] with CT-DNA reported in Chapter 4, this complex was tested in A2780 
and A549 cell lines both in the dark and under light irradiation. 
 
5.1.1 In vitro evaluation of activity via MTT assay: Principle and 
procedure 
 
An important aspect in the development in cancer therapies is ultimately drug 
discovery. To achieve this aspect new compounds with potential anticancer activity are 
continuously prepared.342 The cytotoxicity of natural products and drugs is a very 
important factor to assay in order to determine how toxic these compounds or 
complexes are to cells and tissues. Many studies and assays have been adopted to 
screen the cytotoxicity of chemicals and drug compounds and even plants. The 3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay has been widely 
used as a reliable method to examine cell viability as evidenced by thousands of 
published articles.343-345 
The MTT assay relies on the reduction of a tetrazolium salt to formazan by a colouring 
agent or enzyme called dehydrogenase, which are found in the mitochondria of living 
(viable) cells (Figure 5.4). The yellow, water soluble tetrazolium salt is reduced to the 
non-soluble purple formazan, which crystallises as needle-like crystals from the 
medium containing viable cells. The insoluble formazan product can be solubilized with 
organic solvent like DMSO, SDS (sodium dodecyl sulfate), and isopropanol.346, 347  
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Figure 5.4: The reduction of MTT bromide to formazan product. 
 
The formazan product has a distinct absorbance maximum at wavelength 540 nm and 
this absorbance is directly proportional to the number of viable cells within the 
population and inversely proportional to the degree of cytotoxicity.348 
The absorbance values of wells with cells incubated with the test compound are 
compared to the absorbance values of wells with untreated cells. The decrease in cell 
number indicates cell growth inhibition, and the complex or drug activity is then 
defined as the concentration of the compound that is required to obtain 50% growth 
inhibition in comparison to the growth of untreated cells, which represents 100% 
growth.345, 349 
The 50% inhibitory concentration (IC50) can be expressed as a molar concentration 
(micromolar concentration) or mass per volume, so the IC50 is the concentration of test 
compound that produce 50% decrease in the control level of viable cells 100% (positive 
control) in comparison to the blank control 0% (negative control). 
Since the reading obtained in MTT assay is absorbance (A), the base line for IC50 values 
calculation is the absorbance (A) value of the control wells in the MTT plate, and this 
value should be identical for the dilution that used to prepare the stock solution. By 
using the absorbance of control wells, the absorbance values of the blank control were 
subtracted from all other values then the percent value of inhibition at each 
concentration can be calculated using the following equation: 
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% 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = 1 − (
𝐴𝑜𝑏𝑠
𝐴𝑐𝑜𝑛𝑡𝑟𝑜𝑙
) ×100 
Equation 5.1: Equation of the percent inhibition calculation from the absorbance of 
the 96 well plate. 
 
where Aobs. is the observed absorbance value for the treated cells at different 
concentration, while Acontrol is the absorbance values for the untreated cells, a positive 
control that represent 100% viability.350 
Then the percent inhibition of each concentration can be plotted to allow for the 
calculation of the IC50 value. % cell viability is plotted against the log of the compound 
concentration and fitted as a sigmoidal curve, and the IC50 value extrapolated from the 
graph as the concentration which gives 50% growth inhibition.349, 350 
 
Figure 5.5: Picture of a 96-well plate used in MTT assay. 
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5.2 MTT assay for Ruthenium(II)tach complexes 
 
5.2.1  In vitro evaluation of tachmonoben  
 
In an effort to comprehend the mechanisms of action of a compound, a series of 
modified target compounds that differ structurally from the ‘traditional’ can help to 
evaluate structure activity relationships (SARs).351,352 
Cis-tach [1] does not inhibit the growth of two cell lines, A549 and A2780 up to 
concentration of 250 µM, and is considered as an inactive compound, while the 
previously prepared trisubstituted tach ligand, tachben,178 exhibited a high level of 
toxicity (IC50 6.65±0.21 and 3.03±0.10 in A549 and A2780, respectively).  
These differences in the final IC50 highlight the effect of the tach ‘arms’ in cytotoxicity 
and show the enhancement of activity of the tri-armed tach ligand. This is presumably 
due to increasing lipophilicity which leads to an increase in the ability to cross 
membranes or actively interact with the target (as the aromatic arm is a hydrogen 
bond donor).178 
The results mentioned above in combinations with the SARs hypothesis by Ciano, that 
one arm on the tach moiety is a main requirement to have at least mild toxicity, 
prompted us to modify the structure of tach and synthesise tachmonoben [3] (Chapter 
2). Importantly for the biological evaluation, the purity of [3] was confirmed by 
elemental analysis and NMR spectroscopy and the solubility in media was checked to 
at least 450 µM prior to use in both cancer cell lines. 
The cytotoxic activity of [3] against A549 and A2780 cell lines has been investigated by 
using the MTT assay according to general procedure (Chapter 7). In both cell lines, 
tachmonoben [3] showed a moderate toxicity in comparison with the widely-used drug 
cisplatin as a positive control (Figure 5.6), with an average IC50 value of (66.42±1.32) 
µM against A549 and (64.1±1.9) µM against A2780 cells. The observed IC50 revealed 
Chapter 5 
160 
 
that cytotoxicity depends on the presence of the arm, which seems to support the 
hypothesis discussed earlier relating to the comparison between the nontoxic tach and 
higher toxicity tri-substituted tachben (Table 5.1). The hydrophobic π-donating 
substituent within the tach structure could also enhance the intercellular accumulation 
of tachmb [3]. It may play an additional important role in biomolecular interactions 
and recognition processes.   
 
 
Figure 5.6: IC50 graphs of tachmonoben [3] against A2780 (left) and A549 (right) cells. 
                                                                                           
These results are consistent with previous observations on ruthenium arene 
complexes that showed enhanced cytotoxicity of the complexes with increasing the 
size of the arene ring system.126 
There is a difference between the cytotoxicity of the two cell lines and this attributed 
to the different biological conditions within each system that cause difference in the 
IC50 value for the test compounds.  
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Table 5.1: IC50 and power values for tachmonoben [3] and cisplatin, tach, and tachben 
for comparison.(a) IC50 of Cisplatin and tachben were obtained with the same 
medium and condition for other compounds.178 
 
Compound 
A549 A2780 
IC50 (µM) Power IC50 (µM) Power 
Cisplatina 2.85±0.24 1.3±0.1 0.40±0.01 1.0±0.1 
Tach [1] >300 - >300 - 
Tachbena 6.65±0.21 - 3.03±0.10 - 
Tachmonoben[3] 66.42±1.32 2.4±0.17 64.14±1.9 1.88±0.15 
 
 
5.2.2 In vitro evaluation of Ru-tachmonoben complexes 
 
Although tachmonoben was not very active against A549 and A2780 cell lines, it still 
acts as a promising ligand which prompted us to improve the activity of the modified 
ligand by preparation of the new ruthenium(II) tachmonoben complexes presented in 
Chapter 3. 
Three complexes were synthesised [Ru(tachmb)(DMSO)Cl2] [5], [Ru(tachmb)(PPh3)Cl2] 
[7], [Ru(tachmb)(dppb)Cl]Cl [9] - but only two complexes [7] and [9] passed the purity 
check by elemental analysis (±0.35 % deviation from the calculated values) therefore 
[5] was not tested. 
These two complexes were only slightly soluble in culture medium; thus they were 
initially dissolved in DMSO then diluted with medium. The IC50 values and power values 
for [7] and [9] are given in Table 5.2. The complexes display high activity in comparison 
to cisplatin. In particular, [9] possesses potent activity exceeding that of cisplatin in the 
A549 and A2780 cell lines. 
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Figure 5.7: Logarithmic dose-response curve of [Ru(tachmb)(PPh3)Cl2] [7] (bottom) 
and [Ru(tachmb)(dppb)Cl]Cl [9] (top) against A549 and A2780. 
 
As highlighted before, the higher activity of the two ruthenium(II) modified-tach 
complexes [7] and [9] compared to the non-modified tach complexes supports the 
hypothesis of increased cytotoxic activity by the presence of the benzyl substituent 
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Model Logistic
Equation y = A2 + (A1-A2)/(1 + (x/x0)^p)
Plot D
A1 151.12221 ± 4.61937
A2 5.41315 ± 1.45367
x0 21.82157 ± 1.16429
p 2.82735 ± 0.3467
Reduced Chi-Sqr 0.75142
R-Square(COD) 0.99571
Adj. R-Square 0.99357
Model Logistic
Equation y = A2 + (A1-A2)/(1 + (x/x0)^p)
Plot B
A1 118.51785 ± 2.63528
A2 13.41657 ± 0.94877
x0 16.72921 ± 0.72433
p 2.42777 ± 0.20198
Reduced Chi-Sqr 0.29431
R-Square(COD) 0.99772
Adj. R-Square 0.99658
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within the tach structure. This is evident by comparison with the ruthenium tach 
complexes previously prepared and their biological activity, which was evaluated by 
MTT assay (values are shown in Table 5.2).179 
As shown in the table, the tachmonoben ligand has notably increased the anti-
proliferative action of the complexes compared to the complex reported by Gamble. 
In particular, especially complex [7] has higher cytotoxicity in both cell lines than 
[Ru(tach)(PPh3)(DMSO)Cl]Cl. This behaviour can be explained by the effects of the 
steric hindrance of the phenyl ring, which promotes the incorporation of a chloride 
ligand in to the coordination sphere of the metal rather than the large DMSO molecule. 
In turn, this results in increasing the rate of activation of the compound within a cell 
and nucleus; DMSO is resistant to exchange with water, the important activation step 
for complexes in biological systems, due to a strong Ru-S bond. The slow exchange of 
DMSO was the main reason for the weak anti-proliferative of 
[Ru(tach)(PPh3)(DMSO)Cl]Cl. Such behaviour appears to parallel that of ruthenium 
arene complex [(η6-arene)Ru(en)Cl]+ in which the hydrolysis provides a pathway for 
activation. Again, the aqua ligands are much more reactive, for example, toward 
substitution by guanine bases on DNA.136 Another example of the effect of the leaving 
groups in the activity of complex is given by Alessiao’s complex, [Ru(tacn)en(DMSO)] 
where tacn=1,4,7-triazacyclononane, which it was nonactive due to weak hydrolysis.165 
On the other hand, the tachmonoben [3] increase the lipophilicity of [7] while 
[Ru(tach)(PPh3)Cl2]Cl was poorly soluble which prevent their assessment by MTT assay. 
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Table 5.2: IC50 and p values for [9] and [7] with in comparison to tach complexes in 
both A549 and A2780. 
 
Compound 
A549 A2780 
IC50 (µM) Power IC50 (µM) Power 
[Ru(tachmb)(PPh3)Cl2][7] 21.82±1.16 2.82±0.3 16.73±0.7 2.41±0.20 
[Ru(tachmb)(dppb)Cl]Cl [9] 0.39±0.01 2.4±0.18 0.34±0.03 2.50±0.38 
[Ru(tach)(PPh3)(DMSO)Cl]Cl  149.0±4 2.00±5 67.8±10 1.95±6 
[Ru(tach)(dppb)Cl]Cl  1.15±2 1.76±3 0.39±1 2.27±4 
 
 
5.2.3 In vitro evaluation of Ru-cis tach complexes 
 
The cytotoxicity of the ruthenium-tach complexes described in Chapter 4 was 
evaluated with the MTT assay against the A549 and A2780 cell lines. 
On the basis of their IC50 values, [Ru(tach)(dppp)Cl]Cl, [11] is more cytotoxic than 
[Ru(tach)(FL-I)Cl]Cl [10] and is more cytotoxic than cisplatin (Table 5.3). All previously 
prepared ruthenium(II) tach diphosphine complexes showed similar activity, and from 
the structure activity relationships it has been proposed that phenyl rings are capable 
of forming hydrogen bonds to the amine groups thus protecting the cis-tach amine 
groups when passing through the cell membrane. They create steric bulk around the 
reactive coordination site of the complex as shown in Figure 5.8 and it was proven by 
the X-ray structure for the complexes.179 The flexibility and hydrophobicity have a great 
influence on increasing cytotoxicity as it proved previously,126, 133, 353 thus the more 
flexible ligand dppp has higher cytotoxicity than FL-I. 
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Figure 5.8: Schematic representation of the diphosphine complexes.179 
 
Table 5.3: IC50 values and power values of [10] and [11] against A549 and A2780. 
 
Compound 
A549 A2780 
IC50 (µM) Power IC50 (µM) Power 
[Ru(tach)(FL-I)Cl2]Cl[10] 20.61±1.08 2.32±0.2 18.03±0.74 3.21±0.30 
[Ru(tach)(dppp)Cl]Cl [11] 1.12±0.03 1.98±0.13 0.37±0.02 2.97±0.56 
 
The interaction of [10] and [11] with biomolecules provides potential insight into the 
anti-proliferative activity. Although [10] showed an intercalative mode of interaction 
with DNA models under physiologically relevant conditions, there is not a strong 
correlation between this reactivity and cytotoxicity towards cancer cell lines. This 
bound correlation led to the investigation of proteins as potential targets of ruthenium 
tach complexes, which is supported by the low binding affinity of [10] with BSA protein 
in comparison to [11] that leads to low efficient distribution. These results prompted 
Phenyl rings adjacent to 
coordination site, extending 
beyond initial coordination 
sphere of the metal 
Hydrogen bond donors 
near coordination site 
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us to presume non-classical mechanism of action in comparison to cisplatin; a 
hypothesis which was further confirmed by in vitro evaluation of [12] performed in the 
following section.  
 
5.2.4 In vitro evaluation of photochemistry of Ru [12] 
 
The photochemical reaction of [Ru(tach)(phen)(DMSO)]Cl, [12] was monitored by 
absorption spectroscopy (Figure 4.9) and it exhibited selective photo ejection of the 
DMSO ligand when irradiated with laboratory white light. The kinetics of this photo 
ejection in Tris-HCl buffer at pH 7.2 were monitored using a wavelength of 470 nm 
previously described in Section 4.5. Electrospray ionization mass spectrometry (ESI) 
indicates the ejection of DMSO ligand and the formation of [Ru(tach)(phen)(H2O)]2+ at 
m/z 214.32, which was further conformed by 1H NMR. 
To determine the potency of light sensitive complex [12], cytotoxicity studies by MTT 
assay were performed in A549 and A2780 cell lines. Cells were incubated with complex 
[12] for 20 hours in the dark before irradiation with normal white light for 30 min and 
dark controls were run in parallel. 
The MTT assay indicated that under dark conditions, [12] exhibited weak to no activity 
in both A2780 and A549 cell lines respectively, while on irradiation the cytotoxicity was 
enhanced to 61.22 ± 3.52 µM in A2780 and up to 302.36 ± 5.33 µM in A549. 
These differences in the light and dark IC50 values prompted us to irradiate the cells for 
longer time periods in order to estimate the effect of light over several time points. 
Therefore, the cells were incubated with LED for 30 minutes, 24 hours and 48 hours in 
the two cell lines, in addition to one dark plate as control. 
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Figure 5.9: Viability graph of [12] against A549 (top) and A2780 (bottom), time shown 
are irradiation times. 
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As expected, the compound displayed an enhancement of cytotoxicity upon increasing 
time of light irradiation and shows higher toxicity within 48 hours (Figure 5.10).  
This enhancement of IC50 value upon incubation with LED light (Figure 5.11) can be 
explained by photo ejection of the DMSO ligand upon light activation. This is quickly 
followed by the formation of an aqua complex which can bind to DNA in an 
intercalative manner (as supported in Chapter 4) with a higher binding affinity in the 
light condition rather than dark condition.   
 
Figure 5.10: IC50 values of [12] in the dark and upon light irradiation against 
A2780(top) and A549 (bottom). 
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Although complex [12] exhibited significantly higher binding strength to DNA 
compared to other ruthenium tach complexes, the low cytotoxicity demonstrates that 
there is no significant correlation between this reactivity and toxicity in cancer cells. 
This conclusion is in good agreement with previous presumptions for [10] and [11], 
therefore it is presumed that these complexes behaved like RAPTA compounds which 
are more reactive towards proteins than cisplatin, and even bind to protein in the 
presence of DNA.156, 354, 355 
   
5.3 Structure-Activity Relationship 
 
In an attempt to analyse the activity of ruthenium tach complexes and modified tach, 
there are some features that should be highlighted for further development and 
increased activity of ruthenium tach complexes. 
A structural modification of the cis-tach ligand is a main requirement for increasing the 
activity. Any modification of the tach ligand which leads to a increased susceptibility of 
the complex to form the chloride analogue will lead to higher cytotoxicity of the 
complex. Chloride is a good leaving group inside cells which may be exchanged with 
biological targets such as DNA or protein. 
The diphosphine ligand provides good to excellent activity for ruthenium tach 
complexes and also with arene complexes,216 by providing flexibility and 
hydrophobicity. 
On the basis of IC50 values for [10], [11] and [12], it is apparent that DNA is not the 
main target of these complexes and, instead, protein might be the primary target of 
these molecules. This is clearly evidenced by the study of interaction of these 
complexes with DNA and BSA protein which show that [12] and [10] process a higher 
intercalative potency than [11] but they have lower cytotoxicity. Therefore, their 
stronger binding to DNA does not correlate with increased biological activity. This 
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inconsistent correlation between cytotoxicity and DNA affinity was shown previously 
in dinuclear ruthenium(II) polypyridyl complexes containing three and ten methylene 
chains in their bridging linkers, indicating that the cytotoxicity may not originate from 
DNA targeting.356 
In general, it seems that the DNA does not play important rule in the mechanism of 
action of tach-based complexes, as the decorating of the ruthenium tach compound 
with an intercalating group is not favoured. 
The evidence presented from this study (and others) strongly suggests that the 
presence of more hydrophobic areas within the tach structure, a chloride group as an 
exchange site, and a diphosphine chelating ligand, results in highly active ruthenium 
tach complexes (as shown in the complexes with the general formula [Ru(tach)(P-
P)Cl]Cl179 and [Ru(tachmb)(dppb)Cl]Cl).  
 
5.4 Conclusion 
 
The MTT assay is a quantitative, and reliable colorimetric method when used to 
measure the efficacy of cytotoxic compounds. Two different cell lines were used in the 
study: A549 and A2780. The new ligand tachmonoben [3] and its Ru(II) complexes [7] 
and [9] were assessed using the MTT assay and they have shown very promising 
activity, with complex [9] surpassing the activity of cisplatin in the A2780 line. 
The chelating diphosphine complexes [10] and [11] exhibited high cytotoxicity, as 
expected from the high hydrophobicity of diphosphine ligands. The fluorescent tag on 
[10] and the ‘light switch’ feature with DNA would be useful to follow the subcellular 
localization in future. 
The lightsensitive complex [12] was weakly to non-toxic in the dark on A2780 and A549 
cell lines respectively, however upon irradiation it showed a remarkable phototoxicity. 
The phototoxicity of [12] was performed by pre-treatment of the anticancer cell lines 
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with [12] followed by incubation with an LED to provide the light to the complex. The 
observed increase in activity is due to the activation of the complex by the formation 
of aqua product [Ru(tach)(phen)(H2O)] after irradiation with light, which is proved by 
UV-VIS  and mass spectroscopy (Chapter 4). The aqua product then interacts with the 
biomolecules more easily and leads to an increase in the activity. 
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6 Conclusion and future work 
6.1 Conclusion 
 
The primary objective of this research was to expand the ruthenium tach framework 
by structural modification to one of the amine groups. The incorporation of a benzyl 
functional group via condensation with benzaldehyde followed by reduction of a C=N 
bond was achieved to produce tachmb [3] ligand. The new ligand exhibited a moderate 
effect on cytotoxicity potency in both A549 and A2780 cell lines compared to the non-
active behaviour of free tach and the high cytotoxicity of the tri-substituted tach 
(tachben). This finding supports the hypothesis that the presence of at least one tach 
‘arm’ is required to tune the activity of the tach ligand.    
To introduce the tachmb [3] ligand into the coordination sphere of the ruthenium, the 
easily prepared precursor [Ru(DMSO)4Cl2] was used firstly to produce the highly water 
soluble complex [Ru(tachmb)(DMSO)Cl2] [5]. However, the cytotoxicity of this complex 
was not quantified as a pure sample could not be obtained (as confirmed by elemental 
analysis). Therefore, two other starting materials, [Ru(PPh3)3Cl2] and 
[Ru(dppb)(PPh3)Cl2], were then used and resulted in the formation of two new 
complexes, [Ru(tachmb)(PPh3)Cl2]Cl, [7], and  [Ru(tachmb)(dppb)Cl]Cl, [9], 
respectively. The presence of benzyl substituted tach (tachmb, [3]) within the 
coordination sphere of ruthenium tach complexes promoted the existence of two 
structural isomers of each complex which were identified by NMR spectra. 
Furthermore, the steric demand of the ligand enforces the lability of DMSO and 
increased the exchange of DMSO with a chloride ligand.  The presence of a more labile 
chloride ligand within the coordination sphere of metal may be the explanation for the 
increase in the activity of the complexes. As expected, complexes [7] and [9] showed 
high activity against the A549 and A2780 cell lines while [9] possesses even higher 
cytotoxicity than cisplatin (which exhibited IC50 values of 0.39±0.01 µM A549 and 
0.34±0.03 µM A2780). 
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The library of ruthenium tach complexes were extended further by addition of 
fluorescent probes FL-I and FL-II to visualize the sites of accumulation in the cell. This 
produced complexes [10] and [13] complexes were characterized by NMR and MS 
while the low yield of [13] prevented further study.   
With the goal of gaining deeper insight in to the mode of action of the ruthenium tach 
complexes, fluorescent [Ru(tach)(L1)Cl]Cl [10], highly active [Ru(tach)(dppp)Cl]Cl [11] 
and light sensitive [Ru(tach)(phen)DMSO]Cl2 [12] were chosen to examine their 
interaction with biomolecules (DNA and protein). Absorption fluorescence 
spectroscopy was used to investigate the binding constant of CT-DNA and BSA to the 
ruthenium tach complexes. The results reveal that [11] did not show any activity 
towards CT-DNA while [10] and [12] bind to CT-DNA by an intercalating mode due to 
the planarity of the chelating FL-I and phenanthroline. The light sensitive [12] exhibited 
strong nuclease activity in the presence of light. The binding constant (Kb) values are in 
the range of 3.42 × 104 to 7.52 × 105 M−1, and the apparent binding constants (Kapp) in 
the range from 2.04 × 106 M−1 to 2.05 × 107 M−1, as measured by UV and fluorescence 
spectroscopy. On the other hand, BSA binding properties of the complexes have been 
investigated and all the complexes bind in a 1:1 molar ratio through static mode. The 
high binding constant for BSA is obtained with [11] which is 5.01 × 105 M−1.  
The in vitro evaluation of the complexes showed high activity of complex [11] 
compared to [10] and [12] which supports the assumption that DNA is not the first 
target for ruthenium complexes. 
Furthermore, the light sensitive complex [12] exhibited moderate to high phototoxicity 
upon irradiation with normal light while it was weak to non-active in the dark against 
A549 and A2780 cell lines. This reactivity occurs because complex [12] exhibits photo-
ejection of the DMSO ligand which activates the complex through ligand exchange and 
formation of an aqua complex (as indicated by UV-VIS spectrum, MS spectroscopy and 
NMR spectroscopy). The aqua ligand is more labile than DMSO and therefore allows 
for enhanced coordination to biomolecules.  
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6.2 Future work 
 
In general, the room for the development and future study of ruthenium tach 
complexes is spacious. The work in this thesis ends with two promising complexes; 
fluorescent analogues of ruthenium tach complexes [10] can be used as models for 
intracellular visualization by fluorescence microscopy or confocal microscopy as this 
complex possesses the ‘light-switch’ property which is an important feature when 
designing a molecular probe for cellular imaging. The other promising complex for 
further study is [12], which is a good candidate to be a photoactive compound. These 
complexes have only been evaluated against two cancer cell lines therefore they could 
be evaluated to other tumour types such as A2780cis and A2780AD (drug-resistant 
variants). The evaluation of activity in non-cancerous cells should be performed to 
investigate the selectivity profile. 
The interaction of these complexes with biomolecules can be further studied by NMR 
spectroscopy and mass spectrometry. Furthermore, some crystallization experiments 
of the complexes with DNA sequences and proteins could be performed to obtain a 
deeper understanding of the complex binding.  
Furthermore, density functional theory (DFT) and molecular dynamics (MD) may also 
be used to examine the interaction with nucleic acids and proteins. 
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7 Experimental 
7.1 General 
 
Materials and solvents used were purchased from Sigma-Aldrich UK or from Fisher 
Scientific without further purification. Cis-cis-1,3,5-Cyclohexanetricaboxylic acid was 
purchased from TCI UK and ruthenium trichloride hydrate from Precious Metals 
Online, propane-1,3-diylbis(diphenylphosphane) from Strem Chemicals and butane-
1,4-diylbis(diphenylphosphane) from Lancaster Synthesis. Cis,cis-1,3,5-
triaminocyclohexane (cis-tach) was synthesised acoording to literature procedure,168, 
180, 357 dichloridotris (triphenylphosphane)ruthenium(II),358 dichlorido[fac-
tris(dimethylsulfoxide-κS)] (dimethylsulfoxide-κO)ruthenium(II),102 
[Ru(dppb)(PPh3)Cl2],240 [Ru(tach)(dppp)Cl]Cl, [11],179 [Ru(tach)(phen)(DMSO)]Cl2, 
[12]179 were prepared according to literature procedures, and FL-I and FL-II were kindly 
donated by Prof. Paul Pringle (University of Bristol).  
NMR spectra were obtained using either a Jeol ECS 400, Jeol EXC 400 (1H 399.78 MHz, 
31P 161.83, 13C 100.52) at 293 K or a Bruker Avance 500 spectrometer (1H 500.23 MHz, 
31P 202.50, 13C 125.78) at 295 K. 31P and 13C spectra were recorded with proton 
decoupling. The CD2Cl2 used for NMR experiments was dried over CaH2 and degassed 
with three freeze-pump-thaw cycles. All other solvents were used as received. IR 
spectra were recorded on a Unicam Research Series FTIR using SensIR Technologies 
ATR equipment. High resolution mass spectrometry was performed by the University 
of York mass spectrometry service using the ESI technique on a Bruker Daltronic 
microTOF instrument(ESI-MS). Elemental analyses (CHN) were performed using an 
Exeter Analytical Inc. CE-440 analyser. pH measurements were recorded using a 
MeterLab ION 450 calibrated with Aldrich standard solutions of pH 4, 7 and 10.  
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7.2 Chapter 2 Experimental 
7.2.1 Synthesis of cis tach                                                                                                                                                                                      
7.2.1.1  Cis,cis-1,3,5-cyclohexanetris(benzyl carbamate), [1]                                                                                                                                                                                                                                                             
 
 
Triethylamine (7.02 g, 9.67 mL, 69.38 mmol) and diphenylphosphorylazide (DPPA) 
(19.09 g, 15 mL, 69.38 mmol) were added to a mixture of cis,cis-1,3,5-cyclohexane 
tricarboxylic acid (5.0 g, 23.13 mmol) in 125 mL of benzene as a solvent. The mixture 
was heated at reflux until all the solid had dissolved. Benzyl alcohol (7.50 g, 7.2 mL, 
69.38 mmol) was added and the reaction mixture was heated at reflux for 18 h. The 
resulting cream suspension was filtered and the white solid washed with small 
amounts of cold diethyl ether. The compound was used without further purification.  
Yield: 8.5 g, 15.9 mmol, 69% 
1H NMR: (d6-DMSO) δ 7.35 (15H, m, f+g+h), 5.00 (6H, s, d), 3.41 (3H, m, b), 1.89 (3H, 
bd, aeq), 1.07 (3H, ap.q, aax). 
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7.2.1.2  Cis,cis-1,3,5-triaminocyclohexane trihydrobromide, 
tach·3HBr, [2]HBr. 
                               
                                      
 A solution of HBr 33% wt in acetic acid (60 mL) was added to tach(benzylcarbamate) 
(6 g, 11.28 mmol) and the mixture was left stirring at room temperature for 16 h. 
Ethanol (100 mL) was then added and the mixture was left stirring for a further 24 h. 
The white precipitate formed was isolated by filtration and washed with chilled 
ethanol, then dried under vacuum.  
Yield: 3.4 g, 9.14 mmol, 80% 
1H NMR: (d6-DMSO) δ 3.53 (3H, tt, 3Jax-ax = 12.3 Hz, 3Jax-eq = 4.0 Hz, b), 2.48 (3H, bd, 2J = 
12.3 Hz, aeq), 1.62 (3H, ap.q, 3J = 2J = 12.3 Hz, aax). 
 
7.2.1.3  Cis,cis-1,3,5-triaminocyclohexane, tach, [2] 
 
  
Cis,cis-1,3,5-triaminocyclohexane trihydrobromide, tach·3HBr, (1.0 g, 2.68 mmol) was 
dissolved in the minimum amount of water and loaded on to  a Dowex 1X4-50 (300 g) 
ion exchange column, which had previously been prerinsed with water, 1 M HCl, 1 M 
NaOH and finally with water again till neutral pH. The fractions with basic pH were 
collected and the solvent evaporated. The residue was sublimed at 10-2mbar at 70 °C 
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using a liquid nitrogen cold finger, a bright white solid were obtained and stored under 
inert gas. 
Yield: 0.21 g, 0.63 mmol, 46%. 
1H NMR: (D2O) δ 2.76 (3H, tt, 3Jax-ax = 11.6 Hz, 3Jax-eq = 3.6 Hz, b), 1.95 (3H, ap.d, 2J = 11.6 
Hz, aeq), 0.89 (3H, ap.q, 3J = 2J = 11.6 Hz, aax). 
 
7.2.2 Synthesis of tachmonobenze, tachmb [3] 
 
7.2.2.1 Cis,cis-1,3-di-tert-bythylcarbamate-5-aminocyclohexane, 
tach-diBoc, [3-a]  
 
                              
 
 
 
Tach·3HBr (200 mg, 0.54 mmol) was dissolved in 40 mL methanol then triethylamine 
(109 mg, 150 μL, 1.08 mmol) was added to the mixture. Boc2O (236 mg, 248 μL, 1.08 
mmol) was diluted with 40 mL of MeOH and the resulting solution was slowly added 
dropwise (one drop every 10-12 sec) to the tach solution. The reaction was stirred for 
16 h. The solvent was evaporated and the white solid was dissolved with basic water 
pH 10 (NaOH solution in water) (12 mL) and ethyl acetate (12 mL). The layers were 
separated and the aqueous layer was extracted with ethyl acetate (3×12 mL). An 
emulsion was usually formed during the extraction, which was left with the organic 
layer during the extraction. The organic layers were dried over MgSO4, filtered and the 
solvent was evaporated, leaving a white solid.  
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Yield: 126 mg, 0.38 mmol, 71%.  
1H NMR: (d6-DMSO) δ 6.84 (2H, m, c), 3.46 (3H, s, b+b’), 1.75 (3H, bt, aeq+ a’eq), 1.33 
(18H, s, f), 0.98 (3H, m, aax ,a’ax). 
ESI-MS: positive ion m/z 330.2391 ([M+H]+, error 0.8 mDa). 
 
7.2.2.2 Cis,cis-1-benzylamino-3,5-diaminnocyclohexane, 
tachmonoimbenz.diBoc [3-b]. 
 
 
 
Tach-diBoc (126 mg, 0.40 mmol, 1 eq.) was dissolved in methanol (24 mL) and 
benzaldehyde (40 mg, 42 μL, 0.40 mmol, 1 eq.) was added to the solution. The mixture 
was stirred at room temperature for 16 h and water was removed by adding molecular 
sieves (3 A˚). After cooling to room temperature, the mixture was filtered and 
solutionwas evaporated, leaving a cream solid. The mixture was extracted with 
chloroform (3×15 mL) and the organic layers combined were dried over MgSO4, filtered 
and the solvent removed by rotary evaporation, leaving a white solid. which was 
washed with pentane and diethyl ether.  
Yield: 122 mg, 0.30 mmol, 77%. 
1H NMR:(CD3OD) δ 8.30 (1H, s, c), 7.66 (2H, dd, 3J = 5.9 Hz, 4J = 2.5 Hz, e), 7.32(3H, m, 
f+g), 3.42(1H, m, b), 2.27 (2H, tt, b-), 2.02 (3H, ap.d, 2J = 11.6 Hz, aeq+a-eq), 1.34 (18H, s, 
k), 0.97 (3H, m, aax+a-ax). 
ESI-MS: positive ion m/z 418.2838 ([M+H]+, error 1.4 mDa). 
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7.2.2.3 Cis,cis-1-(benzylamino)cyclohexane, tachmonobenz.diBoc 
[3-c] 
 
Cis,cis-1-(benzylidenamino)cyclohexane, tachmonoimbenz.diBoc (122 mg, 0.30 mmol, 
1 eq.) was dissolved in methanol (20 mL) and sodium borohydride (23 mg, 0.60 mmol, 
2 eq.) was slowly added in portions. The solution was leaved to stirrer at room 
temperature for a further 16 h. The solvent was evaporated and the residue was taken 
with water (15 mL) and extracted with chloroform (4×15 mL). The organic layers 
combined were dried over MgSO4, filtered and the solvent evaporated, leaving a white 
solid that was used without further purification. 
Yield: 98 mg, 0.24 mmol, 78 %. 
1H NMR: (CD3OD) δ 7.23 (5H, m, e+f+g), 3.74 (2H, s, c), 2.68 (2H, tt, b-), 2.13 (1H, m, b), 
2.02 (3H, d, aeq+a-eq), 1.33 (18H, s, k), 0.97 (3H, m, aax+a-ax). 
ESI-MS: positive ion m/z 420.2838 ([M+H]+, error 1.1 mDa). 
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7.2.2.4 Cis,cis-1-benzylamino-3,5-diaminocyclohexane, tachmb 
[3]  
 
                               
 
 
Compound [3-c] (98 mg, 0.24 mmol ) was suspended in 20 mL of MeOH and 4 mL of 
conc. HCl were added. To dissolve the compound, 8 mL of chloroform were added to 
the mixture, which was left stirring in an icebath for 16 h. The solvent was concentrated 
down to about 5 mL and 20 mL of water were added. The mixture was extracted with 
ethyl acetate (2×20 mL) and the organic layers were discarded. The pH of the solution 
was adjusted with NaOH (pH 14) and extracted with ethyl acetate (4×20 mL). The 
organic layers combined were dried over MgSO4, filtered and the solvent evaporated, 
leaving a colourless oil.  
Yield: (27 mg, 0.12mmol, 51%). Found: C 67.66; H 9.42; N 17.96%. Calcd for 
C13H21N3.0.7H2O: C 67.32; H 9.73; N 18.12%.  
 
1H NMR: (CD3OD) δ 7.23 (5H, m, e+f+g), 3.71 (2H, s, c), 2.75 (2H, tt, 3Jax-ax = 12.2 Hz, 3Jax-
eq = 4.0 Hz, b’), 2.52 (1H, m, b), 2.11 (2H, d, 2J = 12.2 Hz, aeq), 2.01 (1H, m, a’eq), 0.97 
(3H, m, aax+ a-ax). 
13C{1H} NMR (D2O 100.5 MHz, 293K): 140.3 (d), 129.4, 128.2 (e+f+g), 52.3 (b-), 51.4 (c), 
43.5 (b), 42.5 (a-), 40.6 (a).  
ATR-IR (cm−1): 3340 (w), 3059 (w), 2926(m), 1570 (m), 1453 (m), 1223 (m), 1168 (w), 
736 (m), 698 (m). 
ESI-MS: positive ion m/z 220.1810 ([M+H]+, error -0.4mDa). 
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7.3 Chapter 3 Experimental 
 
All reactions were performed under an atmosphere of dry nitrogen using standard Schlenk 
line and glove box techniques. Dichloromethane and pentane were purified with an 
Innovative Technologies anhydrous solvent engineering system. Diethyl ether was dried 
over sodium, and d2-dichloromethane over calcium hydride and vacuum transferred prior 
to use. All other chemicals were purchased from Sigma-Aldrich UK. 
 
7.3.1 [Ru(tachmb)(DMSO-S)(Cl)2], [5]Cl 
 
Tachmb [3] (25.0 mg, 0.114 mmol) was added to a solution of dichloro[fac-
tris(dimethylsulfoxide-κS)](dimethylsulfoxide-κO)ruthenium(II) (55.3 mg, 0.114 mmol) 
in water (15 mL). The resulting yellow suspension was heated at 50°C for 60 minutes. 
The pale yellow solution was allowed to cool, then the solvent removed in vacuo. The 
residue was taken up in the minimum volume of methanol, and addition of diethyl ether 
(50 mL) resulted in precipitation of the product, which was isolated by filtration under 
reduced pressure, washed with diethyl ether (2 x 20 mL) and dried in vacuo. 
 Yield: 35.3 mg (66%, 0.075 mmol of [Ru(tachmb)(DMSO)Cl2], Found: C 30.58; H 6.12; 
N 3.96%. Calcd for C15H27Cl2N3ORuS: C 38.38; H 5.80; N 8.95%.  
1H NMR (D2O): δ 7.26(5H, m, e+f+g), 3.82 (2H, s, c), 3.53 (s, 2H, CH, C2), 3.62(1H, m, 
b1), 3.28 (3H, s,  S(2)), 3.13 (1H, s, b2), 2.57 (1H, d, 2J = 14 Hz, b3),2.32(3H, s,  S(1)),  2.26 
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(2H, m, a1), 1.24 (2H, m, 2J = 14 Hz, a2), 1.12 (2H, m, 2J = 14 Hz, a3); 13C{1H}NMR (D2O): 
δ 137.4(d), 128.3, 128.2, and 127.7 (e+f+g), 51.2(c), 49.1(b1), 46.2 (S(2)), 45.3 (S(1)), 
43.5 (b2), 42.4 (b3), 38.6 (a1), 36.2(a2), 35.8(a3). LIFDI: m/z 469.0421 [5] and 335.05 
unknown. ATR-IR (cm−1): 3003 (w), 2918 (m), 1532 (m), 1400 (m), 1313 (m), 1092 (s, 
S–O), 1016 (m), 681 (m). 
 
7.3.2 [Ru(tacmb)Cl2(PPh3)] [7] 
 
 
Tachmb [3] (25 mg, 0.114 mmol) was added to a Schlenk tube charged with 
dichloridotris(triphenylphosphane)ruthenium(II) (110 mg, 0.114 mmol) in 
dichloromethane (15 mL) a red solution was formed and stirred for 3 hours, during 
which time the solution changed colour to orange then finally to yellow solution. The 
unreacted solid was removed by filtration and the filtrate reduced in volume to 
approximately 1 mL in vacuo. The product was precipitated by addition of pentane (15 
mL) as brown powder, and washed twice with pentane (20 mL).   
Yield: 47.6 mg (64%, 0.077 mmol of [Ru(tachmb)(PPh3)Cl2]. Found: C 56.14; H 5.53; N 
5.72%. Calcd for C31H36Cl2N3PRu: C 56.97; H 5.55; N 6.43%. 
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1H NMR (CD2Cl2) for A isomer:δ 7.95 (6H, app. t, 3JHH = 7.3 Hz, 4JHH = 1.5 Hz, k), 7.75 (6H, 
m, n), 7.55 (tt, 3JHH = 7.3 Hz, 4JHH = 1.5 Hz, m), 7.42 (5H, m, e+f+g), 6.39 (1H, d, 2JHH = 
10.8 Hz, N1), 5.21 (2H, d, 2JHH = 10.8 Hz, N2), 4.15 (2H, d, 2JHH = 10.8 Hz, N2), 3.91 (2H, 
s, c), 3.22 (1H, s, b), 2.80 (2H, bs, b-), 2.45 (1H, d, 2JHH = 16.8 Hz, a-), 2.35(2H, d, 2JHH = 
16.8 Hz, a),  2.05 (2H, d, 2JHH = 16.8 Hz a), 1.72(2H, d, 2JHH = 16.8 Hz, a-); 31P{1H} NMR 
(CD2Cl2) δ 67.4; 13C{1H}NMR (CD2Cl2) δ 139.1 (d, 1JPC = 35 Hz, h), 133.68 (d, 2JPC = 10 Hz, 
K), 129.2 (d, 4JPC = 4.1 Hz, n), 128.7 (d, 3JPC = 8.9 Hz, m), 128,45, 128.19 (s, e+f+g), 50.7 
(s, c), 45.2 (s, b), 43.2 (s, b-), 36.3 (s, a-), 32.8(s, a-), 29.4(s, a).  
1H NMR (CD2Cl2) for B isomer: δ 7.99 (6H, app. t, 3JHH = 7.3 Hz, 4JHH = 1.5 Hz, k), 7.79(6H, 
m, n), 7.45 (tt, 3JHH = 7.3 Hz, 4JHH = 1.5 Hz, m), 7.32(5H, m, e+f+g), 6.29 (1H, d, 2JHH = 
10.8 Hz, N1), 5.09(2H, d, 2JHH = 10.8 Hz, N2), 4.25(2H, d, 2JHH = 10.8 Hz, N2), 3.84 (2H, s, 
c), 3.42 (1H, s, b), 2.92 (2H, bs, b-), 2.40 (1H, d, 2JHH = 16.8 Hz a-), 2.37(2H, d, 2JHH = 16.8 
Hz a),  2.25(2H, d, 2JHH = 16.8 Hz a), 1.80(2H, d, 2JHH = 16.8 Hz a-); 31P{1H} NMR (CD2Cl2) 
δ 61.5; 13C{1H}NMR (CD2Cl2) δ 139.9 (d, 1JPC = 35 Hz, h), 133.08 (d, 2JPC = 10 Hz, K), 
129.1(d, 4JPC = 4.1 Hz, n), 128.2 (d, 3JPC = 8.9 Hz, m), 128,05, 127.6 (s, e+f+g), 47.6 (s, c), 
45.6 (s, b), 42.4 (s, b-), 35.6 (s, a-), 31.9 (s, a-), 28.2(s, a). LIFDI: 653.24.  
 
7.3.3 [Ru(tachmb)(dppb)Cl]Cl, [9] 
 
A solution of [Ru(dppb)(PPh3)Cl2], [8] (98 mg, 0.114 mmol) in CH2Cl2 (15 mL) was stirred  
with tachmb [3] (25 mg, 0.114 mmol) for 18 hours. The solution was filtered to remove 
unreacted phosphane, and the filtrate reduced in volume to approximately 1 mL in 
vacuo. (1 mL) and pentane (10 mL) was added and the product collected by filtration, 
and the process repeated. The pale green product was dried in vacuo. The 1H NMR 
could not achieved as the product was easily decomposed in solution. 
Yield: 63 mg (55%, 0.0805 mmol of [Ru(tachmb)(dppb)Cl]Cl.3H2O). Found: C 60.10; H 
6.41; N 5.68%. Calcd for C41H49N3P2ClRu(3 H2O): C 60.22; H 6.04; N 5.14%. 31P{1H} NMR 
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(CD2Cl2) δ 37.1(d, 1P,2Jpp = 35), 41.3(d, 1P,2Jpp = 35), 46.8(d, 1P,2Jpp = 35),48.6(d, 1P,2Jpp 
= 35).ESI-MS: m/z 782.213 ([M+H]+, error 0.8mDa).   
 
7.4 Chapter 4 Experimental 
 
7.4.1 [Ru(cis-tach)(FL-I)Cl]Cl, [10] 
 
 
A solution of [Ru(cis-tach)(DMSO)2Cl]Cl, [4] (50 mg, 0.118 mmol) in methanol (10 mL) 
was heated under reflux with L [1] (146 mg, 0.237 mmol) for 18 h. The solution was 
filtered to remove unreacted L [1] and the solvent was removed in vacuo, recrystallised 
three times in dichloromethane/diethyl ether, collected by filtration and the yellow 
product dried in vacuo. Yield: 72 mg, 68%, 0.0815 mmol of [Ru(cis-tach)(FL-
I)Cl]Cl.2H2O). Found: C 52.65; H 5.80; N 5.39%. Calcd for C33H41N3P2Cl2Ru(2H2O): C 
52.87; H 6.05; N 5.61%. 1H NMR (CD2Cl2) δ 7.81 (4H, m, d(P1)), 7.58 (8H, m, d,e(P2)), 
7.47 (2H, m,f(P2), 7.24 (2H, m, f(P1), 7.21 (2H, dd, 3JHH= 3.8 Hz, 4JHH = 1.5 Hz, m(S), 7.10 
(4H,t, e(P1)), 6.58 (2H, dd, 3JHH= 5.9 Hz, 4JHH = 3.8 Hz, n(S)), 6.48 (2H, dd, 3JHH= 5.9 Hz, 
4JHH = 1.5 Hz, L(S)), 4.22 (2H, d, 2JHH = 12.06 Hz, N2), 3.59 (2H, d, 2JHH = 12.06 Hz, N2), 
3.43 (2H, s,  b-), 2.77 (1H, s, b), 2.11 (1H, d, 2JHH = 15.35 Hz, a), 2.03 (1H, d, 2JHH = 15.35 
Hz, a), 1.84 (2H, d, 2JHH = 15.35 Hz, a-), 1.74(2H, d, 2JHH = 15.35 Hz, a-), 1.49 (2H, s, N1); 
31P{1H}NMR (CD2Cl2) δ 55.24 (s, 2P); 13C{1H} NMR (CD2Cl2) δ 140.7 (s, c), 135.8 (t, d(P1)), 
133.2 (t, d(P2)), 132.6 (t, f(P2)), 131.4 (dd, L(S)), 130.9 (s, f(P1)), 130.8 (s, d,e(P2)), 
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129.3(dd, m(S)), 128.8 (s, e(P1)), 128.02(dd, n(S), 44.5 (s, b+b-), 34.4 (s, a+a-)ESI-MS: 
m/z 882.7231 ([M+H]+, error 1.1mDa).   
 
7.4.2 [Ru(cis-tach)(FL-II)Cl]Cl, [13] 
 
A solution of [4] (45 mg, 0.106 mmol) in methanol (10 mL) was heated under reflux 
with L [2] (137.7 mg, 0.213 mmol) for 18 hours. The solution was filtered to remove 
unreacted ligand, and the solvent removed in vacuo. Small amount of CH2Cl2 was 
added to the residue, followed by diethyl ether (10 mL) and the product collected by 
filtration, and the process repeated. The yellow product was dried in vacuo. Yield: 44 
mg (45%, 0.048 mmol of [Ru(cistach)(FL-II)Cl]Cl. 31P{1H} NMR (CD2Cl2) δ 74.45 (d, 
1P,2Jpp = 8.77 Hz), 69.48(d, 1P,2Jpp = 8.77 Hz) 
ESI-MS: m/z 912.2134 ([M+H]+, error 0.8mDa).   
 
7.4.3 Absorption spectroscopy 
 
UV-Vis spectra were recorded on a spectrophotometer. Samples were analysed in a 
quartz cuvette with a path length of 1 cm with a spectral range of 200 – 600 nm, all the 
spectra were recorded in Tris-HCl buffer 5mM, pH 7.2, unless otherwise stated. The 
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background was corrected for blank solvent absorbance prior to every measurement 
and was collected at room temperature. 
7.4.4 Fluorescence Spectroscopy 
 
Emission spectra were recorded on a fluorescence spectrophotometer with an 
excitation slit width of 10 nm and an emission slit width of 10 nm, PMT detector voltage 
was 700 V and 240 nms-1 scan speed. All experiments were performed using a 1 cm 
path length quartz cuvette. All the spectra were recorded in Tris-HCl buffer 5mM, pH 
7.2, unless otherwise stated. The background was corrected for blank fluorescence 
before each measurement and was collected at room temperature. 
 
7.4.5  Quantum yield calculation 
 
The quantum yield value were measured for ruthenium tach complexes [10], [11], [12] 
and the ligand L [1] by using comparative method,359 and it is calculated using the slope 
of the line determined from the plot of the absorbance against the integrated 
fluorescence intensities, which it was integrated using the software a/e-UV-VIS-IR 
spectral analysis software, and the quantum yield can be calculated using equation 
(4.1). 
For emission quantum yields, reference molecules were chosen to have similar 
absorption and emission spectra as the sample molecule, to minimize errors arising 
from the wavelength dependence of the apparatus. Anthracene (R1), Phenanthrene 
(R2) and Rhodamine 6G (R3) were chosen as a reference and the quantum yield (Qy) of 
each reference sample was calculated relative to each other. At least 5 data points 
were used in the construction of each graph. 
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7.4.6 DNA binding studies 
 
The chemicals and solvents were of analytical reagent grade and were used as received 
unless otherwise noted. Tris–HCl and CT-DNA were purchased from Sigma–Aldrich 
chemicals except Ethidium bromide (EB) donated by York Structural Biology 
Laboratory, Department of Chemistry, University of York. Millipore water was used for 
preparing buffer. 
All the experiments involving with the interaction of complexes with CT DNA were 
carried out buffer containing 5 mM Tris-HCl. The purity of DNA in the buffer was 
determined by UV absorbance ratio A260/A280 of about 1.8/1.9 indicating that the 
DNA was sufficiently free from protein.360 The stock solution of Calf thymus DNA (CT-
DNA) was dissolved in aqueous buffer (30 mM NaCl, 5 mM Tris, pH = 7.2), it was stored 
at 4 °C and used within 4 days. 
 
7.4.6.1 Electronic absorption titration 
Absorption titration experiment were performed with fixed concentrations of the 
complexes. The complexes were dissolved in Tris–HCl buffer (5 mM Tris–HCl, 30 mM 
NaCl, pH 7.2). Absorption titration experiments were performed in the absence and 
presence of DNA with increasing concentration of CT-DNA and keeping the 
concentration of complex constant. While measuring the absorption spectra, an 
appropriate amount of CT-DNA was added to both compound solution and the blank 
solution to eliminate the absorbance of CTDNA itself, before measurements, the 
mixture was mixed well and incubated at room temperature for 5 min. From the 
absorption titration data, the binding constant (Kb) was determined using equation 
4.2.291, 292 
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7.4.6.2 Fluorescence titration 
All fluorescence measurements were carried out by keeping concentration of complex 
constant while varying the DNA concentration from 0 to 10 µM. The fluorescence 
spectra of the complexes were recorded by using the excitation wavelength of 350 nm 
for [10] and [11], and 450 nm for [12]. Before measurements, the mixture was mixed 
well and incubated at room temperature for 5 min.241, 294 
 
7.4.6.3 Competitive DNA binding studies 
In the ethidium bromide (EB) fluorescence displacement experiment, 5 μL of the EB 
Tris solution (1 mM) was added to 1 mL of DNA solution (1 × 10−4 mol/L, at saturated 
binding level), followed by a 1 h incubation in the dark. The complex was then titrated 
into the EB/DNA mixture. Before measurements, the solution was well mixed and 
incubated at room temperature for 5 min. Fluorescence spectra of EB bound to DNA 
were obtained at an excitation wavelength of 520 nm and an emission wavelength of 
584 nm. Triplicate titrations were performed and the apparent binding constants were 
calculated using equation 4.3.297 
 
7.4.7 Protein binding studies 
 
BSA was purchased from Sigma. The concentrations of the stock solutions of BSA in 
Tris–HCl buffer (5 mM Tris–HCl, 30 mM NaCl, pH 7.2) are determined from absorption 
spectroscopy by dividing absorbance at 280 nm by the molar extinction coefficients of 
BSA (ε280 = 66,000 M-1cm-1).  
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7.4.7.1 Absorption studies 
The absorption spectra of BSA in the presence of different concentrations of [10], [11] 
and [12] were recorded in the range of 200-400 nm. The concentration of BSA was kept 
at 5 µM while the concentrations of complexes were varied from 0.0–5.0 × 10-5 M. 
 
7.4.7.2 Fluorescence quenching experiment 
The fluorescence quenching experiment was performed with an excitation slit width 
of 5 nm and an emission slit width of 5 nm, PMT detector voltage was 700 V and 240 
nms-1 scan speed, using bovine serum albumin. The quenching of emission intensity of 
the tryptophan residues of BSA at 343 nm was monitored in the presence of increasing 
concentrations of complexes. The quencher was added in equal increments with 
concentration increasing from 0-50 μM to a fixed concentration of BSA 5 μM. For every 
addition, the mixture solution was shaken and allowed to stand for 5 min and then 
fluorescence spectra were recorded from 300 to 500 nm at an excitation wavelength 
of 296 nm. Triplicate titrations were performed and the quenching constants were 
calculated using equation 4.5.308 
 
7.5 Chapter 5 Experimental 
 
Human lung adenocarcinoma A549 cells were donated by the Department of Biology, 
University of York. Human ovarian carcinoma A2780 cells were purchased from the 
European Collection of Cell Cultures (ECACC), Salisbury, UK. All materials were 
purchased from Gibco/Fisher Scientific, except PBS from Sigma. The experiments were 
achieved in an Envair class II Laminar flow microbiological safety hood BIO 2+ under 
sterile conditions. Cells were counted using a Beckman Coulter Vi-Cell® Analyser and 
the MTT assay result visualised with a Hidex Plate Chameleon™V plate reader. Plates 
were centrifuged with a Beckman Coulter Allegra™25R Centrifuge using a S5700 rotor. 
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Cells were centrifuged with a Thermo scientific megafuge 40R centrifuge. Plates were 
shaken with an Eppendorf Thermomixer® compact. Dulbecco Modified Eagle Medium 
(DMEM) were used to grow A549 cells in the presence of 10% FBS; A2780 cells were 
grown in RPMI 1640 medium enriched with 10% FBS and 1% LGlutamine. All cell lines 
were kept in 25 cm2 cell culture flasks at 37°C in a 90% RH, 5% CO2 Binder BF56 Steri-
Cult incubator. Cells were subcultured when 70-80% confluent with 0.25% EDTA-
trypsin. 
 
7.5.1 In vitro biological evaluation 
 
The colourmetric assay was first described by Mosmann,343 it proceeded in a 96-well 
plate format. The cells were incubated in the wells at a density of 1000 (A549) or 3500 
(A2780) for 18 hours before the addition of tested complexes in a humidified 
atmosphere (37⁰C, 5% CO2). The tested compound should be solubilize first using 
culture medium or DMSO then medium in case of insoluble complex, the DMSO 
percent in wells containing the cells was never higher than 1% and the DMSO was 
added to the control wells as well. Each plate contains control wells, which is contain 
cells without complexes and blank wells that seeded with medium only. 
Cells are usually exposed to testing compounds at different concentration for 72 hours 
then MTT solution (50µL, 2mg/Ml) was added to treated cells and incubated for two 
to three hours where the yellow MTT is reduced to purple formazan in the viable cells 
only while the dead cells did not reduce the MTT formazan. 
After the three hour exposure to MTT solution, the plates were centrifuged at 500 
RPM, 4˚C for 10 min then the growing medium was removed and the formazan was 
dissolved in an organic solvent DMSO (150 µL) to achieved a homogenous solution, 
then the absorbance at 570 nm was recorded using a plate reader, and analysis of the 
results were done by Orgin v8.5 to calculate the cytotoxicity ( inhibition concentration, 
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50%) values.344 All the compounds was tested in at least triplicate and an average IC50 
with its standard deviation was calculated.  
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Appendix. X-Ray Crystallography Data 
 
 Crystal data and structure refinement for ruthenium dimer.  
Identification code  jml1602_twin1_hklf4  
Empirical formula  C9H28Cl2F6NaO5PRuS4  
Formula weight  684.48  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  11.2512(5)  
b/Å  14.1289(6)  
c/Å  15.2670(7)  
α/°  90  
β/°  93.787(4)  
γ/°  90  
Volume/Å3  2421.65(19)  
Z  4  
ρcalcg/cm3  1.877  
μ/mm-1  11.928  
F(000)  1376.0  
Crystal size/mm3  0.114 × 0.06 × 0.044  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.536 to 134.332  
Index ranges  -13 ≤ h ≤ 13, -16 ≤ k ≤ 16, -18 ≤ l ≤ 13  
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Reflections collected  6744  
Independent reflections  6744 [Rint = ?, Rsigma = 0.0459]  
Data/restraints/parameters  6744/0/276  
Goodness-of-fit on F2  1.216  
Final R indexes [I>=2σ (I)]  R1 = 0.0476, wR2 = 0.1377  
Final R indexes [all data]  R1 = 0.0591, wR2 = 0.1399  
Largest diff. peak/hole / e Å-3  1.60/-1.29  
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Abbreviation 
◦                     degree 
˚C                   degree Celsius 
λ                     wavelength 
 ẟ                    chemical shift (NMR) 
π                     Pi 
σ                     sigma 
µ                      micro 
ɳ6                    C6H6 
13C                  carbon 
1H                   proton 
A           adenosine  
A549           Human lung adenocarcinoma  
A2780            Human ovarian carcinoma    
AgOTf            silver trifluoromethanesulfonate 
AgPF6            silver hexafluorophosphate 
aq.          aqueous 
Boc               t-butoxycarbonyl  
BSA               bovine serum albumin  
bpy          2,2’‐bipyridine  
cm                centimetres  
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cm-1                  wavenumber 
CHN                  carbon, hydrogen, nitrogen (elemental analysis) 
cisplatin           cis – [PtCl2(NH3)2] 
COSY                 correlation spectroscopy 
Cp                       ɳ5-cyclopentadienyl 
CT                calf thymus  
d                         doublet 
DCM                   dichloromethane 
dd                        doublet of doublets 
DEPT                   distortionless enhancement by polarisation transfer   
DMEM                 Dulbecco’s modified Eagle’s Medium  
DMF                    dimethylformamide 
DMSO                 dimethylsulfoxide 
DNA                     deoxyribonucleic acid 
dppb                     1,4-bis(diphenylphosphino)butane 
dppz      dipyrido[3,2‐2’,3’‐c]phenazine 
EDTA                   ethylendiaminetetraacetic acid 
en                        1,2-ethylenediamine 
eq                          equatorial  
ESI-MS                 electrospray ionisation mass spectrometry 
EtBr                      ethidium bromide (C21H20BrN3) 
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Et2O                         diethyl ether 
fac                           facial 
FBS                         foetal bovine serum 
FTIR                        fourier transform infrared 
G         guanosine 
G                             grams  
GSH        glutathione  
h                             hour(s) 
HMBC                    heteronuclear multiple bond correlation  
HSQC                     heteronuclear spin-quantum coupling spectroscopy 
Hz                          Hertz 
IC50                        50% growth inhibition concentration 
IR                           infra-red 
J                             coupling constant  
K                            Kelvin  
M                          molar 
m                          multiplet 
m/z       mass to charge ratio         
MeOD                  methanol-d4 
MLCT       metal‐to‐ligand‐charge‐transfer 
min                       minutes 
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mL                           millilitres  
mmol         millimole  
mol                         moles 
MS                          mass spectrometry 
MTT                       3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide 
NMR                      nuclear magnetic resonance 
NOESY                   nuclear overhauser effect spectroscopy  
p-cymene              para-cymene 
PDT         photodynamic therapy 
PDAT                     photoactivated chemotherapy 
phen                    1,10‐phenanthroline  
ppm                        parts per million 
Pt         platinum  
RNA         ribonucleic acid  
Ru         ruthenium  
s         singlet  
t                               triplet 
tt                              triplet of triplets 
UV                             ultra-violet  
Vis                             visible   
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